NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 1 of 125 A Phase 2,
 Randomized, Double -Blind, Placebo -Controlled, Parallel- Group 
Multiple -Center Study with Additional Open- Label Single -Blind and 
Placebo -Controlled 24-Week Histology Cohorts to Evaluate the Safety, Tolerability, 
and Efficacy of NGM282 Adminis tered for Up to 24  Weeks in Patients with 
Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) 
Protoco
l Number  15-0105 
for 
NGM Biopharmaceuticals Australia Pty Ltd 
Original Pr
otocol    16 January 2015 
Amendment 1    27 May 2015 
Amendment 2    2 September 2015  
Amendment 3    20 June  2016 
Amendment 4    8 November 2016 Amendment 5    24 January 2017 Amendment 6    23 August  2017 
Amendment 7    14 February 2018 Amendment 8    4 June  2018 
Amendment 9    29 March  2019 
Confidentiality Statement:  
This document contains proprietary and confidential information of NGM Biopharmaceuticals  Australia Pty Ltd . 
Acceptance of this document constitutes agreement by the recipient that no previously unpublished information 
contained herein will be published or disc losed without the prior written approval of NGM Biopharmaceuticals 
Australia Pty Ltd with the exception that this document may be disclosed to study personnel under your 
supervision who need to know the contents for conducting the study and appropriate Ins titutional Review 
Boards/Ethics Committees under the condition that the personnel have agreed to keep this information 
confidential.  The foregoing shall not apply to disclosure required by governmental regulations or laws; however, 
NGM Biopharmaceuticals  Australia Pty Ltd  shall be promptly notified of any such disclosure.  
[STUDY_ID_REMOVED]
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 4 of 125   
 
 
  
  
  
 
 
 
 
  
 
  
  
  
  
 
 
  
 
 
 
  
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 5 of 125   
   
 
   
 
 
 
 
  
  
 
  
  
 
 
 
  
 
 
  
  
  
  
  
 
  
  
 
 
 
  
 
 
  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 6 of 125   
 
   
 
 
 
 
 
   
  
  
  
 
 
 
 
 
 
   
  
 
 
 
 
 
 
 
  
   
 
  
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 7 of 125   
  
 
  
 
 
  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 8 of 125 3 Table of Contents  
Title Page  .........................................................................................................................................................  1 
1 Study Identification  ...........................................................................................................................  2 
2 Summary of Changes  ........................................................................................................................  3 
9.9.2 Magnetic Resonance Imaging (MRI)  .....................................................................................  6 
10.3 Study- Drug Storage and Appendix D ......................................................................................  6 
Appendix D .....................................................................................................................................  7 
Appendix E ......................................................................................................................................  7 
3 Table of Contents  .............................................................................................................................. 8  
3.1 List of Tables  ...........................................................................................................................  10 
3.2 List of Appendices  ...................................................................................................................  10 
3.3 List of Abbreviations  ...............................................................................................................  11 
4 Synopsis  ..........................................................................................................................................  13 
5 Introduction  .....................................................................................................................................  24 
5.1 Background ..............................................................................................................................  24 
5.1.1  Nonalcoholic Steatohepatitis (NASH)  ............................................................................  24 
5.1.2  Treatment of NASH  ........................................................................................................  25 
5.1.3  Therapeutic Rationale for NGM282 in NASH  ................................................................ 26 
5.2 Nonclinical Studies  ..................................................................................................................  30 
5.2.1  Nonclinical Safety Assessment  .......................................................................................  30 
5.3 Clinical Studies  ........................................................................................................................  31 
5.4 Rationale for Dose Selection of NGM282 for NASH  .............................................................. 31 
5.5 Rationale for the Use of Rosuvastatin for Lipid Management in NGM282 -treated Subjects  .. 33 
5.6 Rationale for MRI -PDFF, LiverMultiScanTM and MRE Assessments  .....................................  33 
5.7 Rationale for a Liver Biopsy at Weeks 12 or 24  ......................................................................  34 
6 Study Objectives  .............................................................................................................................  36 
7 Study Design  ...................................................................................................................................  38 
7.1 Study -Stop Criteria  ..................................................................................................................  41 
8 Enrollment Criteria ..........................................................................................................................  41 
8.1 Double -blind, Open -label Single -blind and Placebo -controlled 24  Week Histology Cohorts  . 41 
8.1.1  Inclusion Criteria  .............................................................................................................  41 
8.1.2  Exclusion Criteria ............................................................................................................  44 
8.2 Discontinuation of Study Treatment for an Individual Subject  ................................................  46 
8.3 Discontinuation of Subjects from Study Participation  .............................................................  47 
9 Study Methods  ................................................................................................................................ 48 
9.1 Schedule of Study Procedures for Double -blind Cohort  .......................................................... 48 
9.2 Study Visit Procedures for  Double -blind cohort  ......................................................................  51 
9.2.1  Day –28 to Day –1 (Screening) Procedures  ....................................................................  51 
9.2.2  Day 1 Procedures  ............................................................................................................  51 
9.2.3  Week 1 Procedures  ..........................................................................................................  53 
9.2.4  Week 2 Procedures  ..........................................................................................................  54 
9.2.5  Week 4 Procedures  ..........................................................................................................  54 
9.2.6  Week 8 Procedures  ..........................................................................................................  55 
9.2.7  Week 12 (End of Treatment)/Early Withdrawal Procedures  ...........................................  56 
9.2.8  Week 16 (E nd of Study) Procedures  ...............................................................................  57 
9.3 Schedule of Study Procedures for Open -label Single -blind Cohort .........................................  58 
9.4 Study Visit Procedures for Open- label cohort .........................................................................  61 
9.4.1  Day –28 to Day –1 (Screening) Procedures  ....................................................................  61 
9.4.2  Day 1 Procedures  ............................................................................................................  62 
9.4.3  Week 2 Procedures  ..........................................................................................................  63 
9.4.4  Week 4 Procedures  ..........................................................................................................  64 
9.4.5  Week 6 Procedures  ..........................................................................................................  65 
9.4.6  Week 8 Procedures  ..........................................................................................................  67 
9.4.7  Week 12 (End of Treatment)/Early Withdrawal Procedures  ...........................................  68 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 9 of 125 9.4.8  Week 18 (End of Study) Procedures  ...............................................................................  69 
9.5 Schedule of Study Procedures for Placebo- controlled 24- Week Histology Cohort  .................  71 
9.6 Study Visit Procedures for Plac ebo-controlled 24 -week Histology Cohort  .............................  74 
9.6.1  Day –28 to Day –1 (Screening) Procedures  ....................................................................  74 
9.6.2  Day 1 Procedures  ............................................................................................................  74 
9.6.3  Week 2 Procedures  ..........................................................................................................  75 
9.6.4  Week 4 Procedures  ..........................................................................................................  76 
9.6.5  Week 6 Procedures  ..........................................................................................................  77 
9.6.6  Week 8 Procedures  ..........................................................................................................  78 
9.6.7  Week 12 Procedures  ........................................................................................................  79 
9.6.8  Week 18 Procedures  ........................................................................................................  80 
9.6.9  Week 24/Early Withdrawal (End of Treatment) Procedures  ...........................................  81 
9.6.10  Week 30 (End of Study) Procedures  ...............................................................................  82 
9.7 Prior and Concomitant Medications  .........................................................................................  83 
9.8 Diet and Activity Control  .........................................................................................................  85 
9.9 Clinical Evaluations  .................................................................................................................  85 
9.9.1  Liver Biopsy  ....................................................................................................................  85 
9.9.2  Magnetic Resonance Imaging (MRI)  ..............................................................................  86 
9.9.3  Pharmacokinet ic Blood Sample Collection and Processing  ............................................ 88 
9.9.4  Clinical Laboratory Evaluations  ......................................................................................  88 
9.9.5  12-Lead Electrocardiograms  ................................... ........................................................  89 
9.9.6  Vital Signs  .......................................................................................................................  89 
9.9.7  Physical Examinations  ....................................................................................................  89 
9.9.8  Weight, Body Mass Index, and Wai st Circumference Measurements  ............................  90 
9.9.9  Local Injection -Site Symptom Assessments (LISSA) .....................................................  90 
10 Study Drug ......................................................................................................................................  91 
10.1 Clinical Supplies  ......................................................................................................................  91 
10.1.1  NGM282  .........................................................................................................................  91 
10.1.2  Rosuvastatin  ....................................................................................................................  91 
10.1.2.1  Drug Supply for Open- Label Single -Blind Cohort .........................................................  91 
10.1.2.2  Drug Supply for Placebo -Controlled 24 -Week Histology Cohort ..................................  91 
10.2 Study -Drug Accountability  ......................................................................................................  92 
10.3 Study -Drug Storage ..................................................................................................................  92 
10.4 Dose Preparation and Administration  ......................................................................................  92 
10.4.1  NGM282  ................................................................................................ ... ......................  92 
10.4.2  Rosuvastatin  ....................................................................................................................  93 
10.4.2.1  Rosuvastatin Treatment Algorithm – Statin  Naïve  .........................................................  94 
10.4.2.2  Rosuvastatin Treatment Algorithm – Statin Experienced  ...............................................  95 
10.5 Removal of Study Blind  ...........................................................................................................  95 
11 Adverse Events  ...............................................................................................................................  96 
11.1 Definition and Grading Intensity of Adverse Events  ...............................................................  96 
11.2 Criteria for Determi ning Relationship to Drug  ................................... ..................................... 97 
11.3 Reporting  ................................................................................................................................. 97 
11.4 Cardiovascular Adjudication  ....................................................................................................  98 
12 Data Analysis and Statistical Considerations  ..................................................................................  98 
12.1 Sample Size ..............................................................................................................................  99 
12.2 Randomization and Enrollment  .............................................................................................. 100 
12.3 Test of Hypothesis and Significance Levels  ..........................................................................  101 
12.4 Study Populations  ..................................................................................................................  101 
12.4.1  Intent -to-Treat Population  .............................................................................................  101 
12.4.2  All Patients Population  ..................................................................................................  102 
12.4.3  Safety Population  ..........................................................................................................  102 
12.4.4  Efficacy Population  .......................................................................................................  102 
12.4.5  Per Protocol Population  ................................................................................................. 102 
12.4.6  Liver Histology Population  ...........................................................................................  102 
12.4.7  Pharmacokinetic Population  ..........................................................................................  103 
12.5 Treatment Exposure  ...............................................................................................................  103 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 10 of 125 12.6 Patient Disposition  .................................................................................................................  103 
12.7 Protocol Deviations  ................................................................................................................  103 
12.8 Demographic Analysis  ...........................................................................................................  103 
12.9 Efficacy and Pharmacodynamics  ...........................................................................................  104 
12.9.1  Efficacy and Pharmacodynamic Endpoints  ...................................................................  104 
12.9.2  Analysis of Primary Endpoint  .......................................................................................  105 
12.9.3  Analysis of Secondary Endpoints  .................................................................................  106 
12.9.4  Analysis of Exploratory Endpoints  ...............................................................................  106 
12.10  Safety  .....................................................................................................................................  107 
12.10.1  Adverse Events  .............................................................................................................  107 
12.10.2  Clinical Laboratory Evaluations  ....................................................................................  107 
12.10.3  Physical Examinations  ..................................................................................................  107 
12.10.4  Vital Signs  .....................................................................................................................  108 
12.10.5  Pregnancy Test  ..............................................................................................................  108 
12.10.6  Electrocardiogram  .........................................................................................................  108 
12.10.7  Injection -Site Reactions  ................................................................................................ 108 
12.10.8  Concomitant Medications  .............................................................................................  108 
12.11  Pharmacokinetics  ...................................................................................................................  108 
12.11.1  Trough Serum Concentrations (All Subjects)  ...............................................................  108 
12.11.2  Single -Dose Ph armacokinetics (Open -Label Single -Blind Subjects)  ...........................  109 
12.11.3  Multiple -Dose Pharmacokinetics (Open- label Single -blind Subjects)  ..........................  110 
12.12  Interim Analysis  .....................................................................................................................  110 
13 Administrative Aspects  .................................................................................................................  111 
13.1 Protocol Adherence  ................................................................................................................  111 
13.2 Disclosure  .............................................................................................................................. 111 
13.3 Monitoring .............................................................................................................................  111 
13.4 Ethics Committee  ...................................................................................................................  112 
13.5 Informed Consent ...................................................................................................................  112 
13.6 Records  ..................................................................................................................................  112 
13.7 Financing and Insurance  ........................................................................................................  113 
Inves tigator Protocol Review and Signature Form  ......................................................................................  114 
Sponsor Protocol Approval and Signature Page  ..........................................................................................  115 
14 References  .....................................................................................................................................  116 
14.1 Clinical Study References  ......................................................................................................  116 
14.2 Nonclinical Study References  ................................................................................................ 116 
14.3 Literature References .............................................................................................................  117 
15 Appendices  ....................................................................................................................................  121 
 
3.1 List of Tables 
Table  1. Estimated Safety Exposure Margin of NGM282  .....................................................................  31 
Table  2. Schedule of Study Procedures for Double -Blind Cohort  .........................................................  49 
Table  3. Schedule of Study Procedures for Open -Label Single -Blind Cohort  .......................................  59 
Table  4. Schedule of Study Procedures for Placebo- Controlled 24 -Week Histology Cohort  ................  72 
 3.2 List of Appendices  
Appendix A.  NASH Clinical Research Network (CRN) NAFLD Activity Score and Fibrosis Score  ........  121 
Appendix B. Food and Drug Administration Toxicity Grading Scale: Clinical Abnormalities in Local 
Injection -Site S ymptom Assessments  ....................................................................................  122 
Appendix C.  Rosuvastatin Package Insert  ..................................................................................................  123 
Appendix D. Ezetimibe Package Insert  .......................................................................................................  124 
Appendix E.  Prohibited Hepatotoxic Agents  ..............................................................................................  125 
  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 11 of 125 3.3 List of A bbreviations  
Abbreviation  Definition /Term  
AAV  Adeno -associated virus  
ADA  Anti-drug antibody  
AE Adverse event  
AFP Alpha fetoprotein  
ALT Alanine aminotransferase  
ANCOVA  Analysis of covariance  
AST  Aspartate aminotransferase  
ATC  Anatomical Therapeutic Chemical  
AUC  Area under the concentration –time curve  
AUS  Australia  
BMI  Body mass index  
C2h post -dose Concentration at 2 hours post -dose 
C4 7-alpha -hydroxy -4-cholesten -3-one 
CBC  Complete blood count (hematology clinical laboratory evaluations)  
CHMP  Committee for Medicinal Products for Human Use (European Medicines Agency)  
CI Confidence interval  
CL/F  Clearance divided by the bioavail able fraction  
Cmax Maximum  drug concentration  
CRA  Clinical Research A ssociate  
CRF  Case Report Form  
CRN  Clinical Research Network  
Ctrough Trough concentration  
CTCAE  Common Terminology Criteria for Adverse Events  
DIO Diet-induced obese  
EC Ethics Comm ittee 
ECG  Electrocardiogram  
ELF Enhanced liver fibrosis  
EOS  End of study  
EOT  End of treatment  
ER Emergency room  
FDA  Food and Drug Administration  
FFA Free fatty acid  
FGF19  Fibroblast growth factor 19  
FXR  Farnesoid X receptor  
GGT  Gamma -glutamyl tra nspeptidase  
GI Gastrointestinal  
GLP  Good Laboratory Practice  
GLP1  Glucago n-like peptide -1 
GRE  Gradient recalled echo  
HCC  Hepatocellular carcinoma  
HCV  Hepatitis C virus  
HDL  High-density lipoprotein  
HDL -C High-density lipoprotein -cholesterol  
HIV Human immunodeficiency v irus 
HOMA -IR Homeostasis model assessment –estimated insulin resistance  
hr Hour(s)  
  
IA Interim analysis  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference o n Harmonisation  
IL-6 Interleukin 6  
INR International Normalized Ratio  
ISR Injection -site reaction  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 12 of 125 Abbreviation  Definition /Term  
ITT Intent -to-treat 
IWRS Interactive Web Response System  
LDL  Low-density lipoprotein  
LDL -C Low-density lipoprotein -cholesterol  
LIF Liver Inflammation Fibrosis  
LISSA  Local injection -site symptom assessment  
LLT Lowest Level Term (MedDRA)  
MAD  Multiple ascending dose  
MedDRA  Medical Dictionary for Regulatory A ctivities  
MRE  Magnetic resonance elastography  
MRI  Magnetic resonance imaging  
MRI -PDFF  Magneti c resonance imaging –proton density fat fraction  
NAb  Neutralizing antibody  
NAFLD  Nonalcoholic fatty liver disease  
NAS  NAFLD Activity Score  
NASH  Nonalcoholic steatohepatitis  
NGM  NGM Biopharmaceuticals, Inc.  
NGM282  Recombinant protein of 190 amino acids ; engineered variant of h umanized FGF19  
NIH National Institutes of Health  
No. Number  
NOAEL  No-observed -adverse -effect level  
NPO  Nothing by mouth  
NZW  New Zealand White  
OCA  Obeticholic acid  
PBC  Primary biliary cirrhosis  
PD Pharmacodynamic s; pharmac odynamic  
PDFF  Proton density fat fraction  
PI Principal Investigator  
PK Pharmacokinetics; pharmacokinetic  
PT Preferred term  
SAD  Single ascending dose  
SAE  Serious adverse event  
SAP Statistical Analysis Plan  
SC Subcutaneous  
SD Standard deviation  
SE Standard error  
SOC  System organ class  
SOP Standard Operating Procedure  
t1/2 Apparent terminal elimination half -life 
T2D Type 2 diabetes  
TEAE  Treatment -emergent adverse event  
TG Triglyceride  
TGF -β Transforming growth factor beta  
Tmax Time to maximum  concentration  
UA Urinalysis  
ULN  Upper limit  of normal  
U.S. United States  
Vz/F Volume of distribution based  on the terminal portion of the c oncentration –time curve divided 
by the bioavailable fraction  
Wk Week 
  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 13 of 125 4 Synopsis  
Title of Study:  A Phase 2, Ran domized, Double -Blind, Placebo -Controlled, Parallel -Group  
Multiple -Center Study with Additional  Open -Label Single -Blind and 
Placebo -Controlled 24 -Week Histology Cohort s to Evaluate the Safety, Tolerability, 
and Efficacy  of NGM282 Administered for Up to 24  Weeks  in Patients with 
Histologically Confirmed Nonalcoholic Steatohepatitis (NASH ) 
Protocol Number:  15-0105 
 
Phase:  2 
 
Investigational 
Product:  NGM282  
 
Objectives:  Primary Objective:  
• Evaluate the treatment effect of NGM282 on absolute liver fat conte nt as 
measured by magnetic resonance imaging– proton density fat fraction  
(MRI -PDFF)  in patients with histologically confirmed NASH . 
Secondary Objectives:  
• Assess the safety and tolerability of NGM282 in patients with NASH with 
up to 24  weeks of treatment  with NGM282 . 
• Evaluate the percentage  change in absolute liver fat content  at End of 
Treatment (EOT) . 
o In the open- label single -blind cohort, additional evaluations will be 
performed  at Week s 6 and 18 weeks  
o In the placebo -controlled 24 -week histology cohort, additional 
evaluations will be performed at Weeks 6, 24, and 30 weeks  
• Evaluate the percentage of normalization for liver fat content at EOT.  
• Evaluate  the change in  liver fat content response  rate as  defined  by a ≥ 5% 
decrease in absolute liver fat content.  
• Evaluate the absolute and percentage changes from Baseline  to EOT as well 
as the percentage of normalization  of the following parameters : ALT, AST, 
triglycerides, bilirubin (total and direct), and GGT.  Percentag e of 
normalization will  also be investigated for a clinically meaningful threshold 
for triglycerides.  
• Evaluate the absolute and percentage changes from Baseline to EOT  of the 
following  (if collected as part of the cohort) : 
o Total cholesterol, HDL -cholestero l (HDL -C), LDL -cholesterol  
(LDL -C), triglycerides , and lipo protein particles   
 In addition, evaluate the absolute and percentage change 
from Baseline to End of Study ( EOS ) of the above lipid 
parameters in the open -label single -blind cohort . 
o  
o Fasting blood glucose, insulin levels,  
, and homeostasis model assessment –estimated 
insulin resistance (HOMA -IR) 
o PRO -C3 and ELF Score ( Placebo Controlled 24 Week Histology 
Cohorts )  
o Body weight, body mass  index (BMI), and waist circumference  
o 7-alpha -hydroxy -4-cholesten -3-one (C4) and serum bile acids  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 15 of 125 Methodology/  
Study Design:  This is a mu ltiple -center evaluation of NGM282 in a randomized, double -blind, 
placebo -controlled, parallel -group cohort with additional open- label single -blind and 
placebo -controlled 24 -week histology cohorts when administered for up to 24 weeks 
as an SC injection in patients with histologically confirmed NASH.  
In the double -blind cohort,  ~75 patients will be randomized across ~20 sites 
worldwide.  
Patient s to be studied will have histologically confirmed NASH as defined by the 
NIH NASH Clinical Research Network and det ermined by a qualified local 
pathologist.  Historical biopsy results within 6 months of Screening may be used for 
inclusion into the study; otherwise, a liver biopsy must be obtained for assessment.  
Patients must have a  nonalcoholic fatty liver disease  (NAF LD) activity score  (NAS) 
of at least 4 , with 1  point in each of the three components, along with the presence of 
fibrosis.  Patients with cirrhosis will be excluded from this study.  Patients will 
undergo an MRI during the Screening period, which must demons trate at least 8% 
total fat content.   
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 16 of 125 Methodology/  
Study Design  
(cont’d): On Day 1, subjects  will be randomized into one of the three  treatment arms 
(NGM282 3 mg, NGM282 6 mg, or placebo) in a 1:1:1 ratio.  Subjects will be 
stratified at randomization acco rding to non- diabetic and diabetic status at Day 1 to 
ensure an even distribution across the three groups.  Study- drug self -administration 
instructions and training will be provided to the subjects  and a weekly study- drug kit 
will be dispensed.  Treatment as signment will be blinded to the sites, study subjects, 
sponsor, and Medical Monitor throughout the study period.  The first dose (Day 1) 
and doses at Weeks 1, 2, 4,  8, and 12 will be self -administered in the clinic, with all 
other doses through Wee k 12 self -administered at home.  Self-administration should 
occur in the morning for every dose in both the clinic and at home.  Subjects will 
return to the clinic on Weeks 1, 2, 4,  and 8 for on -treatment assessments and to 
receive weekly NGM282 study- drug kits . Week  12 will be the EOT clinic visit.  
Subject s will return to the clinic at Week 1 6 (or 4 weeks after last dose) for an EOS 
follow -up visit.  Subjects are requested to undergo MRI performed during Screening 
and at Week 12 (EOT)/Early Withdrawal visit.  
In the open -label single -blind cohort , up to 100 patients  (25 per dosing group) will 
be enrolled from ~6–8 U.S. sites. Subjec ts will be required to meet enrollment 
criteria similar to those of the double -blind cohort with the exception of the 
following , specifically defined in protocol  Section  8.1.2 : 1) historical biopsy window 
extended to 12 months ; 2) limitations on the  use of glucago n-like peptide -1 (GLP1 ) 
agonists ; 3) glycated hemoglobin ( HbA1c) level ≤ 9.5%; 4) LDL levels at Screening 
need to be ≤  165 mg/d L; 5) exclusion of specific lipid -lowering therapies prior to and 
during study period ; 6) no contraindications to receiving statins . The single -blind 
cohort is not randomized.  At Day 1 eligible patients will be sequentially enrolled into 
the study and categorized as either  statin -naïve versus statin experienced  with no 
more than 8 statin experienced subjects  within each dosing group . Subjects will be 
enrolled sequentially initially into the d osing Group 1 and enrollment will be 
continuous within the dosing group.  Sequencing of  the subsequent 2  dosing groups  
will be based on PD and safety parameters  from dosing Group 1. The subsequent  
2 dosing groups  may run in parallel.  A fourth optional dosin g group may be 
conducted based on the safety/tolerability, imaging data , and histology (dosing 
Group 3 only) data from the prior 3 dosing groups . Dosing Group  4 will be  initiated 
only after all subjects in Dosing Group 3 have been enrolled and a minimum of  
10 subjects have completed 12 weeks of treatment in order to do a  preliminary 
review of key  data.  Individual subject treatment assignment will be blinded only to 
the study subjects throughout the study period.  
The first dose of  NGM282 (Day  1) and doses at  Week s 2, 4, 6, 8, and 12  study visits  
will be self -administered in the clinic, with all other doses through out the treatment 
period  self-administered at home.  Self-administration of NGM282 should occur in 
the morning for every dose in both the clinic and at home.  Subjects w ill return to the 
clinic on Weeks 2, 4,  6, and 8 for on -treatment assessments and to receive weekly 
NGM282 study- drug kits . LDL -C will be evaluated at Week s 2, 4, and 8  in all 
subjects for possible increases in lipid levels associated wi th NGM282 
administration . Rosuvastatin will be started in subjects meeting specific LDL -C level 
criteria.  The specific dosing and administration of rosuvastatin will be based on 
whether the subject is statin naïve versus statin experienced and LDL -C levels  at 
Weeks 2, 4 , and 8 . The dosing algorithms are specifically  outlined in  Section  10.4 of 
t
he study protocol . Bottles of rosuvastatin tablets will be dis pensed at Weeks 2, 4, 
and 8, depending on observed lipid levels and dosing algorithm in Section  10.4. 
Week  12 will be the EOT clinic visit and subjects w ill return to the clinic at Week  18 
(or 6  weeks after last dose) for an EOS follow- up visit.  Subjects are  required  to 
undergo MRI performed during Screening and at Weeks 6, 12 (EOT)/Early 
Withdrawal , and 18 (EOS) visits . 
Dosing Groups 3 or 4 will have two other assessments performed to assess liver 
histology in addition to MRI -PDFF. LiverMultiScanTM will be performed during the 
MRI assessments at the same time as the MRI -PDFF assessments (Screening and 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 18 of 125 Number of Patient s: 
 Approximately 75 patients  (25 per treatment group)  will be randomized  in the 
double -blind cohort. Up to 100 addit ional patients  (25 per treatment group)  will be 
enrolled  in the open -label single -blind cohort.  Approximately  75 additional subjects 
(50 active, 25 placebo) will be enrolled in the placebo -controlled 24 -week cohort.  
 
Number of Study 
Sites : 
 Double -blind c ohort: ~ 20 sites worldwide   
Open -label single -blind cohort: ~6–8 U.S. sites  
Placebo -controlled 24 -week histology cohort :  ~10 U.S. sites 
 
Test Product(s), Dose, and  
Mode of Administration:  For the double -blind cohort, t he NGM282 final product will be supplied in pre -filled 
syringes intended to deliver 0.3 mL (3 mg) or 0.6 mL  (6 mg ) for SC  injection.  
Placebo will be provided in volume -matched syringes (0.3 mL and 0.6 mL). For the 
open -label cohort, NGM282 final product will be supplied in pre -filled syring es 
intended to deliver 0. 3 mL (0.3 mg, 1  mg, and 3 mg) for SC injection.  For the 
placebo -controlled 24 -week histology cohort, NGM282 final product will be 
supplied in pre -filled syringes intended to deliver 0.3 mL (1 mg ) dose for SC 
injection.  All s ubject s will be instructed to dose NGM282 each morning and to skip 
the dose if it is past 12 :00 noon and administer the next dose as planned the 
following morning.   
The open -label  single -blind and placebo -controlled 24 -week histology cohorts  will 
also include treatment with rosuvastatin for subject s meeting pre -specified LDL -C 
criteria.  Study -labeled r osuvastatin 20-mg tablets will be supplied in order to deliver 
either 20 mg or 40 mg total daily doses  as outlined in Sectio n 10.4 to manage 
possible LDL- C increase during NGM282 treatment .   
The placebo -controlled 24- week histology cohort only will also include treatment 
with ezetimibe co -therapy that will be prescribed by the Investigator  when su bjects 
have not achieved an adequate LDL -C response or when subjects are unable to  
tolerate rosuvastatin.  Ezetimibe is formulated as 10 mg tablets and can be 
administered with or without food at the same time as rosuvastatin and NGM282  or 
placebo  
 
Durati on of 
Treatment:  In all cohorts, p atients will sig n the Informed Consent F orm at the Screening Visit, 
and will undergo screening assessments to verify eligibility for the study  for up to 
4 weeks  from consent date . In the double -blind cohort, a ll subject s will be treated 
with NGM282 or placebo for 12 weeks and will be monitored for 4 weeks after 
completing their final dose of NGM282 or placebo.  In the open- label single -blind 
cohort, subject s will receive NGM282 in 0.3 mg, 1 mg, or 3 mg doses  for 12  weeks 
and be monitored for 6 weeks after completing final study -drug dose.  In the 
placebo -controlled 24 -week histology cohort, subjects will receive NGM282 or 
matching placebo at 1mg dose for 24 weeks and be monitored for 6 weeks after 
completing final study -drug dose.  
The total duration of individual participation will be ~ 20 weeks  for the double -blind 
cohort, ~22 weeks  for the open- label single -blind cohort, and ~34 weeks for the 
placebo -controlled 24 -week histology cohort.  
 
Criteria for 
Evaluation:  
Safety  In all study cohorts, s afety and tolerability will be assessed by monitoring adverse 
events  (AEs)  and concomitant medications, conducting local injection -site symptom 
assessments (LISSAs) , measuring vital signs and electrocardiograms  (ECGs) , and 
collecting and a nalyzing clinical laboratory blood and urine samples.  
 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 19 of 125 Criteria for 
Evaluation: Pharmacokinetics   In the double -blind cohort, PK will be analyzed to determine the steady -state trough 
and 2- hour post -dose NGM282 levels in  NASH  subject s and to compare to th e levels 
in normal volunteer s and in subject s with type 2 diabetes ( T2D), and to explore 
PK/PD correlations in terms of drug efficacy ( change in  hepatic fat content ), toxicity , 
and other parameters of the disease. 
In the open- label single -blind cohort, the same PK parameters and comparisons will 
be performed as outlined for the double -blind cohort.  In addition , approximately 
8 subjects per dosing group will be given the option to participate in further PK 
sampling at pre-dose and at 1, 2, 4, 8, and 12 hours  after dosing on Day 1 and  
Week  6 in order to further characterize the PK  in this population.  
In the placebo -controlled 24 -week histology  cohort, the same PK parameters and 
comparisons will be performed as outlined for the double -blind cohort.   
 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 22 of 125 Sample Size 
Determination  
(cont’d): The sample size of the placebo -controlled 24 -week histology cohort is based on 1) 
12-week histologic response data from the 3 -mg cohort and 2) estimated placebo 
histologic response rates from controlled Phase 2 studies in NASH.  Preliminary 
12-week histol ogic response data (n=16) demonstrated that 50% of subjects had a 
1-stage improvement in fibrosis with no worsening of NASH or resolution of NASH 
with no worsening of fibrosis.  The placebo histologic response rates from recent 
Phase 2b trials of obeticholic acid, cenicriviroc, liraglutide , and selonsertib were 
14%–20% at timepoints ranging from 24 to 72 weeks.  Based on these data, the 
assumptions of calculated sample -size estimates for 24 -week efficacy used an 
NGM282 response of 50% versus 15% for placebo utilizing 80% power and 
alpha=0.05 with a 2:1 randomization scheme.  Assuming a 15% drop- out rate, the 
planned sample size of 50 NGM282- treated subjects and 25 placebo subjects is 
sufficient to evaluate efficacy and support powering estimates for late-stage clinical 
trials . 
Statistical Methods:  All patients who receive any amount of study drug will be included in the analyses, 
including those who withdraw prematurely from the study.  Patients will be 
summarized within five analysis populations:  
• Intent -to-treat (ITT) population:  all randomized patients  (for the double -blind 
and placebo -controlled 24 -week histology cohorts ) 
• All Patients  population:  all enrolled  patients ( single -blind cohort only)  
• Safety population:  all randomized /enrolled  patients who receive at least one  dose 
(full or partial) and have at least one post -dose safety evaluation  
• Efficacy population: all randomized /enrolled  patients who receive at least 
one dose (full or partial) of study drug and have at least one valid, non -missing 
post-dose effi cacy/PD parameter value  
• Per Protocol (PP) population:  subset of patients in the Efficacy population; will 
include patients who have at least one valid, non -missing post -dose liver fat 
content measurement and excludes those patients who deviate from the co nduct 
of the study or have an AE deemed by the medical monitor to be impactful on the primary endpoint  
• Liver histology population:  subset of patients in the Efficacy population; will 
include patients who have at least one valid, non -missing Baseli ne and EOT 
biopsy and excludes those patients who deviate from the conduct of the study or 
have an AE deemed by the medical monitor to be impactful on the primary 
endpoint  
• PK population:  all randomized/enrolled patients who receive at least one dose 
(full or partia l) of drug, with a pre -dose (Baseline) blood draw, and at least 
one qualified (above the limit of quantification) post -dose sample  
The patient disposition will be presented by randomized treatment group for the 
double -blind and placebo -controlled 24 -week h istology cohorts and by enrolled 
treatment group for the single -blind cohort. The reasons for discontinuation will also 
be summarized.  Treatment exposure will be summarized as extent of exposure to the 
study drug.  Measures of extent of exposure will includ e the total number of doses per 
patient and compliance.  Treatment exposure will be summarized using the Safety 
population by actual treatment group.  Demographic and Baseline characteristics will 
be descriptively summarized by treatment group. Patient dispo sition, demographic, 
and Baseline characteristics will be summarized using the ITT population  for the 
double -blind and placebo -controlled 24 -week histology cohorts and using the All 
Patients population for the single -blind cohort. 
 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 23 of 125 Statistical Methods  
(cont’d) : The primary efficacy endpoint is the absolute change in liver fat content as measured 
by MRI -PDFF from Baseline to EOT . The absolute change from Baseline to EOT  
will be compared between treatment groups using an analysis of c ovariance 
(ANCOVA) model  with treatment group and diabetic status  (double -blind cohort 
only)  as cofactors and Baseline absolute liver fat content as a covariate at the 5% 
level of significance.  The primary endpoint will be evaluated using the Efficacy 
population and the analysis will be repeated using the Per Protocol population.  
The secondary and exploratory PD endpoints will be measured as an absolute as well as percentage change (for specific identified parameters) from Baseline to EOT. The 
secondary and exploratory PD endpoint  analyses will utilize the Efficacy population.  
The absolute change and percentage change from Baseline to EOT  will be compared 
between treatment groups using an ANCOVA model with treatment group and diabetic status  (double -blind cohort only)  as cofactors and Baseline endpoint value as 
a covariate at the 5% level of significance.  In cases where the parameters do not 
follow a normal distribution, a non -parametric approach will be followed to analyze 
the difference between treatment groups.  Categorical second ary endpoints 
(percentage of normalization) will be analyzed through a chi -square test.  
 Further covariates/cofact ors and correlations may be included in the modeling 
depending on the relevance to the endpoint analyzed and will be further described in 
the Statistical Analysis Plan . 
Safety and tolerability will be assessed by the following parameters: AEs, LISSAs, 
clinical laboratory tests, physical examination s, ECGs, vital signs, prior and 
concomitant medications.  All safety analyses will be conducted usi ng the Safety 
population.  Apart from the lipid profile (t otal cholesterol, HDL -C, LDL -C, and 
lipoprotein particles), which will be analyzed as described for the primary and 
secondary endpoints above based on the safety population, all other safety endpoint s 
will be analyzed descriptively only.  
Interim Analys es: A single  interim analysis (IA) is planned to be conducted for the double -blind cohort 
after ~12 patients per arm have completed 12 weeks of treatment.  The final analysis 
of the double -blind cohort w ill be  conducted after all double -blind cohort patients 
have completed Week 16.  The IA will include review of all safety and selected 
efficacy endpoints and is for internal planning purposes.  The final analysis of the 
double -blind cohort will review all en dpoints (safety, efficacy, and exploratory).  The 
double blind will be maintained for the IA as the results in the summary tables will 
be presented only by treatment group.  
There will be no formal interim analysis of the open -label single -blind cohort.  
A single IA is planned to be conducted in the placebo -controlled 24 -week cohort 
after at least 50% of the subjects (2:1 randomization) have completed 24 weeks of 
treatment .  The IA will include review of safety and selected efficacy endpoints  by 
treatment group. The IA is being conducted for internal planning purposes and the 
study will not be stopped early based on the results of the IA.  Therefore, no formal 
hypothesis testing will occur with no effect on available alpha for the final planned analyses.  The fin al analysis is planned to be conducted after all subjects have 
completed Week 30 .  Results for individual subjects will not be shared with study 
investigators.  
Further details of the IA s and final analyses, including statistical considerations and 
analyses , will be included in the SAP.  
 
 
  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 24 of 125 5 Introduction  
5.1 Background 
5.1.1 Nonalcoholic Steatohepatitis (NASH)  
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease ranging from 
simple steatosis to inflammatory steatohepatitis (NASH). The e stimated g lobal prevalence of 
NASH has risen rapidly in parallel with the dramatic rise in population levels of obesity and 
diabetes, resulting in NAFLD now representing the most common cause of liver disease in the Western world  (Swinburn 2011, C enters for Disease Control US Obesity Trends  2014). 
The prevalence of NASH is estimated to be between 2% and 5% in Western adults, rising to as high as 40 %–50% in the morbidly obese patients with type 2 diabetes (T2D)  (Argo  2009, 
Williams  2011). The histologic criteria for the diagnosis of adult NASH include 
macrovesicular steatosis, hepatocyte ballooning , and mild lobular inflammation  
(Kleiner 2005, Brunt 2009). Portal and periportal fibrosis followed by bridging fibrosis and 
cirrhosis are seen in patients with the progression of NASH. Steatosis may be absent in cases of bridging fibrosis or cirrhosis (“burnt- out NASH ”) and is often misdiagnosed as 
cryptogenic cirrhosis  (Caldwell  2004). The NAFLD Activity S core (NA S) is a validated 
score used to grade disease activity in patients with NAFLD and NASH  (Appendix A ). The 
NAS is the sum of the biopsy's individual scores for steatosis (0–3), lobular inflammation (0-2), hepatocellular ballooning (0–2), and fibrosis (0–4).  Fibrosis staging is assessed using a 
separate scoring system  from the NAS  (Kleiner  2005).  
Most patients with NASH are asymptomatic, although some patients may present with fatigue, malaise, and vague right-upper abdominal discomfort. Patients are more likely to initially be identified by elevated liver aminotran sferases on routine exams or hepatic 
steatosis detected incidentally on abdominal imaging. Patients with NASH often have one or more components of the metabolic syndrome such as obesity, hypertension, dyslipidemia, and insulin resistance or T2D , with NASH considered to be the hepatic manifestation of 
metabolic syndrome ( Torres  2012). Most patients are diagnosed with NASH in their forties  
or fifties . Studies vary with regard to the sex distribution of NASH, with some studies 
suggesting it is more common in women while others suggest it is more common in men (Pan 2014). There appear to be ethnic differences in the prevalence of NASH, with a higher 
prevalence of hepatic steatosis in Hispanics compared with whit es or blacks  (Pan 2014).  
The pathogenesis of NASH and progression to fibrosis /cirrhosis is not yet fully understood, 
despite recent advances in understanding complex metabolic and inflammatory pathways that are likely involved in d isease progression . The most widely supported theory implicates 
insulin resistance as the key mechanism leading to hepatic steatosis and subsequent NASH  
(Cusi 2012). This is likely followed by oxidative injury resulting in the necroinflammatory 
component of NASH  (Cusi 2012). Hepatic iron, antioxidant deficienc y, and intestinal 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 25 of 125 bacteria have all been suggested as potential oxidative stressors ( Cusi 2012). Several other 
factors known to be involved in the progression of NASH include inflammatory cytokines, 
adipokines, lipotoxicity, autophagy, and mitochondrial dysfunction ( Tsochatzis 2009). There 
is also growing evidence of a genetic component for the prog ression of NAFLD to NASH as 
well as fibrogenesis in patients with NASH  (Mehta 2014). 
The natural history of NASH is variable from patient to patient and the NAS does not appear 
to be predictive of disease progression. The presence of fibrosis has been the only highly 
predictive factor of patients who will progress to cirrhosis.  Approximately 10%–20% of 
patients with NAFLD will progress to NASH over a 7- year period  (Argo  2009, Bhala  2013). 
Of these patients, roughly 20% will progress to cirrhosis over a 20- year period  (Bhala 2013). 
A recent meta- analysis of paired biopsy studies in NASH patients demonstrated an annual 
fibrosis progression rate of 0.14 fibros is stages in patients with NASH and 1 stage of 
progression over 7.1 years for patients with NASH  (Singh 2014). The mortality rate of 
patients with NASH has been estimated at 1 %–2% per year in patients with fibrosis, largely 
due to cardiovascular disease followed by liver- related causes ( Kim 2013 ). Patients with 
NASH- related cirrhosis can progress to decompensated liver disease, complications of portal 
hypertension, and hepatocellular carcinoma (HCC) . Recentl y, a growing number of cases of 
HCC in NASH patients have been reported without bridging fibrosis or cirrhosis, suggesting 
an independent pathogenic mechanism in this population ( Paradis 2009 ). NASH is rapidly 
growing as the pri mary cause of end -stage liver disease in the U .S. and European populations 
and is expected to be the primary indication for liver transplantation by 2020 ( Charlton  2011, 
Afzali  2012). 
5.1.2 Treatment of NAS H 
The identification of a single therapeutic target has been complicated by the complexity of the pathogenesis of NASH. The treatment goals for NASH have focused on the prevention or reversal of liver injury either by treating the underlying metabolic and inflammatory 
conditions or through directly targeting fibrogenic pathways. Early -stage disease treatments 
have focused on insulin sensitization, decreasing lipids, and antioxidant activity. The endpoints for these treatments have been both improvements in biochemical parameters and histologic improvement in the components of NAS with no worsening or improvement of fibrosis.  More recently, the resolution of NASH on biopsy has been considered a more 
clinically meaningful treatment endpoint. Antifibrotic agent s have targeted the advanced 
fibrosis and cirrhotic populations but have little activity on the underlying disease causing the chronic hepatic injury.   
Weight loss through lifestyle management is considered the first- line treatment strategy for 
NASH and is  associated with improvement in liver histology  and a reduction in 
cardiovascular and metabolic complications ( Promrat 2010; Glass 2015). However, the 
majority of patients are unsuccessful in achieving or maintaining adequate weight loss and 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 26 of 125 require other interventions.  In cases of morbid obesity, bariatric surgery has been successful 
in reversing the metabolic and hepatic injury associated with NASH  (Cazzo  2014).  Currently , 
no agents have been approved by regulatory authorities for the treatment of NASH ; the 
majority of interventions have utilized agents approved for other indications. However, the 
interpretation of the data with many of these agents has been complicated by the study designs and endpoints. The majority of studies are uncontrolled or retrospective cohorts, have small sample sizes and/or are insufficiently powered, were comprised of heterogeneous 
populations, have treatment durations too short (<12  months) to demonstrate a treatment 
effect , and lack consistent definitions of response. Evaluated agents including metformin, 
fibrates, ursodeoxycholic acid, and orlistat have failed to show a significant histologic benefit 
in NASH ( Torres  2012 ). Pilot studies with PPAR -γ agonists (pioglitazone, rosiglitazone)  
have been  undertaken  based on their effects on insulin resistance, inflammatory signaling , 
and fibrogenesis. Both agents have demonstrated improvements in ALT and steatosis with 
pioglitazone having a marginally bett er anti-inflammatory and anti- fibrotic activity  
(Belfort 2006, Neuschwander -Tetri  2003). Vitamin E has also been evaluated in NASH 
patients based on its antioxidant properties. Small pilot studies have demonstrated histologic 
improvement with daily doses of 400–800 IU ( Harrison  2003 ). The PIVENS trial comparing 
pioglitazone or vitamin E to placebo was the f irst well -controlled study to show an impact on 
steatosis, inflammation, hepatocyte ballooning, and fibrosis , with vitamin E having slightly 
better improvements in fibrosis  (Sanyal  2010). Although a treatment benefit was 
demonstrated in this study, the improvements in fibrosis were modest. Additionally, near- and long- term safety and tolerability concerns were observed with both pioglitazone 
(weight gain, edema, bone fractures, malignancy) and vitamin E (hemorrhagic stroke, inhibition of platelet aggregation, malignancy). More recentl y, the farnesoid X receptor 
(FXR) agonis t obeticholic acid (OCA) was evaluated in the FLINT trial in a population 
similar to that in the PIVENS study with comparable primary and secondary endpoints (Neuschwander -Tetri 2014). OCA demo nstrated results comparable to vitamin E v ersus 
placebo in terms of improvements in NAS and fibrosis wher eas vitamin E and pioglitazone 
demonstrated better results compared to OCA in terms of resolution of NASH . Additionally, 
significant increases in pruritus and lipids (requiring treatment on study) were associated 
with OCA.  Although these agents have demonstrated some histologic improvement in 
NASH, a significant medical need for new effective therapies with favorable safety and 
tolerability  profiles  remains . 
5.1.3 Therapeutic Rationale for NGM282  in NASH  
The pathogenesis of NASH involves complex interactions of insulin resistance, dysregulation of lipid and triglyceride metabolism , and bile acid synthesis that  leads to steatohepatitis and 
fibrogenic activity.  The biologic activity of the fibroblast growth factor 19 (FGF19) can 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 27 of 125 potentially impact all of these mechanisms to a varying degree, supporting the evaluation of 
the therapeutic applications of this pathway for the treatment of NASH.  
FGF19 is  a naturally occurring protein selectively expressed and secreted in the 
gastrointestinal (GI ) tract. Studies have shown that the predominant expression is in the 
ileum with some expression observed in the brain, retina, cartilage, and skin ( Schauer 2003, 
Cummings 2007).  
FGF19 acts as an endocrine hormone to regulate systemic glucose homeostasis and bile acid  
synthesis ( Schauer  2003 ). FGF19 is released postprandiall y from the distal small intestine 
into the circulation and functions as a hormone to govern hepatic glycogen synthesis and gluconeogenesis without stimulation of lipogenesis ( Kir 2011, Potthoff 2011).  In normal 
human subjects, the basal level of systemic FGF19 concentration ranges between 200 and 400 pg/mL ( Lundasen 2006, Stejskal  2008).  Systemic FGF19 levels are decreased in patients 
with T2D  or m etabolic syndrome and are normalized after bariatric surgery in diabetic 
human subjects ( Mingrone 2012).  
In mouse models of diabetes and/or obesity, transgenic or viral- mediated FGF19 expression 
resulted in profound metabolic b enefits (similar to gastric bypass surgery), including the 
rapid resolution of hyperglycemia and hyperinsulinemia ( Xie 1999).  Transgenic mice 
over- expressing FGF19 are resistant to diet -induced obesity and have decreased body fat 
mass and improved insulin sensitivity, glucose disposal, and plasma lipid profiles 
(Tomlinson 2002). Subcutaneous (SC) administration of recombinant FGF19 protein into 
leptin -deficient mutant obese or diet-induced obese (DIO) mi ce results in similar metabolic 
effects ( Fu 2004).
 Similar to insulin, FGF19 stimulates hepatic protein and glycogen 
synthesis but does not induce lipogenesis ( Schauer  2012).  
FGF19 has also been found to be associated with disease progression in NASH. Adult patients with biopsy- proven NAFLD and NASH have decreased serum levels of FGF19 
(Eren  2012, Bechman n 2013). Additionally, decreased FGF19 serum l evels are inversely 
correlated with severity of fibrosis/cirrhosis NASH -related liver disease ( Alisi 2013). 
Although normal intestinal secretion of FGF19 occurs in NASH, hepatic β -klotho expression 
is reduced and hepatic response to FGF19 is impaired, and a correlation exists between 
increased hepatocyte ballooning and increased FGF19 levels ( Schreuder 2010, Wojcik  2012). 
The increased understanding of the role of bile acid s in the pathogenesis of NASH further 
supports the therapeutic potential of FGF19. Nonclinical  models demonstrate a significant 
role of dysregulation of bile acid  synthesis in the pathogenesis of NASH  (Tanaka 2012, 
Jia 2013). Increased bile acid  synthesis as well as serum bile acid  and 
7-alpha-hydroxy-4- cholesten -3-one (C4) concentrations , a key marker of CYP7A1 activity,  
correlate with NASH disease severity and fibrotic activity ( Bechman n 2013). Altered bile 
acid composition has been observed in patients with NASH, with a compensatory transition  
from CYP7A1 -mediated classic pathway (toxic bile acid s) to the less toxic alternative 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 28 of 125 pathway ( Lake  2013). Incre ased h epatic concentrations of bile acids are also associated with 
increased apoptosis, Fas, and TNF- R1 activity resulting in hepatocyte injury and stellate cell 
activation  (Faubion 1999 , Higuchi  2003). A significant correlation also exists between 
increases in specific bile acid s and severity of NASH -related hepatic injury  (Aranha 2008). 
Based on the identified beneficial metabolic and bile acid  synthetic activities of FGF19  in 
animal models, the associated reduction of FGF19 levels with obesity and diabetes in 
patients , the associated increase in plasma levels after gastric bypass in humans, and the 
clinical associations of FGF19 deficiency in NASH patients , the FGF19 biologic pathway 
represents a potentially important therapeutic target for the treatment of NASH.  
NGM282 is a recombinant protein of 190 amino acids with a molecular weight of 21.3 kDa and an amino acid sequence 95.4% identical to that of human FGF19. Extensive in vivo 
structure –activity relationship analyses have been conducted to define and manipulate the 
distinct functional domains in FGF19 protein that are responsible for its metabolic and proliferative features.  More than 160 variants of human FGF19 were engineered, of which 
NGM282 was selected as the clinical candidate based on robust efficacy with no evidence of the proliferative activity previously observed in db/db mice.  
NGM282 effectively mimics the actions of FGF19  on glucose homeostasis as demonstrated 
in a series of in vitro and in vivo pharmacology studies. In vitro, NGM282 binds to the 
extracellular portion of mouse and human FGFR1c–β -klotho co -receptor complexes, with 
high nanomolar affinity ( Study 11- MP-NGM282 -1002).  NGM282 has been shown to 
potently trigger FGFR1c- mediated intracellular signaling in mouse - and human-cultured 
adipocytes ( Study 11- MP-NGM282 -1001
). NGM282 also activates intracellular signaling 
pathways in L6 ce lls transfected with FGFR1c –β-klotho complexes of the mouse, rat, rabbit, 
cynomolgus monkey ( Macaca fascicularis ), or human ( Study 13- MP-NGM282 -1004).  
In vivo, daily administration of NGM282 to ob/ob mice for 14 days resulted in significant 
dose-dependent reductions in the levels of non- fasting blood glucose  
(Study 11- PD-NGM282 -1003).  In DIO m ice, fasted blood glucose levels were significantly 
reduced following a 14- day treatment regimen in response to NGM282 as low as the lowest 
dose tested (0.1 mg/kg) ( Study 11- PD-NGM282 -1004).  NGM282 also effectively mimics the 
actions of FGF19 on bile acid  synthesis through the binding of FGFR4c– β-klotho co- receptor  
(Study 12- MP-NGM282 -1006). Bile acid  homeostasis is regulated through gene expression 
of the CYP7A1 enzyme in hepatocytes by bile -acid–dependent synthesis of FGF15/19 in the 
intestine.  In vitro stud ies have demonstrated that NGM282 binds to human hepatocytes with 
affinity similar to that of FGF19  (Studies  11-MP-NGM282 -1002 and 
13-MP-NGM282 -1005). Additionally, NGM282 specifically inhibits only CY7A1 activity 
without inhibiting other bile -acid–synthetic enzymes (Study 12- MP-NGM282 -1006). In vivo 
studies have shown that systemic administration NGM282 can potently and rapidly suppress 
the expression of the Cy p7a1 gene in db/db m ice (Study 11- PD-NGM282 -1001).  NGM282 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 29 of 125 has demonstrated a dose- dependent decrease of Cyp7a1 levels.  Consistent with reduction in 
Cyp7a1 levels , serum C4 levels were also reduced in the 28 -day monkey toxicology study 
(Study 11- TX-NGM282 -1002) and 26-week toxicology study in monkeys 
(Study 13- TX-NGM282 -1004).  Significant reductions in serum C4 levels w ere also observed 
after administration of NGM28 2 in normal volunteers ( Study 12-0101). 
NGM282 has also been evaluated in two distinct animal models of NASH. Adeno- associated  
virus ( AAV)–mediated delivery of NGM282 transgenes into FXR- deficient mice 
demonstrated improvement in the histologic, biochemical, and fibrogenic biomarkers 
associated with NASH -related hep atic injury  (Study 13- PD-NGM282 -1007). Similarly, AAV 
administration of NGM282 in the STAMTM model of NASH in mice showed a significant 
reduction in steatosis, inflam mation , ballooning, and overall body weight versus placebo 
(data on file ). 
The safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NGM282 have been studied in a blinded, placebo-controlled, single-ascending-dose (SAD)/ multiple -ascendi ng-dose (MAD) study in normal subjects ( Study 12-0101).  NGM282 
or placebo was administered to 119 normal subjects as a daily SC  injection in escalating 
doses of 0.1–30 mg in the SAD module and 0.1–20 mg in the MAD module. Multi ple-dose 
PK were consistent with single -dose PK parameters, with no evidence of drug accumulation. 
NGM282 was safe and well tolerated with no serious adverse events ( SAEs) or clinically 
relevant laboratory abnormalities.  Mild to moderate injection -site reactions (ISRs) were the 
most common drug- related adverse event s (AE s), observed mainly with higher doses and 
larger injection volumes. NGM282 had a favorable safety profile and highly predictable PK 
that support once -daily dosing.  
NGM282 has recently been evaluated in 80 patients with T2D, many of whom have 
presumptive NASH  (Study 13-0102). NGM282 was administered for 28 consecutive days in 
patients randomized into one of the four treatment conditions (NGM282 at doses of 2, 5, or 10 mg; or placebo). Dose -dependent improvement in insulin sensitivity and body weight, as 
well as decreases in triglycerides and ALT , were observed compared to placebo  as well as a 
trend to a decrease in fasting blood glucose and a slight increase in HDL . Total cholesterol 
and low-density lipoprotein ( LDL ) were modestly increased with NGM282 at Day 28. This 
increase appears to represent an acute change at Day 14, followed by a decrease from Day  14 
to Day 28, consistent with a mitigation of this rise over time . C4 was suppressed by > 95% in 
subjects treated with the 2- and 5-mg doses. NGM282 was well tolerated with no SAEs  or 
safety signals observed during the study. Mild to moderate GI symptoms (nausea, loose stools) as well as mild ISRs  were the most freq uently reported AEs, both of which were seen 
more frequently at the higher doses. In general, NGM282 was well tolerated in a population with characteristics similar to those in  patients with NASH.  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 30 of 125 Based on the identified activities in animal models as well  as the PK  and favorable safety  and 
tolerability  profile s in normal volunteers and T2D patients, NGM282 represents a potentially 
important therapeutic option for the treatment of NASH through enhanced FGF19 signaling.  
5.2 Nonclinical Studies  
NGM has completed  a series of in vitro and in vivo nonclinical studies supportive of the 
clinical development of NGM 282 in patients with NASH. Please refer to the I nvestigator’s 
Brochure ( IB) for additional information on these studies. 
5.2.1 Nonclinical Safety Assessment  
The nonclinical safety of NGM282 has been assessed in general toxicity studies in CD -1 
mice and cynomolgus monkeys for up to 26 weeks of treatment and in embryo–fetal toxicity 
studies in CD -1 mice and New Zealand White (NZW) rabbits.  NGM282 was 
pharmacologically active in the mouse and monkey for up to 26 weeks of treatment. 
In the monkey, NGM282 was clinically well tolerated as clinical signs were limited to 
increased hair loss at doses ≥ 0.1 mg /kg and slight reductions in body-weight gain at 1 mg/kg 
at 26 weeks of treatment.  In the mouse, NGM282 produced transient clinical signs (e.g., 
hypoactivity or partial eye closure) at doses ≥ 1 mg /kg that were not dose limiting and 
resolved with continued treatment for up to 26 weeks. In the mouse, microscopic findings 
were limited to the liver (minimal to moderate hepatocellular hypertrophy) that was 
associated with slight increases in albumin , total protein,  and liver weight. These changes 
were not considered adverse and were reversible.  
In the mouse and rabbit, NGM282 did not produce any adverse effects on embryo– fetal 
development at the highest doses tested ( 10 mg /kg). In the rabbit, the 
no-observed-adverse- effect level  (NOAEL ) was 1 mg/kg due to maternal toxicity associated 
with body-weight gain reduction and associat ed reduction in fetal uterine weight at 10 mg/kg. 
Based on the cumulative nonclinical safety profile of NGM282 for up to 26 weeks of 
treatment, the NOAEL s in the mouse and monkey were determined to be 1 and 3 mg /kg, 
respectively.  A sufficient safety margin  exists for NGM282 at the proposed maximal clinical 
dose of 6 mg (0.0864 mg/kg) where estimated exposure is estimated to be 2 - or 14- fold 
below that at the NOAELs in the mouse or monkey, respectively ( see Table  1). 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 31 of 125 Table  1. Estimated Safety Exposure Margin of NGM282  
Nonclinical  
Species  NOAEL  
(mg/kg) a Plasma AUC  
(hr  ng/mL) b Exposure Margin Relative to  
Maximum Human Therapeutic Dose c 
Monkey  1 6610  ̴ 14X 
Mouse  3 1062  ̴ 2X 
AUC = area unde r the concentration –time curve; hr = hour; NOAEL = no -observed -adverse -effect level . 
a Determined from the 6 -month chronic toxicity studies . 
b Systemic exposure at Day 1 after a single dose was used as the most conservative estimate of exposure given 
the p resence of anti -drug antibody formation with repeat dosing in animals leading to drug accumulation 
(plasma AUC 7 -fold above Day 1 levels).  
c Based on a maximal therapeutic dose of 6 mg (0.0864 mg/kg based on a 70 -kg patient) where plasma AUC is 
projected to be 482 hr   ng/mL ( Study 12 -0101 ). 
 
5.3 Clinical Studies  
To date, NGM has completed a Phase 1 clinical study in healthy volunteers and Phase 2 
clinical studies in T2D  and primary biliary cirrhosis  (PBC) supportive of the clinic al 
development of NGM282 in patients with NASH. Additionally, blinded safety data from the ongoing Phase 2 clinical trial in NASH patients are also available to further support the open- label  single-blind cohort. Please refer to the IB for additional detai led information on 
these studies.  
5.4 Rationale for Dose Selection of NGM282 for NASH  
The doses selected for the Phase 2 study are supported by both the nonclinical and clinical data generated to date.  The dose range for the first- in-human Phase 1 clinical tr ial  
(0.1–30 mg) was based on a broad approach to dose calculation considering the pharmacology of FGF19, beyond sole reliance on the NOAEL obtained in the GLP 28-day toxicology program. The dose range also took into consideration safe starting -dose princi ples 
for first- in-human administration as outlined in both FDA and CHMP Guidance. 
Dose -proportional changes in PK parameters were observed with both single and multiple 
dosing in the Phase 1 study, consistent with predictions from animal models. All doses were safe and well tolerated , thus establishing the initial clinical safety of this dose range . 
The proposed doses of 0.3, 1, 3, and 6 mg for evaluation in the double- blind as well as the 
single- blind cohorts are based on a cumulative broad approach to dos e calculation 
considering the pharmacology of FGF19 in NASH, clinical data from normal volunteers and patients with T 2D, and exposure safety margin s obtained in the GLP 26-week toxicology 
progr am relative to the clinical doses proposed.  The proposed doses for both cohorts are 
within the current safety margins in both monkeys and mice ( Table  1). The drug exposure is 
comparable between normal volunteers and T2D patients and, therefore, expected to be comparable in the NASH population. 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 32 of 125 The selection of the 0.3, 1, 3, and 6 mg doses i s further supported by the efficacy, safety , and 
tolerability observed in the T2D study in which NGM282 doses of 2, 5, or 10 mg were 
evaluated . The  T2D study patients represent a population similar to the NASH population 
expected to be enrolled in the NASH Phase 2 study. In patients with T2D, doses >  2 mg are 
associated with greater decreases in body weight, fasting blood glucose, triglycerides, HDL , 
and ALT, all of which are parameters associated with potential therapeutic activity in NASH.  
The subsequent decreases in LDL at Day 28 after initial increases at Day 14 are greater with 
doses >  2 mg . A trend toward increased frequency and severity of GI symptoms and ISRs  in 
patients treated with 10 mg was noted ; therefore , lower doses were selected for tolerability.  
Lastly, bile acid  synthesis as measu red by suppression of C4 levels is greatest at doses of 
3 mg based on the data from the Phase 1 normal volunteer study. Furthermore, C4 was 
suppressed by > 95% in T2D patients treated with the 2- and 5-mg doses of NGM282. Based 
on the above data, the selected doses should allow a balance of optimizing biologic activity versus safety and tolerability in the studied population. 
The selection of the lower  doses (0.3  mg and 1 mg) for study in the open-label single-blind 
cohort was based on the robust results of the double-blind cohort demonstrating comparable 
improvements in the non-invasive markers of NASH at 3 mg and 6 mg, with improved tolerability with the 3 mg dose. Subjects enrolled in the open- label single-blind cohort 
received 0.3 mg or 1 mg for 12 weeks in order to establish a minimally effective dose, based on non- invasive measures of liver fat, inflammation , and fibrosis. Additionally, based on the 
rapidity of the treatment effect demonstrated with 3 mg and 6 mg,  
 
This demonstrated sign ificant 
improvement in both NAS and fibrosis scores with 3  mg for 12 weeks. In order to assess the 
histologic response and utility of 1 mg, a 12-week biopsy dosing group (Group 4) is ongoing.  
The selection of the 1 mg dose for the placebo-controlled 24- week histology cohort is based 
on a comparative evaluation of the histologic response, non- invasive parameters, and safety 
in the previous  cohorts in Study 15-0105. Preliminary data from the first 10 subjects at 
12 weeks from the 1 mg histology dosing group (Group 4) demonstrated comparable changes in non- invasive parameters (MRI -PDFF, LMS and ALT) and histology to the 3 mg histology 
dosing group (Group 3). Additionally, there were no new safety signals observed in either cohort. The 1 mg cohort had fewer inj ection site reactions as well as less persistent GI 
symptoms. Therefore, the 1 mg dose was selected to move forward into the placebo-controlled 24 week histology cohort based on the assessment of comparative risk benefit of the 1 mg and 3 mg doses. 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 33 of 125 5.5 Rationale for the Use of Rosuvastatin for L ipid Management in  
NGM282-t reated Subjects  
NGM282 specifically inhibits CYP7a similar to FGF19 through binding to  
FGFR4 c–β-klotho complexes causing  a potent and rapid suppression of cholesterol 
metabolism and a subsequent decrease in bile acid synthesis. The biologic activity of 
NGM282 is similar to FGF19 and has been shown to cause an increase in serum levels of total cholesterol and LDL-C to a varying degree in cynomolgus monkeys (data on file) as well as in normal volunteers ( Study 12 -0101) and T2D patients ( Study 13-0102).  More recent 
data from the blinded safety review in Study 15-0105 demonstrated similar elevations in 
NASH patients.  The clinical outcomes associated with long- term elevations in LDL -C 
associated with NGM282  are unknown. However, the evaluation of lipid- lowering therapies, 
in particular statins, is warranted given the increased cardiovascular risk associat ed with the 
NASH patient  population. The  ability of statin therapy to mitigate FGF -19–mediated  
increases in LDL -C has been demonstrated in both primate and human studies. Recent data 
from obese insulin- resistant primates demonstrated that the increase in LDL -C levels seen 
with NGM282 was substantially reduced with rosuvastatin to pre -treatment baseline levels 
(data on file).  OCA is an FXR agonist shown to cause increases in LDL -C in NASH patients  
(Neuschwander -Tetri 2014).  The use of statins was demonstrated to be safe and well 
tolerated in this population receiving OCA; in addition, LDL -C levels decreased to near 
baseline. The co -administration of OCA and statins is currently being studied in a 
randomized, double- blinded clinical trial ([STUDY_ID_REMOVED]).  Therefore , the impact of statin 
co-therapy with NGM282- induced LDL -C elevations is warranted.  Rosuvastatin was selected 
for its potency and demonstrated clinical effect on cardiovascular outcomes.  Doses of 20 and 
40 mg will be studied in order to evaluate any dose- dependent differences in activity in 
NGM282 -treated subjects.   
5.6 Rationale for MRI -PDFF,  Assessments
  
Improvements in steatosis have been demonstrated to be a key component of a therapeutic response and resolution of NASH. NGM is util izing a change in total liver fat content of at 
least 5% as measured by magnetic resonance imaging–proton density fat fraction (MRI -PDFF) as a primary efficacy endpoint in the Phase 2 Study 15- 0105 in NASH patients. 
MRI -PDFF has been determined to be more sensitive than histology for detecting changes in 
liver fat content in several natural history and therapeutic trials (Meisamy  2011).  
Additionally, it is non -invasive and provides quantitative estimates of fat content throughout 
the entire liver and is less operator dependent and more sensitive than either ultrasound or CT scan ( Kang  2011, Permutt 2012).  A reduction of at least 5% in absolute liver fat and 29% 
relative reductio n in liver fat was associated with histologic improvements in NASH and is 
currently being utilized in several completed and ongoing clinical studies in NASH (Patel  2016).  The double-blind cohort in Study 15-0105 is measuring change in liver fat by 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 34 of 125 MRI -PDFF at Baseline and Week 12 to assess the primary treatment effect.  Data from T2D 
patients treated with NGM282 who had elevated liver enzymes demonstrated a rapid 
reduction in both liver enzymes and C4 after initiating treatment.  Based on the rapid biologic 
activity observed, an additional on- treatment MRI has been added to the open- label 
single- blind cohort  at Week 6  in order to assess the kinetics of fat loss at mid -treatment.  An 
off-treatment MRI  at Week 18 (EOS)  has been added to this cohort as well in order to assess 
the reversibility of fat loss after stopping therapy.  These effect s will be further assessed over 
an extended duration in the placebo-controlled 24-week histology cohort with MRI- PDFF 
assessments collected at Screeni ng and Weeks 6, 12, 24 (EOT), an d 30 ( EOS) .  
 
 
 The so
ftware uses 
the images of the liver to calculate parameters that have been shown to correlate with histological measures of steatosis, hepatic iron overload , and fibrosis of the liver 
(Banerjee 2014).  Additionally, a Liver Inflammation Fibrosis (LIF) score and corrected cT1 
valueare also calculated , both of which have been correlated to liver histology a s well as 
predicting liver -related outcomes ( Banerjee 2014, Pavlides 2016, Perspectum  Diagnostics, 
data on file ). 
 
 
 There are no current imaging techniques 
that can directly detect the specific stage of fibrosis. Most at tempt to detect fibrosis indirectly 
using proposed biomarkers which include: stiffness, diffusion, perfusion, metabolites, and 
image texture with the leading biomarker being liver stiffness ( Younossi 2017).  
 
 
 
 
5.7 Rationale for a Liver Biopsy at Week s 12 or 24  
Liver biopsy remains the gold standard for assessing treatment effect in NASH patients, as measu red by a resolution of steatohepatitis and/or an improvement in fibrosis.  However, 
several non- invasive imaging technologies and biochemical markers have also correlated 
with improvements in liver histology. MRI -PDFF is a highly sensitive measure of steatosis 
with decreases in absolute and relative liver fat of 4.1% and 29.3%, respectively, correlating to > 2 point improvement in NAS after 24 weeks of ezetimibe ( Patel  2016 ). On -treatment 
decline in ALT was associated with the resol ution of NASH and no worsening of fibrosis in 
patients treated with elafibranor for 52 weeks (Ratziu  2016a ). Similarly, a decrease in 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 35 of 125 triglycerides correlated with resolution of NASH after 96 weeks of pioglitazone or vitamin E  
(Corey  2015 ). Increased classic- pathway bile acid  synthesis is associated with increased 
NASH severity and fibrosis ( Bechmann  2013; Lake  2013).  Decreases in bile acid  synthesi s, 
as measured by C4 levels, is observed with FGF19 activity seen with NGM282 and other 
investigational therapies ( Marschall  2012, Djed jos 2016).   
NGM282 was studied in 81 patients with type 2 diabe tes (many with presumptive NASH) for 
28 days at doses of 2, 5, or 10 mg versus placebo ( Study 13-0102).  Rapid and 
dose-dependent improvements in ALT, triglycerides, and C4 were observed compared to placebo, supportive of furthe r evaluation in NASH. An analysis of the double-blind cohort of 
Study 15-0105 was performed on 43 subjects completing 12 weeks of treatment (Harrison  2017). Significant reductions in both absolute and relative liver fat were observed 
after on ly 12 weeks compared to placebo, with the majority of subjects normalizing liver fat 
content. ALT levels also declined rapidly, with significant reductions observed as soon as Week 2 and over 50% of subjects normalizing ALT by Week 12. S ignificant reductions of 
ALT, C4 , and other key biochemical parameters associated with histologic response were 
also observed in NGM282- treated patients.  In addition to the results of the non-invasive 
efficacy data, 12 -week histology has also been evaluate d in the 3-mg cohort using the 
FDA-accepted endpoints. Preliminary 12 -week histologic response data demonstrated 50% 
of subjects had a 1 -stage improvement in fibrosis with no worsening of NASH or resolution 
of NASH with no worsening of fibrosis. Histology assessments will be conducted at 
Week 12 in the open- label single -blind dosing Groups 3 and 4 and at Week 24 in the 
placebo -controlled 24-week histology cohort. The clinical data from these cohorts will 
provide information on the long- term safety and efficacy (histological and noninvasive) of 
NGM282 and support the late- stage development of NGM282 for treatment of NASH with 
fibrosis.  
Although there are currently no approved therapies for the treatment of NASH, several late-stage compounds have demonstrated modest improvements in the resolution of NASH 
and/or fibrosis as well as decreases in key markers that correlat e with these histologic 
changes. However, the treatment duration to achieve these changes is 24–72 weeks (Sanyal 2010, Neuschwander -Tetri  2014, Patel  2016, Ratziu  2016b, Sanyal 2016, 
Loomba 2016).  The changes in MRI -PDFF, A LT, triglycerides , and C4 are significantly 
more rapid and of a greater magnitude by Week 12 versus other therapies for longer treatment periods . Therefore, early changes in histology may be observed supporting an early 
time-point for post- treatment liver histology assessment.  
The primary objective of this additional histologic assessment in dosing Groups 3 or 4 of the open- label single -blind cohort and the placebo -controlled 24-week histology cohort is to 
evaluate if the rapid changes in steatosis and bio markers consistent with the resolution of 
observed NASH translate s to similar clinically meaningful changes in liver histopathology. 
Additional correlative analyses will be performed between liver histology and the various 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 36 of 125 liver imaging studies and exploratory serum biomarkers collected during the study. The 
results of these data will be used to support the development of non-invasive tools for monitoring treatment.  Additionally, these results may also be useful for predicting early 
response and stopping rules.  
6 Study Objectives  
The objectives of this study are as follows: 
Primary Objective:  
• Evaluate the treatment effect of NGM282 on absolute liver fat content as measured 
by MRI- PDFF in patients with histologically confirmed NASH. 
 
Secondary Objectives:  
• Assess the safety and tolerability of NGM282 in patients with NASH with up to 
24 weeks of treatment with NGM282. 
• Evaluate the percentage change in absolute liver fat content at  End of Treatment 
EOT . 
o In the open-label single-blind cohort, additional evaluations will be performed at 6 and 18 weeks. 
o In the placebo-controlled 24-week histology cohort, additional evaluations will be performed at 6, 24, and 30 weeks. 
• Evaluate the percentage of normalization for liver fat content at EOT . 
• Evaluate the change in liver fat content response rate as defined by a ≥ 5% decrease 
in absolute liver fat content.  
• Evaluate the absolute and percentage changes from Baseline to EOT as well as the 
percentage of normalization of the following parameters: ALT, AST, triglycerides, 
biliru bin (total and direct), and GGT. Percentage of normalization will also be 
investigated for a clinically meaningful threshold for triglycerides. 
• Evaluate the absolute and percentage changes from Baseline to EOT  of the following 
(if collected as part of the cohort
): 
o Total cholesterol, HDL -cholesterol (HDL -C), LDL -cholesterol (LDL -C), 
triglycerides, and lipoprotein particles  
 In addition, evaluate the absolute and percentage change from Baseline to EOS of the above lipid parameters in the open- label single -blind 
cohort. 
o  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 37 of 125 o Fasting blood glucose, insulin levels,  
, and homeostasis model assessment –estimated insulin resistance 
(HOMA- IR) 
o Pro-C3 and ELF score (Placebo Controlled 24 Week Histology Cohor t) 
o Body weight, body mass index (BMI), and waist circumference 
o C4 and serum bile acids  
o Bile-mediated absorption as measured by vitamin D, International Normalized 
Ratio (INR), and fecal fat content  
 
• Evaluate the liver histologic response  in Placebo Control led 24 Week Histology Cohort  
o Improvement in liver fibrosis by ≥ 1 stage by NASH Clinical Research Network 
(CRN) criteria with no worsening of steatohepatitis  
o Resolution of NASH (defined as an NAS score of 0 or 1 for inflammation and 0 for ballooning) with no worsening of fibrosis as determined by the NASH CRN criteria.   
• Evaluate the exposure of NGM282 in patients with NASH .  
o In the double- blind and placebo -controlled 24-week histology cohorts, 
NGM282 exposure will be compared to placebo at 2 hours post-dos e at Day 1 
and EOT  and pre-dose at all on-treatment study visits. 
o In the open-label single-blind cohort, NGM282 exposure will be evaluated  at 
2 hours post-dose at Day 1 and EOT  and pre-dose at all on- treatment study 
visits.  Additional PK samples will be co llected at Baseline and 1, 2, 4, 8, and 
12 hours post-dose on Day 1 and Week 6 in a subset of subjects in each 
dosing group. 
o Exposure of all doses from all cohorts will be compared to each other as well as to exposure in other study populations treated with NGM282 (Studies 12-0101, 13-0102, 13-0103, 14-0104, and 15-0106).  
• Evaluate the efficacy and safety  of rosuvastatin administered in response to increases 
in total cholesterol and LDL -C from NGM282 treatment (open- label single -blind and 
placebo -controlled 24-week histology cohorts only).  
• Compare the dose- related changes in the safety, tolerability, PK, and PD pa rameters 
within and across the double-blind and open- label single -blind cohorts. 
 
Exploratory Objectives  
The exploratory objectives of this study are: 
•   
  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 39 of 125 requested to undergo MRI performed during Screening and at Week 1 (EOT) Early 
Withdrawal visit.  
In the open- label single -blind cohort, up to 100 patients (25 per dosing group) will be 
enrolled from ~6 –8 U.S. sites.  Subjects will be required to meet enrollment criteria similar to 
those of the double-blind cohort with the exception of the following, speci fically defined in 
protocol Section  8.1.2: 1)  historical biopsy window extended to 12 months; 2) limitations on 
the use of glucagon- like peptide -1 (GLP1) agonists; 3) glycated hemoglobin (HbA1c) level 
≤ 9.5%; 4) LDL levels at Screening need to be ≤  165 mg/dL; 5) exclusion of specific 
lipid-lowering therapies prior to and during study period; 6) no contraindications to receiving 
statins.  The single -blind cohort is not randomized. At Day 1 eligible patients will be 
sequentially enrolled into the study and categorized as either statin -naïve versus statin 
experienced  with no more than 8 statin experienced subjects within each dosing group. 
Subjects will be enrolled sequentially initially into the dosing Group 1 and enrollment will be continuous within the dosing group. Sequencing of the subsequent 2 dosing groups will be based on PD and safety parameters from dosing Group 1. The subsequent 2 dosing groups may run in parallel. A fourth optional dosing group may be conducted based on the safety/tolerability, imaging data , and histology (dosing Group 3 only) data from the prior 
3 dosing groups. Dosing group sequence and individual subject treatment assignment will be blinded only to the study subjects throughout the study period. 
The first dose of NGM282 (Day 1) and doses at the Week s 2, 4, 6, 8, and 12 study visits will 
be self -administered in the clinic, with all other doses throughout the treatment period 
self-administered at home.  Self-administration of NGM282 should occur in the morning for 
every dose in both the clinic and at home. Subjects will return to the clinic on Weeks 2, 4, 6, 
and 8 for on- treatment assessments and to receive weekly NGM282 study -drug kits. LDL -C 
will be evaluated at Weeks 2, 4, and 8 i n all subjects for possible increases in lipid levels 
associated with NGM282 administration. Rosuvastatin will be started in subjects meeting specific LDL -C level criteria.  The specific dosing and administration of rosuvastatin will be 
based on whether the subject is statin naïve versus statin experienced  and LDL -C levels at 
Weeks 2, 4, and 8. The dosing algorithms are specifically outlined in Section  10.4 of the 
study protocol. Bottles of rosuvastatin tablets will be dispensed at Weeks 2, 4, and 8, depending on observed lipid levels and dosing algorithm in Section  10.4. Week  12 will be 
the EOT clinic visit and subjects will return to the clinic at Week 18 (or 6  weeks after last 
dose) for an EOS follow-up visit. Subjects are required to undergo MRI performed during Screening and at Weeks 6, 12 (EOT)/Early W ithdrawal, and 18 (EOS) visits.  
Dosing Groups 3 or 4 will have two other assessments performed to assess liver histology in addition to MRI -PDFF.  LiverMultiScan
TM will be performed during the MRI assessments at 
the same time as the MRI -PDFF assessments (Screening and Weeks 6, 12, and 18). 
An additional post-treatment liver biopsy will be performed at Week 12. The purpose of this 
biopsy is to assess early changes in liver histopathology (including changes in the NAS, 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 40 of 125 resolution of NASH, and changes in fibros is) and compare and correlate to the liver imaging 
studies and key serum biomarkers collected during the study. The historical liver biopsy 
window for this subset of subjects will be 3 months prior to Screening. Subject s who wish to 
participate in the stud y but do not agree to the second biopsy will be allowed to Screen and 
enroll for other dosing groups if still open and they meet enrollment criteria. Dosing Group 4 will be initiated only after all subjects in Cohort 3 have been enrolled and a minimum of 10 subjects have completed 12 weeks of treatment in order to do a preliminary review of key data.  
In the placebo -controlled 24-week histology cohort , up to 75 subjects (50 active at a single 
dose of NGM282; 25 placebo) will be enrolled from ~10 U.S. sites and treated for 24 weeks 
with a 6 -week safety follow-up. Subjects will be required to meet enrollment criteria similar 
to those of the open- label single-blind cohort as specifically defined in protocol Section  8.1.1 
with the exception of the following: 1) only subjects with Stages 2 and 3 fibrosis at Screening 
will be enrolled.  At Day 1 eligible subjects will be randomized into the study and stratified as 
either fibrosis stage 2 or 3.  The dose of NGM282 to be studied will be 1 mg based on comparative evaluation of the safety, non- invasive efficacy parameters, and histology from 
the completed 3 mg 12-week histology dosing group (Group 3) and preliminary data from a subset of subjects from  the ongoing 1 mg 12-week histology dosing group (Group 4) in the 
open- label single -blind cohort. The active dose selection for this cohort will be blinded to the 
study site and subject s throughout the study period. 
The first dose of NGM282 (Day 1) and doses at Weeks 2, 4, 6, 8, 12, 18, and 24 study visits will be self -administered in the clinic, with all other doses throughout the treatment period 
self-administered at home.  Self-administration of NGM282 or placebo should occur as close 
as possible to the same time each day for every dose.  Subjects will return to the clinic on Weeks 2, 4, 6, 8, 12, 18 and 24 for on- treatment assessments and to be dispensed NGM282  
or placebo study-drug kits through Week 18.  LDL -C (LDL -direct may be used if LDL- C 
was not able to be analyzed) will be evaluated at Weeks 2, 4, 8, and 12 in all subjects for possible increases in lipid levels associated with NGM282 or placebo administration.  
Rosuvastatin will be started in subjects meeting specific LDL -C level criteria.  The specific 
dosing and administration of rosuvastatin will be based on whether the subject is statin naïve versus statin experienced and LDL-C levels at Weeks 2, 4, and 8. A decision about possible second -line lipid -lowering therapy with ezetimibe will be made on a case by case basis for 
subjects that have not achieved an adequate response or are unable to tolerate rosuvastatin.  Bottles of rosuvastatin tablets will be dispensed to all subjects initially and instructions to initiate dosing are dependent on observed lipid levels according to the dosing algorithm in Section  10.4 . Week  24 will be the EOT clinic visit and subjects will return to the clinic at 
Week 30 (or 6  weeks after last dose) for an EOS follow -up visit. Subjects are required to 
undergo MRI performed during Screening and at Weeks 6, 12, 24 (EOT)/Early Withdrawal, and 30 (EOS) visits. 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 41 of 125 This cohort will have two other assessments performed to assess liver  histology in addition to 
MRI -PDFF.    
 An addi
tional 
post- treatment liver biopsy will be performed at Week 24.  The purpose of this biopsy is to 
assess changes in liver histopathology (including changes in the NAS, resolution of NASH, 
and changes in fibrosis) and compare and correlate to the liver imaging studies and key serum biomarkers collected during the study. 
7.1 Study- Stop Criteria  
The entire study or a single dosing arm may be discontinued or not initiated at the discretion 
of the Sponsor based on the occurrence of the following: 
• AEs with respect to their nature, frequ ency, severity, and/or duration 
• Medical or ethica l reasons affecting the con tinued performance of the study 
• Difficulties in the recruitment of patients 
• Cancellation of drug development 
The entire study will be discontinued by the sponsor if there are three  or more related 
Grade  3 or Grade 4 treatment -emergent adverse events (TEAEs) of the same Common 
Terminology Criteria for Adverse Events (CTCAE) category.  
8 Enrollment Criteria 
8.1 Double -blind, Open- label Single -blind and Placebo -controlled 
24 Week Histology Cohorts  
8.1.1 Inclusion Criteria  
Patients who meet the fo llowing criteria may be included in the study: 
1.   Males and females between 18 and 75 years of ag e (except self -identified of Asian 
descent), able to comprehend and willing to sign an Informed Consent Form (ICF). 
2. Histologically confirmed NASH diagnosis  as defined by the NIH NASH Clinical 
Research Network (see Appendix A , Kleiner  2005) and liver biopsy criteria outlined 
below.  A historical biopsy is acceptable if performed within the required time period 
and tissue slides are available for a qualified pathology read.  
Double-B lind Cohort: 
a. NAS of at least 4 with 1 point in each component  
b. Histologic evidence of fibrosis  without cirrhosis  
i.  Fibrosis s tage 1 -3  
c. Liver biopsy within 6 months of Screening.  
Open -Label Single Blind  Cohort: 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 42 of 125 a. NAS of at least 4 with 1 point in each component 
b. Histologic evidence of fibrosis  without cirrhosis  
i. Fibrosis stage 1-3  
c. Liver biopsy within  12 months of Screening.  
i. Dosing Groups 3 or 4 must have a liver biopsy within 3 months of 
Screening in order to serve as the baseline comparison for the 
additional EOT biopsy. 
Placebo -Controlled 24 Week Histology Cohort:  
a. NAS of at least 4 with 1 point in each component 
b. Histologic evidence of fibrosis without cirrhosis  
i. Fibrosis s tage 2-3  
c. Liver biopsy within 3 months of S creening in order to serve as the baseline 
comparison for the additional EOT biopsy. 
3. Total liver fat content of ≥  8% as measured by MRI -PDFF ( MRI may be used for up to 
8 weeks from the date of the original scan , including use for re-screen ed subjects ) 
4. Insulin -resistant or stable T2D   
Double-Blind Cohort: 
a. Stable T2D  is defined as HbA1c ≤  8.5% at Screening. 
b. Diabetes m edications: require  a stable regimen  for at least 3 months prior to 
Day 1  and throughout the study. 
c. Insulin resistance will be based on fasting insulin level ≥ 10uIU/mL. 
Open -Label Single Blind: 
a. Stable T 2D is defined as HbA1c ≤ 9.5%  at Screening. 
b. Diabetes medications (except GLP1 agonists):  require a stable regimen  for at 
least 3 months prior to Day 1 and throughout the study.  
c. GLP1 agonists: require  a stable regimen  for at least 12 months prior to Day 1 
and throughout study 
d. Insulin resistance will be base d on fasting insulin level ≥10uIU/mL. 
Placebo -Controlled 24 Week Histology Cohort:  
Patients with T2D or insulin resistance will be allowed to enroll under the following 
conditions listed below and patients who do not have T2D or insulin resistance can be 
enrolled as long as all othe r criteria are met. 
 
a. HbA1c ≤ 9.0 % at Screening  
b. Patients taking diabetes medications (except GLP1 agonists) require a “stable” 
regimen for at least 3 months prior to Day 1  and throughout study.  
i. GLP1 agonists  and pioglitazone : require a stable regimen for at least 
12 months prior to Day 1 and throughout the study.  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 43 of 125 ii. Stable insulin dosing is defined as reasonable dosage adjustments to 
maintain glucose control. 
5. Other therapies  for NAFLD or NASH: requires a stable regimen for at least 3 months 
prior to the  Screening biopsy of record and throughout the study. May include vitamin 
E, milk thistle, thiazolid inediones and pentoxifylline.  
Double- Blind  Cohort: 
Includes statins.  
Open -Label Single Blind  and Placebo Controlled 24 Week Histology Cohorts : 
Includes statins if  the conditions below are met.  Other therapies may include 
vitamin E  (> 800 IU Placebo cohort only), milk thistle, thiazolidinediones (open-
label, single -blind only) or pentoxifylline.   
a. Patient can be defined as  statin naïve or experienced at Screening ba sed on 
the following definitions : 
i. Statin -naïve : no administration of statins within 3 months prior to 
enrollment. 
ii. Statin experienced : administration of < 50% of the maximal dose 
of current statin therapy. 
b. Requires a stable regimen for at least 3 months pri or to Screening through 
Week 2. 
The following are the acceptable daily doses of approved statin therapies, including 
combination preparations of statins and other lipid lowering agents.  Also listed under Concomitant Medications in  Section  9.7.  
• Atorvastatin: < 40 mg/d 
• Fluvastatin: < 40 mg/d 
• Lovastatin: < 40 mg/d (immediate release), < 30 mg/d (extended release) 
• Pitavastatin: < 2 mg/d 
• Pravastatin: < 40 mg/d 
• Rosuvastatin: < 20 mg/d (Note: must be < not < 20 mg/d)  
• Simvastatin: < 40 mg/d 
6. The following liver enzyme parameters must be met at Screening:  
a. ALT and AST < 250 IU/L  
b. Abnormal ALT  defined as : ≥ 30 IU in males and ≥ 19 IU in females 
d. AST  ≥ 30 IU/L except for  patients with a historical biopsy within 3 months of 
screening with NAS of at least 4 with 1 point in each component and fibrosis stage 2 or 3 (Placebo -Controlled Cohort only) 
 
7. The following additional laboratory parameters must also be met at Screening: 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 44 of 125 a. Total bilirubin must be within normal range.  For patients diagnosed with 
Gibert’s Syndrome, please contact medical monitor/designee 
b. INR ≤  1.3 (in the absence of warfarin or other anticoagulant therapy) 
c. Creatinine clearance ≥  90 mL/min as calculated by Cock croft-Gault equation  
d. Alpha fetoprotein (AFP)  < 100 ng/mL 
e. LDL C ≤ 185 mg/dL (except Double- blind cohort  and ≤ 165 mg/dL for the 
Open -Label Single Blind  ) 
f. LDL -C must also be ≥  50 mg/dL for statin naïve  patients ( Placebo cohort 
only) 
g. Platelet count must be within normal limits  150-450 K/uL (Placebo -
Controlled Cohort only)  
8. Female patient s must be of non-childbearing potential defined as women  who have had 
a hysterectomy, bilateral oophorectomy, medically documented ovarian failure, or are documented postmenopausal (follicle stimulating hormone > 40  mIU/mL) . 
9. Female patients of childbearing potential defined as including women < 55 years of age 
with 2 years of amenorrhea (absence of menstruation) must have a negative serum pregnancy test at Screening and urine pregnancy test at the Day  1 visit prior to dosing. 
10. Female patients of childbearing potential and male patients with a female partner of childbearing potential must agree to consistent and adequate birth control from 
Screening to 30 days after the last dose of study medication.  
One of the following forms of contraception is required and male patients must also use 
a condom. 
a. Hormone -containing contraceptive  
b. Intrauterine device with a failure rate < 1% per year 
c. Cervical cap or diaphragm with spermicidal agent 
d. Sterilization  (tubal ligation or vasectomy) 
11. Able and willing to comply with the dosing instructions for study- drug administration 
and abl e to complete the study schedule of assessments.  
8.1.2 Exclusion Criteria  
The following criteria will exclude patient s from the study: 
1. Clinically significant acute or chronic  liver disease of a n etiology other than  NASH  
2. Evidence of drug-induced steatohepatitis secondary to amiodarone, corticosteroids, estrogens, methotrexate, tetracycline, or other medications known to cause hepatic steatosis  
3. History or presence of  cirrhosis  (compensated or decompensated)  as determined by  
histology, relevant medical complication s, and/or laboratory parameters  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 45 of 125 4. Prior liver transplantation  
5. Any acute cardiovascular event (e.g. myocardial infarction, stroke, severe arrhythmia or 
hospitalization for any cardiac related event) or evidence of active cardiovascular 
disease within 6  months of Screening 
6. History of bypass or bariatric surgery or planned procedure during the study period.  Removal of a gastric balloon or lap band is permitted if surgery performed within 6 months prior to Day 1. 
7. Type 1 diabetes  
8. History of clinically significan t unstable or untreated  illness or any other major medical 
disorder that may interfere with patient  treatment, assessment, or compliance with the 
protocol 
9. Any contraindication or inability to obtain an MRI   
10. Inability to obtain or any contraindication to li ver biopsy (if a historical biopsy with 
viable tissue slides are not available within the required time period ) 
11. Screening ECG with clinically significant abnormalities as determined by the Investigator 
12. Positive for HBsAg, anti-HIV, or anti -HCV plus HCV -RNA. Patients who are 
anti-HCV positive but HCV-RNA negative (secondary to treatment or viral clearance) 
are eligible as long as there is evidence of viral negativity for a minimum of 12 weeks.  
13. History of malignancy diagnosed or treated within 2 years (recen t localized treatment of 
squamous or non- invasive basal cell skin cancers is permitted; cervical carcinoma in 
situ is allowed if appropriately treated prior to S creen ing); patients under evaluation for 
malignancy are not eligible. 
14. Clinically -relevant drug or alcohol abuse within 12 months of screening. A positive 
drug screen will exclude patients unless it can be explained by a prescribed medication; the diagnosis and prescription must be approved and documented as such by the Investigator. 
15. Use of any prohi bited concomitant medications as described in  Section  9.7 prior to 
Day1. 
16. Prior participation in a clinical trial of NGM282  
Double Blind Cohort :  
Prior participat ion in a clinical trial of NGM282 is excluded . 
Open Label Single Blind  and Placebo Controlled 24 Week Histology Cohorts : 
Prior participation  in a clini cal trial of NGM282 is excluded  unless previously 
enrolled into a placebo arm of the trial.  
17. Patient  with severe al lergic or anaphylactic reactions to recombinant therapeutic 
proteins, fusion proteins, or chimeric, human, or humanized antibodies. 
18. Participation in a study of another investigational agent within 28  days or five half- lives 
of the drug (whichever is longer ) prior to Screening  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 46 of 125 19. Any acute or chronic condition that, in the opinion of the Investigator, would limit the 
patient’s ability to complete and/or participate in this clinical study . 
20. Pregnancy or lactation 
21. Use of ezetimibe, colesevelam, cholestyramine, niacin, PCSK9 inhibitors, or other lipid-lowering agents within 3 months of Screening (except Double -blind cohort).  
Placebo -Controlled 24 Week Histology Cohort Only 
Use of any other lipid lowering agents or combination preparation of statins except ezetimibe when approved by MM/designee as second line lipid management therapy, within 3 months of Screening and throughout study 
a. colesevelam, cholestyramine, niacin, PCSK9 inhibitors (evolocumab or alirocumab), colestid, fibrates, fenofibrates, pharmacologic/prescribed fish oil 
22. History or presence of ALT elevations  or significant side effects indicative of statin 
intolerance (exc ept Double- blind  cohort). 
23. Use of weight loss medications including: orlistat, phentermine, topiramate, qsymia, lorcaserin hydrochloride, naltrexone hydrochloride, liraglutide  (use is for weight loss 
not T2D, e.g. Saxenda
), benzphentamine, diethylpropion and phendimetrazine, within 
3 months of screening and throughout study 
 
Additionally  for all cohorts, the Investigator has discretion to re peat assessments if he/she 
believes there is a good chance the results were spurious and do not accurately represent the patient’s true values.  Repeat assessments must be conducted within the Screening Period. 
8.2 Discontinuation  of Study Treatment  for an Indi vidual Subject  
Study treatment will be discontinued if any of the following CTCAE categories are observed : 
• Any related G rade 3 TEAE  
• Any Grade 4 or higher TEAE 
Additionally, subject s will be evaluated for possible discontinuation if the following changes 
in liver- related laboratory parameters are observed:  
• Elevation of ALT > 2x above subject- specific baseline value (calculated using the 
median of the Screening and Day 1 value) and total bilirubin > 2x ULN: 
o ALT, AST , and total bilirubin must be re- tested with in 72 hours.  
o Subject s with persistent elevations above the defined thresholds should be 
evaluated for discontinuation of study drug(s), independent of whether they are symptomatic or not. 
• Elevation of only ALT > 2x above subject -specific baseline:  
o ALT, A ST, and total bilirubin must be re -tested within 72 hours.  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 47 of 125 o Subject s with persistent elevations above the defined thresholds who are 
symptomatic  should be evaluated for discontinuation of study drug(s). 
o Subjects with persistent elevations above the defined thresholds who are 
asymptomatic  may continue treatment under protocol-defined close 
observation criteria . 
o Subject s continuing treatment under close observation should implement 
study procedures and assessments as part of the study conduct: 1. Repeat liver en zyme and serum bilirubin te sts two or three times weekly. 
The f requency of retesting can decrease to once a week or less if 
abnormalities stabilize or the trial drug has been discontinued and the subject is asymptomatic.   
2. Repeat additional tests to evaluate liver synthetic function (e.g., INR, direct bilirubin) as appropriate.  
3. Obtain a detailed history of symptoms and prior or concurrent diseases.  
4. Obtain  a history of concomitant drug use (including nonprescription 
medications and herbal and dietary suppleme nt preparations), alcohol use, 
recreational drug use, environmental toxin exposure , and special diets.  
5. Rule out acute viral hepatitis and other acute or chronic hepatobiliary diseases. 
For the double-blind cohort, dose reductions will be allowed on a case by case basis for 
subjects receiving 6 mg or matched 6 mg placebo  for safety or tolerability , but must be 
approved by the Medical Monitor. If approved, the subject will be decreased to 3 mg  or the 
matched 3 mg placebo to be aligned with whether they were initially receiving active drug or placebo prior to the dose reduction. Subjects receiving 3 mg  or matched 3 mg placebo will 
not be allowed to dose-reduce during the study period. 
For the open- label single -blind cohort, no dose reductions will be allowed.  
For the placebo-controlled 24- week histology cohort  no dose reductions  will be allowed . 
Additionally, ALT, AST, and all lipid la boratory results are blinded starting with  Week 2 
onward.  The Medical Monitor will be reviewing and monitoring all laboratory results and if any of the liver related testing parameters are observed, investigators will be notified immediately to discuss further evaluation.  
8.3 Discontinuation  of Subjects  from Study Participation 
Subject s will be informed that they are free to withdraw from the study at any time and for 
any reason. The Principal Investigator (PI) may remove a subject  from the study if, in the 
PI’s opinion, it is not in the best interest of the subject  to continue the study. Subject s may be 
discontinued due to a change in compliance with an inclusion/exclusion criterion that is clinically relevant and affects subject safety, occurrence of AEs, occurrence of pregnancy, or 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 48 of 125 administration of non- permitted concomitant medication that might affect subject safety or 
study assessments/objectives.  Notification of discontinuation will be made immediately to 
the Sponsor’s Medical Monitor. In case of premature discontinuation of study participation, 
efforts will be made to perform all final EOT and EOS visits/assessments.  The date the 
subject is withdrawn from the study and the reason for discontinuation will be recorded on the subject’s Case Report F orm (CRF).  All withdrawn subjects will be followed until 
resolution of any AEs or until any unresolved AEs are judged by the PI to have s tabilized.  
9 Study Methods  
9.1 Schedule of Study Procedures  for D ouble -blind Cohort  
The Schedule of Study Procedures for the double-blind cohort is shown in Table  2. The visits 
should occur as close to the intended dates as possible.  However, there is an acceptable 
± 3 day window for individual scheduled visits. Subjects attending any visits out of windows 
from Day 1 to Week 12/Early Withdrawal (EOT) visit should be brought back into compliance with the overall study- visit schedule as soon as possible thereafter.  Subjects will 
then return to the clinic at Week 16 (or 4 weeks after last dose) for an EOS follow-up visit. 
The Investigator has discretion to repeat assessments if he/she believes the results do not 
accurately represent the patient’s true values.  Repeat assessments must be conducted within 
the 4- week  (±5 days) Screening Period. 
 
  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 49 of 125 Table  2. Schedule of Study Procedures  for Double -Blind Cohort  
Study Procedure  Days –28 to – 1 
(Screening) a Day 1 Wk 1  Wk 2  Wk 4  Wk 8  Wk 12 (EOT)/ 
EW Wk 16 
(EOS)  
Informed consent X        
Demographics  X        
Medical history  X        
Inclusion/exclusion criteria  X X       
Height X        
Body weight , BMI, waist 
circumference  X X     X X 
Physical exam  X X   X X X X X 
12-lead ECG  X X  X   X X 
Vital signs  X X X X X X X X 
Liver biopsy  b (or tissue slides)  X        
MRI c X      X  
Prior and concomitant 
medications  X X X X X X X X 
Randomization   X       
Study drug self- administration 
training  X X X X    
Dispense study drug  X X X X X   
Medication compliance    X X X X X  
Adverse event (AE) evaluations    X X X X X X X 
LISSA evaluations  d  X X X X X X X 
PK blood samples e  X X X X X X X 
Chemistry [fasted ≥ 10 hours]  X X X X X X X X 
Complete blood count (CBC)  X X X X X X X X 
Urinalysis  (UA) X X   X  X X 
Fasting lipid panel   X   X  X  
Lipoprotein particles   X     X  
         
HbA1c X X     X  
Insulin level  and HOMA- IR X X     X  
Stool sample   X     X  
Hepatitis an d HIV screen  X        
Urine drug screen X        
 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 51 of 125 9.2 Study Visit Pr ocedures for Double -blind cohort  
9.2.1 Day –28 to Day –1 (Screening) Procedures  
Subject s will report to this visit fasted.  The following screening procedures will be performed 
for all potential subject s at a visit (or visits) conducted within 28 days prior to dosing: 
• Obtain informed consent. 
• Collect demographic data. 
• Ascertain medical history . 
• Assess inclusion/exclusion criteria. 
• Measure height . 
• Measure body weight , BMI , and waist circumference. 
• Conduct physical examination.  
• Obtain 12- lead ECG (after subject has been supine for at least 5  minutes). 
• Measure vital signs (incl uding temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Obtain MRI (prior to any histologic evaluation ). 
• Obtain viable tissue slides from eligible historical liver biopsy or undergo a liver biopsy 
procedure to obtain new tissue. 
• Record prior and concomitant medications. 
• Obtain 10- hour fasted clinical laboratory s amples for the following:  
• Chemistry  
• Complete blood count (CBC) 
• HbA1c 
• Insulin  
• HOMA- IR calculation  
• INR 
• AFP 
• Serum pregnancy test (all female subject s) 
• Obtain clinical laboratory samples for HIV antibody and hepatitis screen. 
• Obtain urine samples for the following: 
• Urinalysis (UA) 
• Selected drugs of abuse 
9.2.2 Day 1 Procedures 
Subject s will report to this visit fasted.  The Day 1 visit should be a minimum of 14 days from 
the Screening visit in order to allow for adequate separation of the repeated Chemistry (liver 
function tests) and INR assessments.  The following procedures will be performed at the 
Day 1 Visit:  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 52 of 125 Pre-dose: 
• Reassess inclusion/exclusion criteria. 
• Measure body weight, BMI, and waist circumference. 
• Conduct physical examination. 
• Obtain 12- lead ECG (after su bject  has been supine for at least 5  minutes). 
• Measure vital signs (including  temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Record concomitant medications. 
• Record AE s. 
• Obtain 10- hour fasted clinical laboratory samples  for the following:  
• Chemistry  
• CBC  
• Lipid panel  
• Lipo protein particles  
•  
• HbA1c 
• Insulin  
• HOMA- IR calculation  
• C4 and serum bile acid s 
• Vitamin D  
• INR 
•  
• Cytokines 
•  
• PK (pre-dose) 
• Anti-drug antibodies ( ADAs ) 
• Neutralizing antibodies ( NAbs) 
• Exploratory  biomarkers 
• Obtain stool sample for microbiome and fecal fat assessment.  
• Obtain urine samples for the following: 
• Pregnancy test  
• UA 
 
In-clinic dosing: 
• Confirm inclusion/exclusion criteria  and no change in clinical symptoms or other 
evidence of a si gnificant change in liver function from Screening. 
• Perform randomization.  
• Dispense initial study -drug kit/diary  (for recording of date/time of study -drug dosing). 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 53 of 125 • Provide study-drug self- administration training . 
• Oversee subject ’s study-drug self- administration . 
 
Before clinic discharge:  
• Obtain 2-hour post- dose PK  sample . 
• Record AE s. 
• Perform local injection -site symptom assessment ( LISSA ) evaluation. 
• Schedule subject  for Week 1  visit . 
9.2.3 Week 1  Procedures  
Subject s will report to this visit fasted and not dosed with NGM282 . The following 
procedures will be performed at the Week  1 visit: 
Pre-dose: 
• Measure vital signs (including  temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Record concomitant medications. 
• Record AE s. 
• Perform LISSA evaluation.  
• Obtain 10- hour fasted clinical laboratory samples for the following:  
• Chemistry  
• CBC  
• PK (pre -dose) 
 In-clinic dosing: 
• Collect old study -drug kit/diary and conduct reconciliation. 
• Dispense new study- drug kit/diary . 
• Oversee subject ’s study-drug self- administration (from new kit).  
 Before clinic discharge (20 minutes after dosing): 
• Record AEs.  
• Perform LISSA evaluation . 
• Schedule subject  for Week 2  visit . 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 54 of 125 9.2.4 Week 2  Procedures  
Subjects will report to this visit fasted and not dosed with NGM282. The following 
procedures will be performed at the Week 2  visit: 
Pre-dose: 
• Conduct physical examination. 
• Obtain 12- lead ECG (after subject has been supine for at least 5  minutes). 
• Measure vital signs (including  temperature, respiratory rate, and seated blood pressure 
and puls e). 
• Record concomitant medications. 
• Record AE s. 
• Obtain 10- hour fasted clinical laboratory samples for the following:  
• Chemistry  
• CBC  
• PK (pre-dose) 
• ADAs  
• NAbs 
• Perform LISSA evaluation. 
 
In-clinic dosing: 
• Collect old study -drug kit/diary and conduct reconcilia tion. 
• Dispense new study- drug kit/diary . 
• Oversee subject ’s study-drug self- administration (from new kit).  
 
Before clinic discharge (20 minutes after dosing): 
• Record AEs.  
• Perform LISSA evaluation . 
• Schedule subject  for Week 4  visit . 
 
9.2.5 Week 4 Procedures  
Subje cts will report to this visit fasted and not dosed  with NGM282 . The following 
procedures will be performed at the Week 4 visit: 
Pre-dose: 
• Conduct physical examination. 
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Record concomitant medications. 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 55 of 125 • Record AEs.  
• Obtain 10- hour fasted clinical laboratory samples for the following:  
• Chemistry  
• CBC  
• Lipid panel 
•  
• Cytokines 
• PK (pre-dose) 
• ADAs  
• NAbs  
• Obtain urine samples for UA. 
 
In-clinic dosing: 
• Collect old study -drug kit/diary and conduct reconciliation. 
• Dispense new study- drug kit/diary.  
• Oversee subject ’s study-drug self- administration (from new kit).  
 Before clinic discharge (20 minutes after dosing): 
• Record AEs.  
• Perform LISSA evalua tion. 
• Schedule subject  for Week 8  visit . 
9.2.6 Week 8  Procedures  
Subject s will report to this visit fasted and not dosed with NGM282. The following 
procedures will be performed at the Week 8 visit: 
Pre-dose: 
• Conduct physical exam. 
• Measure vital signs (including  temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Record concomitant medications. 
• Record AE s. 
• Perform LISSA evaluation .  
• Obtain 10- hour fasted clinical laboratory samples for the following:  
• Chemistry  
• CBC  
• PK (pre-dose) 
• ADAs  
• NAbs  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 56 of 125  
In-clinic dosing: 
• Collect old study -drug kit/diary and conduct reconciliation. 
• Dispense new study- drug kit/diary . 
• Oversee subject ’s study-drug self- administration (from new kit).  
 Before clinic discharge (20 minutes after dosing): 
• Record AEs.  
• Perform LISSA evalu ation . 
• Schedule subject  for Week 12 (End of Treatment) visit. 
9.2.7 Week 12 (End of T reatment) /Early Withdrawal  Procedures 
Subject s will report to this visit fasted and not dosed with NGM282. The following 
procedures will be performed at the Week 12/Early Withdrawal  Visit:  
Pre-dose: 
• Measure body weight , BMI , and waist circumference. 
• Conduct physical examination. 
• Obtain 12- lead ECG (after subject has been supine for at least 5  minutes). 
• Measure vital signs (including  temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Obtain a MRI examination. 
• Record concomitant medications. 
• Record AE s. 
• Obtain 10- hour fasted clinical laboratory samples for the following:  
• Chemistry  
• CBC  
• Lipid panel  
• Lipo protein particles  
•  
• C4 and serum bile acid s 
• Vitamin D  
• HbA1c 
• Insulin level  
• HOMA- IR calculation  
• INR 
•  
• Cytokines 
•  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 57 of 125 • Serum pregnancy test (all female subjects)  
• PK (pre-dose) 
• ADAs  
• NAbs 
• Exploratory  biomarkers 
 
• Obtain stool sample for microbiome and fecal fat assessment . 
• Obtain urine sample for UA . 
• Perform LISSA evaluation . 
 
In-clinic dosing: 
• Collect old study -drug kit/diary and conduct reconciliation. 
• Oversee subject ’s study-drug self- administration (from old kit) (not applicable for Early 
Withdrawal subject s). 
 Before clinic discharge (and approximately 20 minutes after dosing): 
• Obtain 2-hour post- dose PK sample.  
• Record AEs.  
• Perform LISSA evaluation . 
• Schedule subject  for Day Week 16 (End of Study) Visit. 
 
(NOTE:  Before- clinic -discharge assessments [PK sampling, AE recording, and LISSA 
evaluation] are not applicable for Early Withdrawal subjects. However, Early 
Withdrawal subjects should be scheduled for a 4 -week Follow- up Visit.)   
9.2.8 Week 16 ( End of Study ) Procedures 
This visit will be performed 4 weeks after  the last dose of study medication. Subject s will 
report to this visit fasted.  The following procedures will be performed at the Week 16 visit:  
• Measure body weight , BMI, and waist circumference. 
• Conduct physical examination. 
• Obtain 12- lead ECG (after subject has been supine for at least 5  minutes). 
• Measure vital signs (including  temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Record concomitant medications. 
• Record AE s. 
• Obtain 10- hour fasted clinical laboratory samples for the following:  
• Chemistry  
• CBC  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 58 of 125 • PK 
• Vitamin D  
• INR 
•  
• Serum pregnancy test (all female subjects)  
• ADAs  
• NAbs 
 
• Obtain urine sample for UA. 
• Perform LISSA evaluation. 
 
9.3 Schedule of Study Procedures  for O pen-l abel Single -blind Cohort 
The Schedule of Study Procedures for the open- label single -blind cohort is shown in Table  3. 
The visits should occur as close to the intended dates as possible.  However, there is an 
acceptable ± 3-day window for individual scheduled visits. Subjects attending any vis its out 
of windows from Day 1 to Week 12/Early Withdrawal (EOT) visit should be brought back 
into compliance with the overall study -visit schedule as soon as possible thereafter.  Subjects 
will then return to the clinic at Week 1 8 (or 6 weeks after last dose) for an EOS follow-up 
visit.  
The Investigator has discretion to repeat assessments if he/she believes the results do not accurately represent the patient’s true values.  Repeat assessments must be conducted within 
the Screening Period. 
  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 59 of 125 Table  3. Schedule of Study Procedures  for Open -Label Single -Blind Cohort  
Study Procedure  Days –28  
to –1 
(Screen ing) a Day 1  Wk 2  Wk 4  Wk 6  Wk 8  Wk 12 
(EOT)  /EW Wk 18 
(EOS)  
Informed consent  X        
Demographics X        
Medical history  X        
Inclusion/exclusion criteria  X X       
Height  X        
Body weight, BMI, waist 
circumference  X X     X X 
Physical exam  X X  X X X X X X 
12-lead ECG X X   X  X X 
Vital signs  X X X X X X X X 
MRI b X    X  X X 
         
Liver b iopsy d X      Xc  
IWRS screening registration  X        
IWRS enrollment registration  X       
Prior and concomitant medications X X X X X X X X 
Adverse event  (AE)  evaluations   X X X X X X X 
LISSA evaluations e  X X X X X X X 
Chemistry 
[fasted ≥ 10 hours] X X X X X X X X 
Complete blood count  (CBC) X X X X X X X X 
HbA1c  X X     X X 
Insulin level and HOMA -IR X X     X X 
         
International Normalized Ratio 
(INR) X X     X X 
Alpha fetoprotein (AFP)  X        
Pregnancy test f X X     X X 
Hepatitis and HIV screen  X        
Urinalysis (UA)  X X   X  X X 
Urine drug screen X        
Fasting lipid panel  X X X X X X X X 
Lipoprotein particles   X   X  X X 
         
Lipase   X  X X X X X 
Stool sa mple   X     X  
  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 61 of 125 9.4 Study Visit Procedures  for O pen- label cohort  
9.4.1 Day –28 to Day –1 (Screening) Procedures  
Subject s will report to this visit fasted.  The following screening procedures will be performed 
for all potential subjects at a visit (or visits) conducted within 28 days prior to dosing: 
• Obtain informed consent. 
• Collect demographic data.  
• Ascertain medical history.  
• Assess inclusion/exclusion criteria.  
• Measure height.  
• Measure body weight, BMI, and waist circumference.  
• Conduct physical examination.  
• Obtain 12- lead ECG (after subject has been supine for at least 5  minutes ). 
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Obtain an MRI assessment (preferably prior to any histologic evaluation  unless a 
historical biopsy is available ). 
• Obtain a LiverMultiScanTM reading (dosing G roups 3 or 4 only). 
• Obtain viable tissue slides from eligible historical liver biopsy or undergo a liver biopsy procedure to obtain new tissue. 
• Conduct Interactive Web Response System (I WRS) screening registration.  
• Record prior and concomitant medications. 
• Obtain 10- hour fasted clinical laboratory samples for the following:  
• Chemistry  
• CBC  
• Lipid panel  
• HbA1c  
• Insulin  
• HOMA- IR calculation  
• INR 
• AFP 
• Serum pregnancy test (all female subjects)  
• Obtain clinical laboratory samples for HIV antibody and hepatitis scre en. 
• Obtain urine samples for the following: 
• UA 
• Selected drugs of abuse 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 62 of 125 9.4.2 Day 1 Procedures 
Subjects will report to this visit fasted.  The Day 1 visit should be a minimum of 14 days from 
the Screening visit in order to allow for adequate separation of the repeated Chemistry (liver 
function tests) and INR assessments.  The following procedures will be performed at the 
Day 1 Visit:  
Pre-dose: 
• Reassess inclusion/exclusion criteria.  
• Measure body weight, BMI, and waist circumference.  
• Conduct physical examination. 
• Obta in 12- lead ECG (after subject has been supine for at least 5  minutes).  
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Record concomitant medications. 
• Record AEs.   
• Perform LISSA evaluation. 
• Obtain 10-hour fasted clinical laboratory samples for the following:  
• Chemistry   
• CBC  
• HbA1c  
• Insulin  
• HOMA- IR calculation  
•  
• Lipid panel  
• Lipo protein particles  
•  
• Lipase  
• C4 and serum bile acid s 
• Vitamin D  
• INR 
•  
• Cytokines 
• PK (pre -dose) 
• ADAs  
• NAbs  
• Exploratory biomarker  #1 
• Exploratory biomarker #2 
• Enhanced liver fibrosis ( ELF) panel 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 63 of 125 •  
   
 
• Obtain stool sample for microbiome and fecal fat assessment.  
• Obtain urine samples for the following: 
• Pregnancy test  
• UA 
 
In-clinic dosing and assessments: 
• Confirm inclusion/exclusion criteria  and no change in clinical symptoms or other 
evidence of a significant change in liver function from Screening. 
• Confirm no new medications have been started or dose changes of medications during 
Screeni ng 
• Register subject  in IWRS for study- drug kit assignment .  
• Dispense initial NGM282 study- drug kit/diary (for recording of date/time of study -drug 
dosing). 
• Provide NGM282 study-drug self- administration training.  
• Oversee subject ’s NGM282  study-drug self-adm inistration.  
• In a subset of subjects, PK samples will be collected at pre -dose and 1, 2, 4, 8, and 
12 hours after dosing.  
 
Before clinic discharge (and approximately 20 minutes after dosing: 
• Obtain 2-hour post-dose PK sample (only in subjects not  particip ating in the PK 
sub-study). 
• Record new AEs  after NGM282 dosing. 
• Perform LISSA evaluation. 
• Schedule subject  for Week 2 visit.  
9.4.3 Week 2 Procedures  
Subjects will report to this visit fasted and not dosed  with NGM282 . The fo llowing  
procedures will be performed at the Week 2 visit: 
Pre-dose: 
• Conduct physical examination. 
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Record concomitant medications. 
• Record AEs.   
• Perform LISSA evaluation. 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 64 of 125 • Obtain 10-hour fasted cli nical laboratory samples for the following:  
• Chemistry  
• CBC  
• Lipid panel 
• PK (pre -dose) 
• ADAs  
• NAbs  
 
In-clinic dosing and dispensing: 
• Collect old NGM282 study-drug kit/diary and conduct reconciliation. 
• Dispense new NGM282 study- drug kit/diary  
• Dispense new  rosuvastatin  study drug (if indicated as outlined in  Section  10.4) 
• Oversee subject ’s NGM282 study-drug self- administration (from new kit).  
 Before clinic discharge ( and approximately 20 minutes after dosing):  
• Record new AEs  after NGM282 dosing. 
• Perform LISSA evaluation. 
• Schedule subject  for Week 4 visit. 
 Lipid -Lowering Therapy Assessment:  
• Evaluate LDL -C level from  Week 2 visit when available.  
• Based on the Week 2 LDL -C level, i nitiate/switch  rosuvastatin therapy  as outlined in 
Section  10.4  of the study protocol. The subject should be called by the study site 
personnel to instruct on the specific administration of the rosuv astatin therapy.  
 
9.4.4 Week 4 Procedures  
Subjects will report to this visit fasted and not dosed  with NGM282 . The following 
procedures will be performed at the Week 4 visit: 
Pre-dose: 
• Conduct physical examination. 
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Record concomitant medications. 
• Record AEs.  
• Perform LISSA evaluation. 
• Obtain 10- hour fasted clinical laboratory samples for the following:  
• Chemistry  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 65 of 125 • CBC  
• Lipid panel 
• Lipase  
• PK (pre -dose) 
• ADAs  
• NAbs  
 
In-clinic dosing and dispensing: 
• Collect old NGM282 study-drug kit/diary and conduct reconciliation. 
• Collect old rosuvastatin bottle  and conduct reconciliation. 
• Dispense new NGM282 study- drug kit/diary  
• Dispense new  rosuvastatin study drug. 
• Oversee subject ’s NGM 282 study-drug self- administration (from new kit).  
 Before clinic discharge ( and approximately 20 minutes after dosing):  
• Record new AEs after NGM282 dosing. 
• Perform LISSA evaluation. 
• Schedule subject  for Week 6 visit.  
 
Lipid -Lowering Therapy Assessment:  
• Evaluate LDL -C level from  Week 4 visit when available.  
• Based on the Week 4 LDL -C level, i nitiate /switch/continue/dose increase rosuvastatin 
therapy as outlined in  Section  10.4 of the study protocol. The subject should be called by 
the study site personnel to instruct on the specific administration of the rosuvastatin therapy. 
9.4.5 Week 6 Procedures  
Subjects will re port to this visit fasted and not dosed with NGM282. The following 
procedures wi ll be performed at the Week 6 visit: 
Pre-dose: 
• Conduct physical examination. 
• Obtain 12- lead ECG (after subject has been supine for at least 5  minutes).  
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Obta in an MRI  assessment  (preferably prior to any histologic evaluation unless a 
historical biopsy is available). 
• Obtain a LiverMultiScan
TM reading (dosing Groups 3 or 4 only). 
• Record concomitant medications. 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 66 of 125 • Record AEs.  
• Perform LISSA evaluation. 
• Obtain 10- hour fasted clinical laboratory samples for the following:  
• Chemistry  
• CBC  
• Lipid panel 
• Lipoprotein particles  
• Lipase  
• C4 and serum bile acid s 
•  
• Cytokines 
• PK (pre -dose) 
• ADAs  
• NAbs  
• Explorator y biomarker #1 
• Exploratory biomarker #2 
• ELF panel 
•  
  
 
• Obtain urine samples for UA. 
 
In-clinic dosing and dispensing: 
• Collect old NGM282 study-drug kit/diary and conduct reconciliation. 
• Dispense new NGM 282 study- drug kit/diary.  
• Oversee subject ’s NGM282 study-drug self- administration (from new kit).  
 Before clinic discharge ( and approximately 20 minutes after dosing):  
• Record new AEs after NGM282 dosing. 
• Perform LISSA evaluation. 
• In a subset of subjects, PK samples will be collected at pre -dose and 1, 2, 4, 8, and 
12 hours after dosing. 
• Schedule subject  for Week 8 visit.  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 67 of 125 9.4.6 Week 8 Procedures  
Subjects will report to this visit fasted and not dosed  with NGM282 . The following 
procedures will be performed at the Week 8 visit: 
Pre-dose: 
• Conduct physical exam. 
• Measure vital signs (includin g temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Record concomitant medications. 
• Record AEs.  
• Perform LISSA evaluation.  
• Obtain 10- hour fasted clinical laboratory samples for the following:  
• Chemistry  
• CBC  
• Lipid panel 
• Lipase  
• PK (pre -dose) 
• ADAs  
• NAbs  
 
In-clinic dosing and dispensing: 
• Collect old NGM282 study-drug kit/diary and conduct reconciliation. 
• Collect old rosuvastatin study-drug and conduct reconciliation. 
• Dispense new NGM282 study- drug kit/diary  
• Dispense new rosuvastatin study- drug. 
• Oversee subject ’s NGM282  study-drug self- administration (from new kit).  
 Before clinic discharge ( and approximately 20 minutes after dosing):  
• Record new AEs after NGM282 dosing. 
• Perform LISSA evaluation. 
• Schedule subject  for Week 12 (End of Treatment) visit.  
 Lipid -Lowering Therapy Assessment:  
• Evaluate LDL -C level from  Week 8 visit when available.  
• Based on the Week 8 LDL -C level, i nitiate /switch/continue/dose increase rosuvastatin 
therapy as outlined in  Section  10.4 of the study protocol. The subject should be called by 
the study site personnel to instruct on the specific administration of the rosuvastatin therapy. 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 68 of 125 9.4.7 Week 12 (End of Treatment)/Early Withdrawal Procedures 
Subjects will re port to this visit fasted and not dosed  with NGM282 . The following 
procedures will be performed at the Week 12/Early Withdrawal Visit:  
Pre-dose: 
• Measure body weight, BMI, and waist circumference.  
• Conduct physical examination. 
• Obtain 12- lead ECG (after subj ect has been supine for at least 5  minutes).  
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Obtain an MRI assessment (preferably prior to any histologic evaluation unless a 
historical biopsy is available ). 
• Obtain a LiverMultiScanTM reading (dosing G roups 3 or 4 only). 
• Undergo a liver biopsy procedure to obtain new tissue (dosing Groups 3 or 4 only). 
• Record concomitant medications. 
• Record AEs.  
• Perform LISSA evaluation. 
• Obtain 10- hour fasted clinical laboratory samples for the following:  
• Chemistry  
• CBC  
• HbA1c  
• Insulin level  
• HOMA- IR calculation  
•  
• INR 
• Serum pregnancy test (all female subjects) 
• Lipid panel  
• Lipo protein particles  
•  
• Lipase  
• C4 and serum bile acid s 
• Vitamin D   
•   
• Cytokines 
• PK (pre -dose) 
• ADAs  
• NAbs  
• Exploratory biomarker  #1 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 69 of 125 • Exploratory biomarker #2 
• ELF panel  
•  
  
 
• Obtain stool sample for microbiome and fecal fat assessment.  
• Obtain urine sample for UA. 
 
In-clinic dosing: 
• Collect old NGM282 study-drug kit/diary and conduct reconciliation. 
• Collect old rosuvastatin bottle  and conduct reconciliation. 
• Dispense new rosuvastatin (only for subjects who were on statin therapy at Baseline). 
• Oversee subject ’s NGM282  study-drug self- administration (from old kit) (not applicable 
for Early Withdrawal subjects).  
 Before clinic discharge (and approximately 20 minutes after dosing): 
• Obtain 2-hour post-dose PK blood sample. 
• Record AEs.  
• Perform LISSA evaluation. 
• Schedule subject  for Week 18 (End of Study) Visit. 
 
(NOTE:  Before- clinic -discharge assessments [PK sampling, AE recording, and LISSA 
evaluation] are not applicable for Early Withdrawal subjects. However, Early 
Withdrawal subjects should be scheduled for a 6 -week Follow- up Visit.)   
9.4.8 Week 1 8 (End of Study) Procedures  
This visit will be performed 6 weeks after the last dose of study medication.  Subject s will 
report to this visit fasted.  The following procedures will be performed at the Week 18 visit:  
• Measure body weight, BMI, and waist circumference.  
• Conduct physical examination. 
• Obtain 12- lead ECG (after subject has been supine for at least 5  minutes).  
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure and pulse). 
• Obtain an MRI assessment (preferably prior to any histologic evaluation unless a 
historical biopsy is available ). 
• Obtain a LiverMultiScan
TM reading (dosing G roups 3 or 4 only). 
• Record concomitant medications. 
• Record AEs.  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 70 of 125 • Obtain 10- hour fasted clinical laboratory samples for the following:  
• Chemistry  
• CBC  
• HbA1c  
• Insulin level  
• HOMA- IR calculation  
•  
• INR 
• Serum pregnancy test (all female subjects) 
• Lipid panel  
• Lipo protein particles  
•  
• Lipase  
• C4 and serum bile acid s 
• Vitamin D   
•   
• Cytokines 
• PK (pre -dose) 
• ADAs  
• NAbs  
• Exploratory biomarker  #1 
• Explorat ory biomarker #2 
• ELF panel  
•  
  
 
• Obtain urine sample for UA. 
• Perform pre-dose LISSA evaluation  only. 
• Collect old rosuvastatin bottle  and conduct reconciliation (only for subjects who were on 
statin therapy at Baseline) . 
  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 71 of 125 9.5 Schedule of Study Procedures for P lacebo -controlled 24 -Week 
Histology Cohort 
The Schedule of Study Procedures for the placebo -controlled 24-week histology cohort is 
shown in Table  4. The visits should occur as close to the intended dates as possible.  
However, there is an acceptable ± 3-day window for individual scheduled visits unless 
stipulated otherwise for specific procedures.   
The screening window may be extended an additional 2 weeks (for a total window of 42 
days) if additional time is needed to complete procedures.  Medical Monitor/designee approval will be required and will not be considered a protocol deviation: 
Subjects attending any visits out of windows from Day 1 to Week 24/Early Withdrawal 
(EOT) v isit should be brought back into compliance with the overall study- visit schedule as 
soon as possible thereafter.  Subjects will then return to the clinic at Week 30 (or 6 weeks 
after last dose) for an EOS follow -up visit. 
The Investigator has discretion to repeat assessments i f he/she believes the results do not 
accurately represent the patient’s true values.  Repeat assessments must be conducted within 
the Screening Period. 
  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 72 of 125 Table  4. Schedule of Study Procedures for Placebo -Controlled 24- Week Histology 
Cohort  
Study Procedure  D –28 to –1 
(Screening) a D 1 W 2 W 4 W 6 W 8 W 12 W 18 W 24/  EW 
(EOT)  W 30  
 (EOS)  
Visit Window (Days)  ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 
Informed consent X          
Demographics  X          
Medical history  X          
Prior  and concomitant 
medications  X X X X X X X X X X 
Inclusion/exclusion criteria  X X         
Height X          
Body weight, BMI, waist 
circumference  X X     X  X X 
Physical exam  X X   X  X X X X X 
12-lead ECG  X X     X  X X 
Vital signs  X X X X X X X X X X 
Adverse event s (AEs) k  X X X X X X X X X X 
Chemistry  [fasted ≥ 10 hrs] X  X je X e X e X e X e X e X e X e X e 
Complete blood count  (CBC)  X X X X X X X X X X 
HbA1c  X X     X  X X 
Insulin level and HOMA -IR X X     X  X X 
           
International Normalized Ratio  
(INR)  X X     X  X X 
Alpha fetoprotein  (AFP)  X          
Pregnancy test f X X       X X 
Hepatitis and HIV screen  X          
Urinalysis (UA)  X X     X  X X 
Urine drug screen  X          
Fasting lipid panel  X X e X e X e X e X e X e X e X e X e 
Lipoprotein particles   X  X  X X  X X 
Lipase  X  X  X X  X X 
C4 and serum bile acids   X X X X X X X X X 
Vitamin D   X     X  X X 
PK blood samples g  X X X X X X X X X 
Anti-drug antibodies (ADAs)   X X X X X X X X X 
Neutralizing ant ibodies (NAbs)   X X X X X X X X X 
ELF Panel   X   X  X  X X 
Exploratory plasma biomarkers 1, 2   X X X X X X X X X 
  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 74 of 125 i Compli ance with Rosuvastatin will be assessed at Week 30  for statin -experienced  subjects only 
j Baseline ALT  reported result calculated using the median of the Screening and Day 1 value 
k Adverse events will be monitored and  recorded from patient signing informed consent through follow -up. 
l Subjects will be instructed to self -inject NGM282  or placebo as close to th e same time as possible each day in the abdomen  
  and administer the next dose  the following morning.  Subjects will not self -inject NGM282 at home on clinic visit days.  
9.6 Study Visit Procedures  for P lacebo -controlled 24-week Histology 
Cohort 
9.6.1 Day –28 to Day –1 (Screening) Procedures  
Subject s will report to clinic  fasted.  The following screening procedures should be performed 
within 28 days prior to dosing. The screening window may be extended an additional 
2 weeks ( for a total window  of 42 days) if additional time is needed to complete procedures. 
Medical Monito r/designee approval will be required and will not be considered a protocol 
deviation: 
• Obtain informed consent. 
• Collect demographic data.  
• Ascertain medical history.  
• Record prior and concomitant medications. 
• Assess inclusion/exclusion criteria.  
• Measure height.  
• Measure body weight, BMI, and waist circumference.  
• Conduct physical examination.  
• Obtain 12- lead ECG (after subject has been supine for at least 5  minutes).  
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Obtain blood and urine for 10-hour fasted laboratory sample collection   
• Obtain an MRI assessment (preferably prior to any histologic evaluation  unless a 
historical biopsy is available ).  Re-screen subjects may use previously obtained MRI if 
within 8 weeks from original procedure.  
•  
 
• Obta
in viable tissue slides from historical liver biopsy  (within 3 months of screeni ng) or 
undergo a liver biopsy procedure to obtain new tissue. 
• Record AEs  (starting from the when the patient signs informed consent) 
• Register screened subject in IWRS  
9.6.2 Day 1 Procedures 
Subjects will report to clinic fasted  or be rescheduled.  The Day 1 visit should be a minimum 
of 14 days from the Screening visit in order to allow for adequate separation of repeated 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 75 of 125 chemistry (liver function tests) and INR laboratory assessments as necessary . The following 
procedures will be performed at the Day 1 Visit:  
Pre-dose: 
• Reassess inclusion/exclusion criteria.  
• Measure body weight, BMI, and waist circumference.  
• Conduct physical examination. 
• Obtain 12- lead ECG (after subject has been supine for at least 5  minutes).  
• Measure vital signs (including temperature, respirator y rate, and seated blood pressure 
and pulse). 
• Record concomitant medications. 
• Record new and/or changes to AEs.   
• Obtain blood and urine for 10-hour fasted laboratory sampl es 
– Reminder to perform urine pregnancy test for females of child bearing potential 
 
In-clinic dosing and assessments:  
• Reconfirm eligibility  and no change in clinical symptoms or other evidence of a 
significant change in liver function from Screening. 
• Confirm no new or changes to medications  
• Randomiz e subject  in IW RS for NGM282 study drug kit assignment.  
• Dispense initial NGM282 study drug kit s (2) and home diary  
• Provide NGM282 study drug self- administration training.   
• Oversee subject ’s NGM282  study drug self- administration . 
• Perform LISSA evaluation. 
 
Before clinic discharge: 
• Obtain 2-hour post-dose PK sample.  
• Remind  subject  to bring study drug kits /diary and to not self-inject NGM282 at home on 
clinic visit days  
• Schedule Week 2 visi t and remind subject for home dosing to administer NGM282 or 
placebo  as close as possible to the same time each day  
9.6.3 Week 2 Procedures  
Subjects will report to clinic  fasted and not dosed with NGM282 . The fo llowing  procedures 
will be performed: 
Pre-dose: 
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure 
and pulse). 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 76 of 125 • Obtain blood for 10-hour fasted clinical laboratory samples (if not fasted , chem istries and 
lipid panel will need to be retested)  
– Results are blinded for ALT, AST, Total Cholesterol, LDL, HDL and  
triglycerides  
• Record concomitant medications. 
• Record new and/or changes to AEs.   
 
In-clinic dosing and dispensing: 
• Collect old NGM282 study-drug kit/diary and conduct reconciliation. 
• Dispense new NGM282 study-drug kits (2) and diary . 
• Dispense rosuvastatin medication/diary   
• Oversee subject ’s NGM282 study-drug self- administrat ion (from new kit).  
• Perform LISSA evaluation. 
 
Before clinic discharge:  
• Remind  subject  to bring study drug kits /diary and to not self -inject NGM282 at home on 
clinic visit days.  
• Schedule Week 4 visit and remind subject for home dosing to administer NGM282 or 
placebo as close as possible to the same time each day  
 
Lipid -Lowering Therapy Assessment:  
• NGM Medical Monitor /designee will e valuate LDL -C level as outlined in Section  10.4 
and inf orm site to:  
– Start or not start rosuvastatin therapy 
– Continue with current therapy 
– Switch to rosuvastatin therapy   
• The site will then contact the subject with further instructions  
9.6.4 Week 4 Procedures  
Subjects will report to clinic fasted and not dosed with N GM282. The following procedures 
will be performed: 
Pre-dose: 
• Conduct physical examination. 
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure and pulse). 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 77 of 125 • Obtain blood for 10-hour fasted clinical laboratory samples (if n ot fasted chem istries and 
lipid panel will need to be retested)  
– Results are blinded for ALT, AST, Total Cholesterol, LDL, HDL and  
triglycerides  
• Record concomitant medications. 
• Record new and/or changes to AEs.  
 
In-clinic dosing and dispensing: 
• Collect old  NGM282 study-drug kit/diary and conduct reconciliation. 
• Collect old rosuvastatin medication bottle /diary  and conduct reconciliation. 
• Dispense new NGM282 study-drug kits (2) and diary . 
• Dispense new rosuvastatin medication /diary . 
• Oversee subject ’s NGM282 st udy-drug self- administration (from new kit).  
• Perform LISSA evaluation. 
 
Before clinic discharge: 
• Remind  subject  to bring study drug kits /diary and to not self -inject NGM282 at home on 
clinic visit days.  
• Schedule Week 6 visit and remind subject for home dosing to administer NGM282 or 
placebo as close as possible to the same time each day  
 
Lipid -Lowering Therapy Assessment:  
• NGM Medical Monitor/designee will evaluate LDL -C level as outlined in Section  10.4 
and inform site to: 
– Start or not start rosuvastatin therapy  
– Continue current therapy  
– Titrate rosuvastatin therapy  
– Switch to rosuvastatin therapy   
• The site will then contact the subject with further instructions  
9.6.5 Week 6 Procedures  
Subjects will re port to clinic  fasted and not dosed with NGM282. The following procedures 
will be performed: 
Pre-dose: 
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure and pulse). 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 78 of 125 • Obtain blood for 10-hour fasted clinical labor atory samples (if not fasted , chem istries and 
lipid panel will need to be retested)  
– Results are blinded for ALT, AST, Total Cholesterol, LDL, HDL and  
triglycerides  
• Obtain an MRI  assessment .  
• Record concomitant medications. 
• Record new and/or changes to AEs. 
 
In-clinic dosing and dispensing: 
• Collect old NGM282 study-drug kit/diary and conduct reconciliation. 
• Dispense new NGM 282 study- drug kit s (2) and diary. 
• Oversee subject ’s NGM282 study-drug self- administration (from new kit).  
• Perform LISSA evaluation. 
 
Before clinic discharge: 
• Remind  subject  to bring study drug kits /diary and to not self -inject NGM282 at home on 
clinic visit days.  
• Schedule Week 8 visit and remind subject for home dosing to administer NGM282 or 
placebo as close as possible to the same time each day  
9.6.6 Week 8 Procedures  
Subjects will report to clinic  fasted and not dosed with NGM282 . The following procedures 
will be performed: 
Pre-dose: 
• Conduct physical exam. 
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Obtain blood for 10-hour fasted clinical laboratory samples (if not fasted , chem istries and 
lipid panel will need to be retested)  
– Results are blinded for ALT, AST, Total Cholesterol, LDL, HDL and  triglycerides  
• Record concomitant medications.  
• Record new and/or changes to AEs.  
 
In-clinic dosing and dispensing: 
• Collect old NGM282 study-drug kit/diary and conduct reconciliation. 
• Collect old rosuvastatin medication bottle/diary  and conduct reconciliation. 
• Dispense new NGM282 study-drug kit s (4) and diary . 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 79 of 125 • Dispense new rosuvastatin medication /diary . 
• Oversee subject ’s NGM282  study-drug self- administration (from new kit).  
• Perform LISSA evaluation.  
 
Before clinic discharg e: 
• Remind  subject  to bring study drug kits /diary and to not self -inject NGM282  at home on 
clinic visit days.  
• Schedule Week 12 visit and remind subject for home dosing to administer NGM282 or 
placebo as close as possible to the same time each day  
 
Lipid -Lowering Therapy Assessment:  
• NGM Medical Monitor/designee will evaluate LDL -C lev el as outlined in Section  10.4 
and inform site to: 
– Continue with current therapy 
– Titrate rosuvastatin therapy  
• The site will then contact the subject with further instructions  
9.6.7 Week 12 Pr ocedures  
Subjects will report to clinic  visit fasted and not dosed with NGM282 . The following 
procedures will be performed: 
 
Pre-dose: 
• Measure body weight, BMI, and waist circumference.  
• Conduct physical examination. 
• Obtain 12- lead ECG (after subject has be en supine for at least 5  minutes).  
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure 
and pulse). 
• Obtain blood and urine for 10- hour fasted clinical laboratory samples (if not fasted , 
chem istries and lipid panel will ne ed to be retested) 
– Results are blinded for ALT, AST, Total Cholesterol, LDL, HDL and  
triglycerides  
• Obtain an MRI assessment .  
• Record concomitant medications. 
• Record new and/or changes to AEs. 
 
In-clinic dosing and dispensing: 
• Collect old NGM282 study-drug kit/diary and conduct reconciliation. 
• Collect old rosuvastatin medication bottle /diary  and conduct reconciliation. 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 80 of 125 • Dispense new NGM282 study-drug kits (5) and diary . 
• Dispense new rosuvastatin medication /diary .  
• Oversee subject ’s NGM282  study-drug self-adm inistration (from new kit).  
• Perform LISSA evaluation. 
 
Before clinic discharge: 
• Obtain 2-hour post-dose PK blood sample. 
• Remind  subject  to bring study drug kits /diary and to not self -inject NGM282 at home on 
clinic visit days.  
• Schedule Week 18 visit and remind subject for home dosing to administer NGM282 or 
placebo as close as possible to the same time each day  
 
Lipid -Lowering Therapy Assessment:  
• NGM Medical Monitor/designee will evaluate LDL -C level as outlined in Section  10.4 
and inform site to: 
– Continue with current therapy 
– Evaluate additional lipid-lowering therapy with ezetimibe  for statin non -
responder 
– For subjects taking statins, evaluate tolerability and if deemed necessary, subj ect 
may be considered for alternative second- line lipid lowering therap y with 
ezetimibe . 
• The site will then contact the subject with further instructions  
9.6.8 Week 18 Procedures  
Subjects will report to clinic  fasted and not dosed with NGM282 . The following procedures 
will be performed: 
Pre-dose: 
• Conduct physical examination.  
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure and pulse). 
• Record concomitant medications. 
• Record new and/or changes to AEs.  
• Obtain blood for 10-hour fasted clinical laboratory samples (if not fasted chem istries and 
lipid panel will need to be retested)  
– Results are blinded for ALT, AST, Total Cholesterol, LDL, HDL and  
triglycerides  
 
In-clinic dosing and dispensing: 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 81 of 125 • Collect old NGM282 study-drug kit/diary and conduct reconciliation. 
• Collect old rosuvastatin medication bottle/diary  and conduct reconciliation. 
• If subject is taking statins, evaluate tolerability and continue therapy to Week 24 for 
statin naïve or Week 30 for statin experienced  
• Dispense new NGM282 study-drug kits (5) and diary . 
• Dispense new rosuvastatin medication /diary . 
• Oversee subject ’s NGM282  study-drug self- administration (from new kit).  
• Perform LISSA evaluation.  
 
Before clinic discharge: 
• Remind  subject  to bring study drug kit s/diary and to not self-inject NGM282 at home on 
clinic visit days.  
• Schedule Week 24 (End of Treatment) visit and remind subject for home dosing to administer NGM282 or placebo as close as possible to the same time each day  
  
9.6.9 Week 24/Early Withdrawal (End of Tre atment) Procedures  
Subjects will report to clinic  fasted and not dosed with NGM282 . The following procedures 
will be performed : 
Pre-dose: 
• Measure body weight, BMI, and waist circumference.  
• Conduct physical examination. 
• Obtain 12- lead ECG (after subject has  been supine for at least 5  minutes).  
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure and pulse). 
 
• Obtain blood and urine for 10- hour fasted clinical laboratory samples  (if not fasted , 
chem istries and lipid panel wil l need to be retested)  
– Results are blinded for ALT, AST, Total Cholesterol, LDL, HDL and triglycerides  
• Obtain an MRI assessment  
– MRI should be obtained before the last dose of NGM282 (standard Table 4 visit window applies)  
•   
• Unde
rgo a liver biopsy procedure to obtain new tissue 
– Results will be blinded .  
– Biopsy should be obtained before the last dose of NGM282 with a visit window of -7 days and +3 days 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 82 of 125 • Record concomitant medications. 
• Record new and/or changes to AEs. 
 
In-clinic dosing and dispensing: 
• Collect old NGM282 study-drug kit/diary and conduct reconciliation. 
• Collect old rosuvastatin medication bottle /diary  and conduct reconciliation. 
• If stain experienced subject is taking statins, evaluate tolerability and continue therapy to 
Week 30  
• Statin naïve subjects taking statins are to discontinue therapy 
• Dispense new rosuvastatin medication /diary  to statin experienced subjects taking therapy  
• Oversee subject ’s NGM282  study-drug self-administration (from old kit) (not applic able 
for Early Withdrawal subjects).  
• Perform LISSA evaluation. 
 
Before clinic discharge: 
• Obtain 2-hour post-dose PK blood sample (except early withdrawal subjects) . 
• Schedule Week 30 (End of Study) Visit. 
 
9.6.10 Week 30 (End of Study) Procedures  
This visit will b e performed 6 weeks after the last dose of study medication.  Subject will 
report to clinic fasted.  The following procedures will be performed: 
• Measure body weight, BMI, and waist circumference.  
• Conduct physical examination. 
• Obtain 12- lead ECG (after subje ct has been supine for at least 5  minutes).  
• Measure vital signs (including temperature, respiratory rate, and seated blood pressure and pulse). 
• Obtain blood and urine for 10- hour fasted clinical laboratory samples  
– Results are blinded for ALT, AST, Total C holesterol, LDL, HDL and  
triglycerides  
• Obtain an MRI assessment  
• Record concomitant medications. 
• Record new and/or changes to AEs.  
• Perform LISSA evaluation . 
• Collect old rosuvastatin medication bottle /diary  and conduct reconciliation for statin 
experienced  subjects taking therapy  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 83 of 125 9.7 Prior and Concomitant Medications  
Concomitant therapies are any prescription or over- the-counter preparations used by a 
subject while participating in this study and must be recorded from 28 days prior to Day 1 
until end of study.   
Subject s should refrain from the use of any new medications or products or change in the 
dose or frequency of exis ting therapies during Screening and throughout the study.  The 
Medical Monitor should be informed of any changes or addition of medications during this 
time period.  
Prohibited Medications from 28 days prior to Day 1 and throughout study:  
• Investigational agents, other than NGM282, or devices for any indication 
• Known hepatotoxic agents 
• Agents used for the treatment of any condition listed in the exclusionary enrollment 
criteria (see Section  8.1.2) 
• Any hepatotoxic herbal medications other than standard vitamin supplements  
Placebo -Controlled 24 Week Histology Cohort  Only : 
• Investigational agents, other than NGM282, or devices for any indication 
• Agents used for the treatment of any condition listed in the exclusionary enrollment criteria (see Section  8.1.2) 
• Hepatotoxic agents outlined in ( Appendix E ). 
o All other hepatotoxic agents will be left to the discretion of the PI. 
There  should be clear documentation in the patient study records of PI 
approval of use. 
 
Prohibited Medications within 3 months  of Screening and throughout study:  
• Ezetimibe, colesevelam, cholestyramine, niacin, PCSK9 inhibitors, or other 
lipid-lowering agents (except Double-blind) 
Placebo -Controlled 24 Week Histology Cohort Only:  
• Contraindicated medications according to rosuvastatin package insert 
(Appendix C ) 
o Includes cyclosporine, gemfibrozil, protease inhibitors (atazanavir, ritonavir, lopinavir, simeprevir), coumarin anticoagulants, fenofibrates,  
niacin  and colchici ne 
• Contraindicated medications according to ezetimibe package insert ( Appendix D ) 
o Includes cyclosporine, fenofibrate , cholestyramine and coumarin 
anticoagulants  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 84 of 125 • Use of any other lipid lowering agents or combination preparation of statins, 
within 3 months of Screening and throughout study, except ezetimibe when 
approved by MM/designee as second line lipid management therapy. 
o colesevelam, cholestyramine, niacin, PCSK9 inhibitors (evolocumab or alirocumab), colestid, fibr ates, fenofibrates, pharmacologic/prescribed fish 
oil 
o Use of weight loss medications including: orlistat, phentermine, topiramate, qsymia, lorcaserin hydrochloride, naltrexone hydrochloride, liraglutide  (for weight loss not T2D, e.g. Saxenda), benzphentamine, 
diethylpropion and phendimetrazine 
 
Acceptable Medications that require a stable regimen prior to and throughout study: 
Double-Blind and Single-Blind, Open- Label Cohorts:  
• Diabetes medications (except GLP1 agonists): require s a stable regimen  for at 
least 3 months prior to Day 1. 
• GLP1 agonists:  requires a stable regimen 12 months  prior to Day  1. 
• Weight- loss medications : requires stable regimen for at least  3 months  prior to 
Day 1 with no safety or tolerability events.  
• Other therapies for NAFLD or NASH : requires a stable regimen for at least 
6 months prior to Screening biopsy and throughout the study. May include vitamin E, milk thistle, thiazolidinediones and pentoxifylline. 
 
Placebo -Controlled 24 Week Histology Cohort  Only: 
• GLP1 agonists and pioglitazone:  requires a stable regimen 12 months  prior to 
Day1. 
• Procedural Medications use (e.g. Anti-anxiety medication for MRI scan, 
anesthetic for liver biopsy) will be at the discretion of the PI and documented accordingly. 
• Other therapies for NAFLD or NASH:  requires a stable regimen for at least 
3 months prior to Screening biopsy and throughout the study. May include vitamin E  (>800 IU), milk thistle, and pentoxifylline.  
 
Statin Use:  
Double-Blind Cohort: 
Includes  statins . 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 85 of 125 Open -Label Sing le-Blind and Placebo -Controlled 24 Week Histology Cohorts:  
Includes statins if the following conditions are met: 
1. Subject can be defined as statin naïve or experienced at Screening based on 
the following definitions : 
a. Statin -naïve : no administration of statins within 3 months prior to 
enrollment. 
b. Statin experienced : administration of < 50% of the maximal dose of 
current statin therapy.  
2. Requires a stable regimen for at least 3 months prior to Screening through Week 2. 
The following are the acceptable daily doses of currently approve d statin therapies , 
including c ombination preparations of statins and other lipid -lowering agents . 
• Atorvastatin: < 40 mg/d 
• Fluvastatin: < 40 mg/d 
• Lovastatin: < 40 mg/d (immediate release), < 30 mg/d (extended release) 
• Pitavastatin:  < 2 mg/d 
• Pravastatin: < 40 mg/d 
• Rosuvastatin : < 20 mg/d ( Note:  must be < not < 20 mg/d)  
• Simvastatin:  < 40 mg/d  
 
9.8 Diet and A ctivity Control 
Subject s should maintain their normal level of physical activity, diet, and lifestyle throughout 
the entire study (i.e., will not begin a new exercise program or participate in any unusually 
strenuous physical exertion).  
9.9 Clinical Evaluations  
9.9.1 Liver Biopsy  
Subject s who meet the Screening criteria of an available liver biopsy tissue specimen within 
6 months of Screening for the double-blind cohort and 12 months for the single-blind 
open-label cohort will not be required to undergo a liver biopsy. For the dosing Groups 3 or 4 of the open- label single-blind cohort and for the placebo-controlled 24-week histology 
cohort, the liver biopsy must be performed within 3 months of Screening in order to serve as the Baseline comparison for the additional Week 12 biopsy. All other subject s will be 
required to undergo a liver biopsy per the study site’ s local standard -of-care procedure during 
the Screening pe riod and prior to randomization . Tissue from all subject s will be prepped and 
read by a qualified pathologist for review for the absence/presence of NASH . Liver biopsies 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 86 of 125 with histologically confirmed NASH will be further assessed by a qualified pathologist using 
the NAS and Fibrosis Score established and validated by the NASH Clinical Research Network  (see Appendix A ). Liver biopsies will be assessed for degree of steatosis (0 –3), 
lobular inflammation (0 –3), hepatocell ular ballooning (0 –2), and fibrosis (0 -4). The first 
three components will be added together to determine the NAS that ranges from 0 to 8. Liver  biopsies with a NAS of <
 4 will be considered exclusionary. Subjects with liver 
biopsies with Stage 0 (no fibro sis) or Stage 4 fibrosis (cirrhosis) will be excluded from this 
study. For the placebo-controlled 24-week histology cohort, only subjects with Stage 2 or 
Stage 3 fibrosis will be allowed to enroll into the study. 
The Screening  and EOT biopsies for dosing Groups 3 or 4 of the open- label single -blind 
cohort and all subjects in the placebo -controlled 24-week histology cohort will be read by a 
single central pathologist. The biopsies will be read and scored using the same NASH Clinical Research Network (CRN) scores as the inclusion biopsies.  These will be read 
unpaired and blinded to subject and reported separately from the inclusion biopsy.  
For the placebo-controlled 24- week histology, only the Week 24 biopsy results will be 
blinded to the site and subject.  S creening  biopsy re sults will  not be blinded.  The Week 24 
biopsy should be obtained before the last dose of NGM282 with a visit window of - 7 days 
and +3 days. 
9.9.2 Magnetic Resonance Imaging  (MRI)  
All enrolled subject s will have a B aseline (from the Screening result)  and EOT  MRI  of the 
liver to evaluate liver volume and liver fat.  Open -label single-blind cohort subjects are 
requested to undergo an additional MRI at Week s 6 and 18.  
Subjects in the placebo controlled 24–week histology cohort will have an MRI performed at 
Screening and at Weeks 6, 12, 24, and 30. None of the treatment or post treatment MRI results (other than incidental findings) will be provided to the sites.  MRI-PDFF should be performed before the last dose of NGM282 
MRI -PDFF will be reported on all MRI imaging scans.  Scans should be performed at high 
field strength (3T preferred, 1.5T acceptable), without the administration of oral or 
intravenous contrast material.  MRI examinations will include a six -echo gradient recalled 
echo (GRE) sequence (2 D preferred, 3D acceptable),  
 
The initial study MRI examination will be performed during the Screening period prior to randomization. A n MRI -PDFF val ue of >
 8% at Screening as assessed by the central 
radiology core is one of the inclusion criteria for the study. Therefore, for patients who 
require a liver biopsy as part of the trial (for whom no recent liver biopsy is available), it is 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 87 of 125 recommended that  liver biopsy be scheduled no sooner than 7 business days after (electronic) 
transmission of the screening MRI examination to the central radiology core to allow 
adequate time for processing and reporting of the result. MRI -PDFF results will be reported 
to the individual site no more than 5 business days after the MRI examination is received.  
For both Screening and EOT /Early Withdrawal MRI examinations, subject s should consume 
nothing by mouth (NPO) for 4 hours prior to their MRI appointment.  Medications and small 
amounts of water are acceptable.  
Prior to MRI, all subjects should undergo safety assessment per institutional protocols and per the guidelines of the local Institutional Review Board.  Subjects should be questioned 
regarding claustrophobia, pregnancy or potential pregnancy, size or weight exceeding the capabilities of the MRI system, metal implants, and other potential safety issues.  
Detailed instructions for MRI procedures and provision of examination to a central reader will be presented in a sep arate MRI Manual.   
LiverMultiScan
TM imaging will be also be collected during the MRI to obtain  the MRI -PDFF 
assessments in dosing Groups 3 or 4 of the open- label single-blind cohort and all subjects in 
the placebo- controlled 24 -week  histology cohort. This scan is optional and will only be 
performed where the imaging technology is available and adequate. The subjects will be required to stay in the MRI machine approximately 10 minutes longer than the standard MRI procedure. The software uses the images of the liver to calculate parameters that have been shown to correlate with histological measures of steatosis, hepatic iron overload , and fibrosis 
of the liver ( Banerjee 2014).  Additionally, an LIF score and corrected cT1 value are also 
calculated , both of which ha ve been  correlated to liver histology as well as predicting 
liver- related outcomes ( Banerjee 2014, Pavlides 2016, Perspectum Diagnostics, data on file).  
Detailed in structions for the LiverMultiScan
TM software and provision of the imaging to a 
central reader will be presented in a separate manual.  
 
 
. There are no current imaging techniques 
that can directly dete ct the specific stage of fibrosis. Most attempt to detect fibrosis indirectly 
using proposed biomarkers which include: stiffness, diffusion, perfusion, metabolites, and 
image texture with the leading biomarker being liver stiffness ( Younossi 2017).  
 
 
 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 88 of 125 9.9.3 Pharmacokinetic Blood Sample Collection and Processing  
In all cohorts , blood samples for PK analysis of NGM282 levels will be collected before 
dosing on all study visits. On Day 1 and Week 12, an additional PK blood sample will be 
collected 2 hours post- dose (±20 mins) . Additionally, in the open- label single -blind cohort, 
up to 8 subjects per dosing group in the single -blind open-label cohort will be given the 
option to participate in further PK sampling at pre -dose (Baseline) and at 1, 2, 4, 8, and 
12 hours (± 20 mins) after dosing on Day 1 (Baseline) and Week 6. Subjects participating in 
the PK  sub-study will not obtain an additional 2 -hour post- dose sample.  
Processing, storage, and shipping instructions for these PK blood samples will be presented in the study Lab Manual.  
9.9.4 Clinical Laboratory Evaluations 
Clinical laboratory evaluations including chemistry (fasted at least 10  hours) , CBC, and UA 
will be collected as outlined in the respective Schedules of Study Procedures (double-blind, 
Table  2; open-label, Table  3; placebo-controlled 24 -week histology, Table  4). 
Laboratory assessments of fasted lipid panel (total cholesterol, LDL, HDL, and TG) , 
lipoprotein particles,  HbA1c, insulin, HOMA -IR, and FFAs will be performed as outlined in 
the respective Schedules of Study Procedures (double-blind, Table  2; open-label, Table  3; 
placebo -controlled 24-week histology, Table  4). For the placebo-controlled 24 week 
histology, test results will be monitored by the sponsor’s medical monitor/designee, but are blinded to the site and subject for ALT, AST, Total Cholesterol, LDL, HDL and triglycerides  
for Week 2 – Week 30 sample collect ions.  LDL -direct may be used if LDL -C was not able 
to be analyzed. 
Laboratory assessments for C4 and serum bile acid s will be performed as outlined in the 
respective Schedules of Study Procedures (double-blind, Tabl e 2; open- label,  Table  3; 
placebo -controlled 24-week histology, Table  4).  
Laboratory assessm ents for changes in bile -mediated absorption as measured by vitamin D 
and INR wi ll be performed as outlined in the respective Schedules of Study Procedures 
(double- blind, Table  2; open -label, Table  3; placebo -controlled 24-week histology, Table  4).  
 
 
Cytokines (IL -6, and TGF -β) and hs-C RP will be assessed  as outlined in the respective 
Schedules of Study Procedures (double-blind, Table  2; open- labe
 l, Table  3).  
Hepatitis screen and HIV antibody sc reen will be performed at Screening.   
A urine screen for drugs of abuse will be performed at Screening.  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 89 of 125 A stool sample will be collected at Day 1 and Week 12 in only the double- blind and 
open- label single -blind cohorts . Stool samples will be analyzed for microbiome ( bacterial 
composition) and fecal fat content  (double-blind, Table  2; open-label, Table  3). 
A serum qualitative pregnancy test (all female  patients of child bearing potential ) will be 
performed at Screening  and Week 24/ EOT and Week 30/ EOS.  A urine pregnancy test (all 
female patients of child bearing potential ) will be performed at Day 1  (pre-dose). 
AFP will be measured at Screening.  
Samples for analysis of ADAs, NAb s, and exploratory biomarkers will be collected as 
outlined in the respective Schedules of Study Procedures (double-blind, Table  2; open- label,  
Table  3; placebo -controlled 24-week histology, Table  4). All NAb samples will be collected 
as scheduled, and analyzed only if necessary based on ADA results.   
Exploratory biomarkers, ELF panel,  will be assessed  as 
outlined in the respective Schedules of Study Procedures (open- label,  Table  3; 
placebo -controlled 24-week histology, Table  4).  
Processing, storage, and shipping instructions f or the above will be presented in a separate 
Lab Manual.  
9.9.5 12-Lead Electrocardiograms  
12-lead ECGs will be performed after the subject  has been supine for at least 5 minutes, and 
as outlined in the respective Schedules of Study (double- blind, Table  2; open -label, Table  3; 
placebo -controlled 24-week histology, Table  4).  
9.9.6 Vital Signs  
Vital signs (including  temperature, respiratory rate, and  seated  blood pressure and pulse) will 
be obtained at Screening and at all study visits  as outlined in the respective Schedules of 
Study Procedures (double-blind, Table  2; open- label,  Table  3; placebo -controlled 24- week 
histology, Table  4). 
Seated blood pressure and pulse will be measured after the subject has been seated for at least 
5 minutes.  
9.9.7 Physical Examinations  
A routine physical examination will be performed at selected study visits in each of the 
cohorts as outlined in the Schedule of Study Procedures (double-blind, Table  2; open-label, 
Table  3; pla cebo -controlled 24-week histology, Table  4. 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 90 of 125 9.9.8 Weight , Body Mass Index , and Waist Circumference Measurement s 
Subject s will be weighed, BMI calculated,  and waist circumference measured at Screening , 
and selected study v isits as outlined in the Schedule of Study Procedures (double- blind, 
Table  2; open- label,  Table  3; placebo- controlled 24-week histology, Table  4). Formal 
instructions for recording weight and measuring waist circumference will be provided to 
sites.  
9.9.9 Local Injection -Site Symptom Assessments (LISSA)  
Injection -site evaluation will be made and documented (including photographs, as needed) by 
the PI or clinic staff using a L ISSA  (Appendix B ). 
The LISSA is to be administered pre - and post- dose (approximately 20 minutes after 
injection) at Day 1  through EOT in the double-blind and open- label single -blind cohorts. 
A single assessment will be performed at the Week 16 (double- blind cohort)  or Week 18 
(open- label single -blind cohort) , to assess any prior dose injection site reactions . 
For the placebo-controlled 24- week histology cohort, LISSA evaluations are to be performed 
at each clinic visit from Day 1 through Week 30.   
The instructions below are to be followed for the pre-dose LISSA : 
• The injection site area(s) should be examined for any ISRs at every visit. 
• If a single ISR is observed, the LISSA should be used to rate that ISR . 
• If multiple ISRs are observed, the LISSA should be used to rate the most severe ISR. 
• The study visit note should document the total number of ISRs seen on examination. 
The LISSA is intended to be a “snapshot” of the ISRs at the time  of clinic assessment.  The 
LISSA is not intended to capture ISR data (frequency, severity, duration, etc.) in  between 
clinic visits.  As with any other potential AE , Investigator judgment should be used as to 
whether any ISR is recorded as an AE . Mild to Se vere Reactions ( LISSA Grade s 1–3) are 
reported as AEs at the discretion of the investigator unless standard SAE criteria are met and then must be reported as an SAE. Life -threatening ( LISSA Grade 4) meet  SAE  criteria and 
must be reported as such. 
LISSAs ma y be performed if necessary and as clinically indicated by the PI to capture ISRs  
outside of the routine scheduled assessment time points. 
The 2007 FDA Toxicity Grading Scale (Appendix B ) will be used to assess any  ISRs  (U.S. 
Department of Health and Human Services 2007 ). The documented record will include all of 
the symptoms, severity, and any local reaction (including pain, tenderness, redness, and 
swelling) and size of injection -site sk in reactions identified and observed by the subject  or 
clinic personnel.  LISSA scores will be documented on the subject ’s CRF.  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 91 of 125 10 Study Drug 
10.1 Clinical Supplies  
10.1.1 NGM282 
NGM282 is formulated in aqueous isosmotic buffer solution with 0.01% polysorbate-20. It is 
filled into 1 -mL, type I glass syringes, with a 29- g staked needle, needle shield, grey rubber 
plunger, and plastic plunger rod. Filled syringes are labeled and packaged into trays and cardboard cartons.  
In the double-blind cohort, NGM282  is provided as a sterile solution for injection in a 
single-use, pre -filled syringe for SC  administration  at doses of 3 and 6 mg , and 
volume- matched placebo. In the single -blind cohort, NGM282 is provided as a sterile 
solution for injection in a single -use, pre- filled syringe for SC administration at doses of 0.3, 
1, and 3 mg . In the placebo-controlled 24-Week histology cohort NGM282 is provided as a 
sterile solution for injection in a single -use, pre- filled syringe for SC administration at 1  mg 
dose and volume- matched placebo. 
The drug product is manufactured for NGM under current Good Manufacturing Practice 
regulations  
that has undergone FDA inspection. 
10.1.2 Rosuvastatin 
10.1.2.1 Drug S upply for Open -Label Single -Blind Cohort  
For the open- label single -blind cohort, r osuvastatin will be supplied as 20-mg pink, round, 
convex- shaped , coated tablets with “RU20” on one side and blank on the other side in bottles 
of 30 tablets (NDC 16252-617-30).  The active ingredient is rosuvastatin calcium and inactive 
ingredients include microcrystalline cellulose, lactose monohydrate, sodium carbonate monohydrate, sodium lauryl sulfate, crospovidone, magnesium stearate, titanium dioxide, polyethylene glycol, polyvinyl alcohol, talc, ferric  oxide yellow, ferric oxide red, FD&C Red 
40, and indigotindisulfonate sodium.  
10.1.2.2 Drug S upply for Placebo -Controlled 24- Week Histology Cohort  
For the placebo-controlled 24- week histology cohort, rosuvastatin will be supplied. 
Rosuvastatin calcium tablets 20 mg are light pink colored, round, biconvex, film coated tablets  debossed with '1181' on one side and plain on other side in bottles of 90 tablets ( NDC 
13668-181-90). The active ingredient is rosuvastatin calcium and inactive ingr edients include
 
crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose,  titanium dioxide, triacetin  and ferric oxide red.  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 92 of 125 10.2 Study -Drug Accountability  
The PI is responsible for ensuring that a current record of inventory/drug accountability 
(NGM282 and rosuvastatin) is maintained.  Inventory records must be readily available for 
inspection by the study monitor and are open to inspection by regulatory authorities at any time.  Each shipment of drug supply for the study wil l contain a  shipping manifest t o assist 
the PI in maintaining current and accurate inventory records. 
Upon receipt of the investigational drug, the designated site personnel will visually inspect 
the shipment, verify the number and condition of study drug received, and confirm receipt of study drug.  
At the completion of the study and after all drug accountability has been performed by the 
site CRA, all unused study-drug supplies will be returned to the Sponsor (or designee) or disposed of by the clinic, pe r the Sponsor’s (or designee’s) written instructions.  
10.3 Study -Drug Storage 
NGM282  syringes are  to be stored  at the clinical site  in the provided packaging and 
refrigerated at 2 °C–8°C (36°F–46°F) in a secure, controlled- access location protected from 
light. A t the subject’s home, NGM282  syringes are to be stored in the provided packaging 
protected from light and refrigerated.   All drug excursions should be reported immediately to 
Sponsor to confirm NGM 282 stability. 
Rosuvastatin calcium tablets should be stor ed at room temperature, at 68° F–77°F  
(20°C– 25°C) and in a dry place.  Excursions are permitted to 59°F–86°F (15°C– 30°C) 
Please refer to package insert USP Controlled Room Temperature.  (Appendix D) 
Subjects will be instructed to take care in keeping both study drugs out of the reach of 
children and other family members . 
10.4 Dose Preparation and Administration  
10.4.1 NGM282 
Subjects will be instructed to dose with NGM282 at relatively the same time each day .  For 
visit days in the clinic, subjects will not do se at h ome.  
Study- drug syringes should be brought to room temperature (~15-20 minutes) prior to use  
and administered  as a SC injection in the abdomen. On Day 1, subject s will be trained on SC 
self-injecting . During the on- treatment visits , SC self -injecting  will occur in the clinic under 
observation by clinic staff.  Re-training will be provided as required. Written  dose preparation 
and administration instructions will be provided to subject s. Subject s will be required to 
complete a daily study-drug administration diary.  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 93 of 125 10.4.2 Rosuvastatin 
Only subjects in the open- label single -blind and placebo-controlled 24-week histology 
cohorts who meet specific on -treatment criteria will be instructed to dose r osuvastatin based 
on the LDL -C levels at Weeks 2, 4 , and 8 or at the discretion of the medical monitor . 
Additionally, subjects in the placebo- controlled 24 -week histology cohort who have not 
achieved an adequate response or are unable to tolerate statin therapy may  be considered for 
second-line lipid-lowering therapy with ezetimibe  at the discretion of the medical monitor.  
Ezetimibe is formulated as 10mg tablets and can be administered with or without food at the 
same time as rosuvastatin.  This must be approved by the Sponsor’s Medical Monitor prior to dosing with ezetimibe an d will be prescribed by the Investigator. The specific treatment 
algorithms will be based on whether subjects are statin naïve  (Section  10.4.2.1) versus statin 
experienced  (Section  10.4.2.2) at Baseline as outlined in the following figures for subjects in 
both the open- label single -blind and placebo -controlled 24-week histology cohorts: 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 96 of 125 11 Adverse Events 
11.1 Definition and Grading Intensity of Adverse Events  
An AE is defined as any untoward medical occurrence in a subject  of clinical investigational 
participatio n administered a pharmaceutical product , whether or not considered drug related. 
A TEAE is an AE that is reported after a dose of study drug. 
AEs include the following: 
• Unfavorable changes in general condition 
• Subjective or objective signs/symptoms 
• Concomitant diseases or accidents  
• Clinically relevant adverse changes in laboratory para meters observed in a subject 
in the course of a clinical study  
AEs comprise all disturbances of general health status, subjective and objective disease 
symptoms (including laboratory abnormalities), and accidents observed in the context of a 
clinical trial, irrespective of a possible causal relationship with the administration of the trial 
substance.  Events occurring in the framework of a clinical trial during drug- free and 
post-treatment periods or under placebo are also to be designated as AEs. 
All AEs  regardless of how identified (e.g., volunteered, elicited, noted on physical 
examination) will be recorded throughout the study from the time the patient signs informed 
consent through Follow-up.  
Subjects will be followed for resolution of AEs, by querying the subject s for an ongoing AE 
until resolved or until any unresolved AEs are judged by the PI to have stabilized or if lost to follow-up. Resolution of all AEs will be promptly documented by the clinic on the subject’s CRF.  
Any pregnancy diagnosed during the study must be reported immediately to the PI and Sponsor, including pregnancy in female partners of male subjects.  The pregnancy will be 
followed to term and/or outcome and this outcome must be reported to the Sponsor. Pregnancy, in and of itself, is not regarded as an AE or SAE unless the birth results in a congenital anomaly/birth defect or there is suspicion that the study medication may have interfered with the effectiveness of a contraceptive medication or method.  
The PI will rate the severity of A Es using the CTCAE v4.03 to grade the severity . Each 
CTCAE v4.0 3 term is a Medical Dictionary for Regulatory Activities  (MedDRA) Lowest 
Level Term  (LLT).  The CTCAE displays Grades 1 through 5 with unique clinical 
descriptions of severity for each AE.  Not a ll Grades are appropriate for all AEs.  Therefore, 
some AEs are listed with fewer than five options for Grade selection.  Grade 5 (Death) is not 
appropriate for some AEs and , therefore , is not an option.  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 97 of 125 11.2 Criteria for Determining Relationship to Drug  
The PI will make a blinded determination of the relationship of the AE to NGM282 
(including placebo) in the double-blind cohort. An open-label determination of the relationship of the AE to NGM282 and a separate open-label determination of the relationship of the  AE to rosuvastatin will be made in the open- label single -blind cohort. The 
PI will make a blinded determination of the relationship of the AE to NGM282 (including placebo) and a separate open -label determination of the relationship of the AE to rosuvastatin 
in the placebo -controlled 24-week histology cohort. All determinations of relationship will be 
made using a four-category system (not related, possible, probable, or definite) according to the following guidelines: 
• NOT RELATED = an AE that does not foll ow a reasonable temporal sequence from 
administration of the drug and that can be reasonably explained by other factors, 
including underlying disease, complications, concomitant drugs, or concurrent treatment; 
• POSSIBLE  = an AE that follows a reasonable temporal sequence from the 
administration of the drug (including the course after withdrawal of the drug) and that cannot be excluded as being possibly caused by the drug (e.g., existence of similar reports attributed to the drug and/or its analogues; reactions attributable to the pharmacological effect of the drug), although other factors such as underlying disease, complications, concomitant drugs, or concurrent treatment are presumable;  
• PROBABLE = an AE that follows a reasonable temporal sequence from admin istration 
of the drug (including the course after withdrawal of the drug) and that can be excluded as being possibly caused by other factors, such as underlying disease, complications, concomitant drugs, or concurrent treatment. 
• DEFINITE = an AE that follows a reasonable temporal sequence from administration 
of the drug (including the course after withdrawal of the drug), follows a known or 
hypothesized cause–effect relationship, and (if appropriate) satisfies the following:  
• Positive results obt ained in drug sensitivity tests  
• Toxic level of the drug present in blood or other body fluids 
11.3 Reporting  
An SAE is any untoward medical occurrence at any dose that results in any of the following outcomes: 
• Death  
• A life -threatening event (i.e., places the subject, in the view of the PI, at immediate risk 
of death) 
• Inpatient hospitalization or prolongation of existing hospitalization 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 98 of 125 • A persistent or significant incapacity  or substantial disruption of the ability to conduct 
normal life functions  
• A congenital anomaly/birth defect  
• Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered SAEs when, based upon appropriate medical 
judgment, they may jeopardize the subject  and may require medical or surgical 
interven tion to prevent one of the outcomes listed in this definition. 
An unexpected adverse drug event is any adverse drug event the specificity or severity of which is not consistent with the current IB or, if an IB is not required or available, the specificity or severity of which is not consistent with the risk information described in the general investigational plan or elsewhere in the current application.  
An AE is associated with the use of the drug if a reasonable possibility exists that the event may have been caused by the drug. 
SAEs that are unexpected and related  to either NGM282 or rosuvastatin are reportable to 
Regulatory Authorities. All SAEs will be reported by the PI to the Sponsor and will be 
reported to the responsible Ethics Committee (EC)  in accordance with local requirements. 
The Sponsor’s assigned Safety Representative will be notified in writing (e.g., email or 
facsimile) within 24 hours of when an SAE is first recognized or reported . The Safety 
Representative will subsequently notify the Sponsor and the Sponsor’s assigned Medical Monitor of all reported SAEs. 
11.4 Cardiovascular Adjudication 
An external independent Cardiovascular Adjudication Committee (CAC) will adjudicate 
serious adverse events (SAEs). The CAC members will be independent of the S ponsor , the 
clinical study sites and Investigators. The blinded medical review of known or suspected 
Major Adverse Cardiovascular Event ( MACE ) will primarily focus on CV death, myocardial 
infarction, cerebrovascular accident (stroke), and hospitalization f or heart failure.   Sites may 
be asked to provide additional source documentation relevant to any event reported to the 
CAC as they would to study safety personnel for any serious safety event.  F urther details are 
retained in  the CAC Charter for the NGM282  Program. 
 
12 Data Analysis and S tatistical Considerations  
Data analysis will be performed according to the Sponsor’s or its representative s’ Standard 
Operating Procedures (SOPs).  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 99 of 125 Details of statistical parameters and methods to be applied will be provided in  a detailed 
Statistical Analysis Plan (SAP) prior to database lock (unblinding).  The general analytical 
approach for all endpoints will be descriptive in nature.   
Unless otherwise stated, the following statistical approaches will be taken:  
• Continuous varia bles:  Descriptive statistics will include the number of non -missing 
values, mean, standard deviation (SD), median, minimum, and maximum. The minimum 
and maximum values will be presented to the same number of decimal places as recorded in the CRF; mean, median, and SD will be presented to one more decimal place than the raw data.  
• Categorical variables:  Descriptive statistics will include frequency counts and 
percentages per category.  Percentages will be rounded to one decimal place, with the 
denominator being the number of subject s in the relevant population . 
• Imputation: No missing data will be imputed. 
• PK data:  Descriptive statistics will include the coefficient of variation.  Arithmetic mean 
and SD will be substituted with geometric mean and SD for all PK- concentration 
descriptive statistics.  
• Confidence intervals (CIs): CIs will be two -sided and will use 95% confidence levels. 
Any analyses requiring significance testing will use a two- sided test at the 5% 
significance level.  
• Baseline:  Baseline will be defined  for each patient and will be defined as the last 
available, valid, non- missing assessment prior to start of first study -drug administration. 
Unknown, Not Done, Not Applicable, and other classifications of missing data will not be considered when calculating Baseline observations. However, valid categorical observations will be considered for B aseline calculations.  
• Analyses:  Parametric tests will be used where all statistical requirements are met (e.g., 
normal distribution).  In the event that statistical re quirements are not met, non- parametric 
alternatives will be utilized.  
12.1 Sample Size  
For the double-blind cohort, a sample size of 75 subjects was selected (25 subjects per 
treatment arm).  
Allowing for a dropout rate of 10% the following sample- size sensitivi ty calculations were 
based on a minimum number of 22 subjects per treatment group completing the trial.  
A 5% difference in total liver fat content is the minimal appreciable difference that would be 
considered clinically relevant between the active treatm ent arms and the placebo treatment 
group. If the NGM282 3-mg and 6-mg groups are assumed to  have at least a 6% reduction in 
liver fat when compared to Baseline along with a reduction of 1% or less from B aseline in 
the placebo group, with a 5% level of significance, the following illustrates sample -size 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 100 of 125 power calculations based on varying common standard deviations to achieve an overall 
(overall F -test) statistically significant treatment effect: 
Method  Mean Absolute Change from Baseline  
Common 
SD Effect 
Size Power  NGM282 
6 mg  NGM282 
3 mg Placebo  
One-way 
analysis of 
variance  
(equal n’s)  6% 6% 1% 8% 0.0868  54% 
6% 6% 1% 7% 0.1134  66% 
6% 6% 1% 6% 0.1543  80% 
6% 6% 1% 5% 0.2222  92% 
SD = standard deviation.  
 
A maximum sample size of 100 subjects was selected (with a minimum of 15 subjects per 
treatment arm, up to a maximum of 2 5 subjects per treatment arm) for the single -blind cohort 
design. 
The sample size for the open- label single-blind cohort was not based on a formal sample- size 
calculation.  Inste ad, it was based on the results of the interim analysis that was conducted 
when ~15 subjects per arm had completed 12 weeks of treatment . Although the results of this 
interim analysis are still blinded, the magnitude of the treatment differences observed 
indicate that a sample size of 15 –20 subjects per treatment arm is sufficient to give an initial 
indication of efficacy for further exploration.  
The sample size of the placebo -controlled 24-week histology cohort is based on 1) 12- week 
histologic response data from the 3 -mg cohort and 2) estimated placebo histologic response 
rates from controlled Phase 2 studies in NASH. Preliminary 12 -week histologic response 
data (n=16) demonstrated that 50% of subjects had a 1-stage improvement in fibrosis with no 
worseni ng of NASH or resolution of NASH with no worsening of fibrosis. The placebo 
histologic response rates from recent Phase 2b trials of obeticholic acid, cenicriviroc, liraglutide , and selonsertib were 14%–20% at timepoints ranging from 24 to 72 weeks. Based 
on these data, the assumptions of calculated sample- size estimates for 24 -week efficacy used 
an NGM282 response of 50% versus 15% for placebo utilizing 80% power and alpha=0.05 with a 2:1 randomization scheme. Assuming a 15% drop- out rate, the planned sample size of 
50 NGM282- treated subjects and 25 placebo subjects is sufficient to evaluate efficacy and 
support powering estimates for a late -stage clinical trial.  
12.2 Randomization and Enrollment  
For the double-blind cohort, a t Day 1 all eligible subjects will b e randomized via IW RS to 
one of the three treatment arms (NGM282 3 mg , NGM282 6 mg, or placebo) in a 1:1:1 ratio. 
The proportion of subjects with diabetes ( categori zed on a dichotomous scale ) will be 
balanced across the three groups to ensure an even distr ibution across the three  groups. 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 101 of 125 Diabetes status for balancing (“no diabetes ” or “ diabetes”), will be based on medical history, 
Screening labs, current medications , and clinical assessments.  
The single-blind cohort is not randomized. Subjects will initial ly be enrolled sequentially into 
dosing G roup 1 and enrollment will be continuous within and between each dosing groups. 
Sequencing of the dosing Groups 2 and 3 will be based on PD and safety parameters from 
dosing Group 1 and may run in parallel to each o ther. A fourth optional dosing group may be 
conducted based on the safety/tolerability, imaging data and histology (dosing Group 3 only) data from the prior 3 dosing groups. Dosing Group 4 will be initiated only after all subjects in Cohort 3 have been enrolled and a minimum of 10 subjects have completed 12 weeks of treatment in order to do a preliminary review of key data. Dosing group sequence and individual subject treatment assignment will be blinded only study subjects throughout the study period. 
For the placebo-controlled 24- week histology cohort , at Day 1 all eligible subjects will be 
randomized via IW RS to one of the two  treatment arms (NGM282 1 mg  or placebo) in a 
2:1 ratio . The Sponsor, study sites, and subjects will be blinded to treatment assign ment.  The 
randomization schedule will be stratified by subject’s fibrosis stage 2 or 3 based on the 
screening qualification liver biopsy.   
12.3 Test of Hypothesis and Significance L evels  
The null hypothesis being tested for this study will be that there is no difference in the 
absolute change in liver fat content from B aseline between the NGM282 and the Placebo 
treatment groups at EOT  for the double-blind cohort. The alternative hypothesis being tested 
will be that there is at least a 5% difference in the absolute change in liver fat content from 
Baseline between the NGM282 and the Placebo treatment arms at Week 12 for the 
double-blind cohort. A two -sided analysis will be conducted at a 5% significance level.  
Comparisons across the cohorts will be exploratory an d further outlined in the SAP. 
12.4 Study Populations 
The study populations are detailed below. Details of any other populations for analysis will 
be described in the SAP.  
12.4.1 Intent -to-Treat Population  
All randomized subjects in the double- blind and placebo -contro lled 24-week histology 
cohorts) will be included in the Intent -to-Treat ( ITT) population. All B aseline characteristics 
and demographic data will be summarized using the ITT population. The ITT population will be based on randomized treatment if this differ s from actual treatment received.  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 102 of 125 12.4.2 All Patients  Population 
For the open- label single -blind cohort, a ll enrolled  subject s will be included in the All 
Patients  population. All Baseline characteristics and demographic data for the open- label 
single- blind cohor t will be summarized using the All Patients  population. The All Patients  
population will be based on enrolled treatment if this differs from actual treatment received.  
12.4.3 Safety Population 
All randomized/enrolled  subject s who receive at least one dose (full o r partial) of study drug 
and have at least one post-dose safety evaluation will be included in the Safety population. 
All safety endpoints will be summarized using the Safety population and will be based on actual treatment received if this differs from th e randomized /enrolled  treatment.  
12.4.4 Efficacy Population  
All randomized/enrolled  subject s who receive at least one dose (full or partial) of study drug 
and have at least one valid, non-missing post- dose efficacy /PD parameter value will be 
included in the Efficacy population. All efficacy and PD endpoints will be summarized and 
analyzed using the Efficacy population. This will be the main population for the analysis of efficacy and PD endpoints. The Efficacy population will be based on randomized/enrolled  
treatment if this differs from actual treatment received.  
12.4.5 Per Protocol Population 
The Per Protocol (PP) population will constitute a subset of the Efficacy population and will include subjects that have at least one valid, non -missing post-dose liver fat conten t 
measurement . Subjects in the Efficacy population who deviate from the conduct of the study 
or have an AE deemed by the Medical Monitor to be impactful on the primary endpoint will be excluded from the PP population. This will be the secondary population for the analysis of 
efficacy and PD endpoints. The PP population will be based on actual treatment received if it 
differs from that to which the patient was randomized/enrolled . 
12.4.6 Liver Histology Population 
The l iver histology population will constitute a  subset of patients in the Efficacy population 
and will include patients w ho have at least one valid, non- missing Baseline and EOT  liver 
biopsy. Subjects in the Efficacy population who deviate from the conduct of the study or have an AE deemed by the Medical Monitor to be impactful on the primary endpoint will be 
excluded from the PP population. This will be the secondary population for the analysis of efficacy and PD endpoints. The PP population will be based on actual treatment received if it differs from th at to which the patient was randomized/enrolled. 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 103 of 125 12.4.7 Pharmacokinetic Population  
All randomized/enrolled  subjects who receive at least one dose (full or partial) of drug, with 
a pre-dose (Baseline) blood draw, and at least one qualified (above the limit of 
quantification) post- dose sample will be included in the PK  population. Subject s with 
protocol violations will be assessed  by the medical  monitor for inclusion in the 
PK population. PK summaries and analyses will be conducted using the PK population. 
The PK population will be based on actual treatment received if it differs from that to which 
the patient was randomized /enrolled . 
12.5 Treatment Exposure  
Individual data listings for treatment exposure will be presented for each subject. Treatment exposure will be summarized as extent of exposure to the study drug. Measures of extent of exposure include the total number of doses per subject  and compliance.  Treatment 
compliance is defined as the number doses administered per protocol/number of doses prescribed per protocol. Treatment exposure will be summarized using the S afety population 
by actual treatment. 
12.6 Patient Disposition  
Individual data listings for patient disposition will be presented for each patient, including 
enroll ment date, treatment start date, treatment d iscontinuation date, discontinuation reason, 
and population flags. The number and percentage of patients entering and discontinuing the study will be presented by randomized treatment group  for the double- blind  and 
placebo -controlled 24-week histology cohorts  and by enrolled treatment group for the 
open- label single- blind cohort . The reason s for discontinuation will also be summarized.  
Patient disposition will be summarized using the ITT population for the double-blind and placebo -controlled 24-week histology cohorts and the All Patients population for the 
open- label single -blind cohort . 
12.7 Protocol Deviations 
Individual data listings for protocol deviations will be presented for each patient.  Protocol 
deviations will be summarized using the ITT population for the double- blind  and placebo-
controlled 24 -week histology cohorts and the All Patients population for the open- label 
single- blind cohort . 
12.8 Demographic Analysis 
Individual data listings for demographic and B aseline characteristics will be presented for 
each patient. Demographic and B aseline characteristics will be descriptively summarized by 
randomized treatment group  for the double- blind and placebo- controlled 24-week histology 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 104 of 125 cohorts and by enrolled treatment group for the open- label single-blind cohort. Q uantitative 
and/or categorical summaries will be presented for demographics, medical history, and other 
Baseline characteristics.  Demographic and B aseline characteristics will be summarized using 
the ITT population for the double-blind and placebo-controlled 24- week histology cohorts 
and the All Patients population for the open- label single-blind cohort. 
12.9 Efficacy  and P harmacodynamics 
Individual data listings for efficacy and PD variables will be presented for each patient. Efficacy and PD summaries and analyses will use the E fficacy population.  
12.9.1 Efficacy and Pharmacodynamic Endpoint s 
The primary efficacy endpoint for this study will be the absolute change in liver fat content as measured by MRI -PDFF in patients subjects with histologically confirmed NASH  after 
12 or 24 weeks of treatment . 
Secondary Objectives:  
• Evaluate the percentage change in absolute liver fat content at EOT . 
o In the open-label single-blind cohort, additional evaluations will be performed at Weeks 6 and 18. 
o In the placebo -controlled 24- week histology cohort, additional evaluations will be 
performed at Weeks 6, 24, and 30. 
• Evaluate the percentage of normalization for liver fat content at EOT . 
• Evaluate the change in liver fat content response rate as defined by a ≥  5% decrease in 
absolute liver fat content.  
• Evaluate the absolute and percentage changes from Baseline to EOT as well as the 
percentage of normalization  of the following parameters: ALT, AST, triglycerides, 
bilirubin (total and direct), and GGT. Percentage of normalization will also  be 
investigated for a clinically meaningful threshold for  triglycerides.  
• Evaluate the absolute and percentage changes from Baseline to EOT  of the following: 
o Total cholesterol, HDL -C, LDL -C, triglycerides, and lipoprotein particles   
o FFAs  
o Fasting blood glucose , insulin levels, , and HOMA -IR 
o Pro-C3 and ELF scores ( Placebo Controlled 24 Week Histology Cohorts ) 
o Body weight, BMI, and waist circumference 
o C4 and serum bile acids  
o Bile-mediated absorption as measured by vitamin D, INR,  and fecal fat content  
• Evalu ate the liver histologic response  in Placebo Controlled 24 Week Histology Cohorts  
o Improvement in liver fibrosis by ≥ 1 stage by NASH Clinical Research Network 
(CRN) criteria with no worsening of steatohepatitis  

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 105 of 125 o Resolution of NASH (defined as an NAS score of 0 or 1 for inflammation and 0 for 
ballooning) with no worsening of fibrosis as d etermined by the NASH CRN 
criteria.   
• Evaluate the exposure of NGM282 in patients with NASH . 
• In the double- blind and placebo -controlled 24-week histology cohorts, NGM282 
exposure will be compared to placebo at 2 hours post -dose at Day 1 and EOT and 
pre-dos e at all on -treatment study visits.  
• In the open-label single-blind cohort, NGM282 exposure will be compared across the 
dosing groups at 2 hours post-dose at Day 1 and Week 12 and pre- dose at all 
on-treatment study visits.  Additional PK samples will be c ollected at Baseline and 1, 
2, 4, 8, and 12 hours post-dose on Day 1 and Week 6 in a subset of subjects in each 
dosing group. 
Exposure of all doses from both double- blind and open- label single -blind cohorts will be 
compared to each other as well as to exposur e in other study populations treated with 
NGM282 (Studies 12- 0101, 13-0102, 13-0103, 14-0104, and 15 -0106).  
The impact of rosuvastatin administered in response to increases in total cholesterol and 
LDL -C from NGM282 treatment will be evaluated.  
Exploratory Parameters:  
•  
  
  
  
  
 
  
  
 
  
 
  
 
 
12.9.2 An
alysis of Primary Endpoint 
The analysis of the primary endpoint will be based on the Efficacy population. 

NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 106 of 125 The absolute change in liver fat content from Baseline to EOT  will be compared be tween 
treatment groups using an analysis of covariance ( ANCOVA) model with treatment group 
and diabetic status  (double-blind cohort only) as cofactors and Baseline endpoint as a 
covariate.  Least square means with standard errors (SE s), differences in least  square means 
with SE, 95% CIs for the difference in least square means, and corresponding p- values will 
be presented.  Further covariates/cofacto rs may be included in the modeling depending on the 
relevance to the endpoint analyzed and will be further described in the SAP. 
In cases where the parameters do not follow a normal distribution, a non- parametric approach 
will be followed to analyze the difference between treatment groups.  
The primary analysis for the primary endpoint will be repeated for the Per Protocol 
population. 
12.9.3 Analysis of Secondary Endpoint s 
The analysis of secondary PD endpoints will be based on the Efficacy population, for all three cohorts separately . 
For continuous secondary endpoints the same method of analysis as for the primary endpoint will be followed.  Further covariates/cofactors may be included in the modeling depending on 
the relevance to the endpoint analyzed and will be further described in the SAP. 
Categorical secondary endpoints (percentage of normalization) will be analyzed t hrough a 
chi-square test.  The difference between proportions along with 95% CIs for the difference 
between proportions will be presented by treatment-group comparisons.  
The analyses in the open- label single -blind cohorts will be stratified by statin use  at Baseline 
whereas they will be stratified by fibrosis stage in the placebo -controlled 24-week histology 
cohort. The effect of statin use on lowering LDL cholesterol will also be explored  both  the 
open- label single -blind and placebo -controlled 24 -week histo logy cohorts. In addition, 
sensitivity analyses will be performed to investigate the effect on the efficacy endpoints of 
statin use in the open- label single -blind cohorts and fibrosis stage on the placebo-controlled 
24-week histology cohort.  
Comparisons between the 3 cohorts will be performed and further detailed in the SAP.  
12.9.4 Analysis of Exploratory Endpoints  
The analysis of exploratory endpoints will be based on the Efficacy population. For continuous exploratory endpoints the same method of analysis as fo r the primary 
endpoint will be followed. Further covariates/cofacto rs may be included in the modeling 
depending on the relevance to the endpoint analyzed and will be further described in the 
SAP.  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 107 of 125 12.10 Safety  
Safety and tolerability will be assessed by clinical review of the following parameters:  AEs, 
clinical laboratory tests, physical examination , and vital signs. All safety analyses will be 
conducted using the safety population. 
12.10.1 Adverse Events  
AEs, including serious AEs, will be coded using the MedDRA. The number and percentage 
of subjects experiencing an AE will be summarized for each system organ class (SOC) and preferred term (PT) by treatment group.  In addition, AEs will be tabulated according to 
intensity, causality , and relation to the study drug. Individual data listings for AEs will be 
presented for each subject . 
All AE summaries will be restricted to TEAEs only.  TEAEs  are defined as AEs that 
commence on or after the time of start of first study -drug administration.  AEs without an 
onset date or time will be defined as treatment emergent, except if an incomplete date (e.g., month and year) clearly indicates that the event started prior to the start of first administration of study drug or if the AE stop date indicates that the event started or stopped prior to the start of first administration of study drug.  
For the summaries of AEs, subject s who experience the same AE (in terms of the MedDRA 
preferred term) more than once will be counted only once for that event. Separate summaries will be provided for AEs by intensity, causality, and relationship to study drug.  
All AEs will be listed.  SAEs will be summarized and listed.  
12.10.2 Clinical Laboratory Evaluations 
The absolute and percentage changes from B aseline to EOT and EOS of t otal cholesterol, 
HDL -C, LDL-C, and lipo protein particles will be analyzed through inferent ial statistics and 
will be based on the Safety population. Observed values and absolute changes from B aseline to EOT and EOS for routine chemical 
laboratory values will be summarized descriptively at e ach time point for each treatment 
group and overall. Shift tables may also be presented for select chemistry and hematology 
laboratory parameters, as defined in the SAP.  
Individual data listings of laboratory results will be presented for each subject . Laboratory 
values will be compared to normal ranges; out-of- range and clinically significant laboratory 
values will be identified in the listings. 
12.10.3 Physical Examinations  
Individual data listings for physical examination results will be presented for each subj ect. 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 108 of 125 12.10.4 Vital Signs  
Observed values as well as absolute changes from B aseline will be summarized descriptively 
for all vital- sign parameters, by time point and treatment group. Individual data listings will 
be presented for each subject . 
12.10.5 Pregnancy Test  
Indivi dual listings for urine and serum pregnancy test data will be presented for each subject. 
12.10.6 Electrocardiogram  
Observed values as well as absolute changes from B aseline will be summarized descriptively 
for all ECG parameters, by time point and treatment group. Individual data listings will be 
presented for each subject . 
12.10.7 Injection -Site Reactions 
Frequency tabulations of ISR  results will be presented at each time point by treatment group.  
12.10.8 Concomitant Medications  
Concomitant medications will be classified using the current version of the World Health 
Organization Drug Dictionary  Enhanced  (2012). Concomitant medications are medications 
taken at least once from 28 days prior to Screening through the End of Study visit. Medications stopped on the 28 days prior to Screening time point will not be considered a conc omitant medication.  
Individual data listings will be presented for each subject, with separate listings for prior medications and concomitant medications.  In addition, concomitant medi cations will be 
summarized by Anatomical Therapeutic Chemical (ATC) classes and PT using frequency counts and percentages.  For the summaries of concomitant medications, subjects who take 
the same medication (in terms of the preferred term) more than once w ill be counted only 
once for that medication. 
12.11 Pharmacokinetics  
12.11.1 Trough Serum Concentrations  (All Subjects)  
The following PK parameters will be calculated using validated PK software, WinNonlin, 
Version 5.3 (or higher; Pharsight Corporation; Cary, NC, U.S.): 
• Day 1; Weeks 1, 2, 4, 8, 12, 18, and 24: trough concentration (C
trough) 
• Day 1 and Week 12 or Week 24: C trough; concentration at 2 hours post- dose (C 2h post -dose) 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 109 of 125 PK data will be used to evaluate the accumulation of NGM282 in the plasma of NASH 
patients f ollowing multiple -dose administration at 3 and 6 mg per day. This will be done by 
comparing the steady- state trough NGM282 levels in NASH patients to results obtained on 
Day 1 in the same subject  and, more generally , in the dosing cohort. In  addition, 
determination of NGM282 concentrations 2 hours post-dose on Day 1 and EOT  will enhance 
information obtained on accumulation and provide an indication of expected maximum drug concentration (C
max) in patients.  This information will be directly compared to Phase  1 
results obtained in healthy volunteers as well as those obtained in patients with T2D , PBC, 
and primary sclerosing cholangitis . In addition, PK data will be used to explore PK/PD 
correlations in terms of drug efficacy and toxicity, where data allow.  Actual sample times 
will be used in the data analysis. 
12.11.2 Single -Dose Pharmacokinetics (Open -Label Single -Blind Subjects)  
The Day 1 PK data will be used to evaluate the single-dose PK of NGM282 in PBC patients at 0.3, 1, and 3 mg per day, using the PK population. For each subject, the following PK 
parameters will be  calculated, whenever possible, based on the serum concentrations of 
NGM282  collected at pre -dose and 1, 2, 4, 8, and 12 hours after dosing on Day 1. 
• C
max - maximum observed concentration 
• Tmax - time t o maximum concentration 
• AUC 0–t - area under the concentration –time curve from Hour 0 to the last measurable 
concentration, calculated using the linear trapezoidal rule  
• AUC 0–∞ - area under the concentration–time curve extrapolated to infinity, calculated 
using the formula: 
AUC 0–∞ = AUC 0–t + zt
λC
 
where C t is the last measurable concentration and λZ is the apparent terminal elimination 
rate constant  
• t1/2 - apparent terminal elimination half -life, where t 1/2 = (ln2)/λ Z 
• CL/F - clearance divided by the bioavailable fraction calculated using this formula: 
Dose/AUC 0–∞ 
• Vz/F - volume of distribution based on the terminal portion of the concentration–time 
curve divided by the bioavailable fraction, Dose / (AUC 0–∞ × λ z) 
The effect of dose level on NGM282 exposure will be assessed by evaluating C max and 
AUC 0–t. Any substantial change in t 1/2, CL/F, or V z/F with dose will also be noted.  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 110 of 125 Further details will be specified in the SAP.  
12.11.3 Multiple -Dose Pharmacokinetics (Open -label Single -blind Subjects ) 
Week 6 PK data  will be used to evaluate the effect of repeat dosing and potential 
accumulation of NGM282 following administration at 0.3, 1, and 3 mg  per day , using the PK 
population. For each subject, the same PK parameters as listed in  Section  12.11.2 will be 
calculated whenever possible, based on the serum concentrations of NGM282 collected at 
pre-dose and 1, 2, 4, 8, and 12 hours after dosing on Week 6. Where possible, AUC 0–∞, t1/2, 
CL/F , and V z/F will be  used for the evaluation of time invariance in PK characteristics.  
Accumulation will be assessed by calculating C max,  Week 4 /Cmax, Day 1  and AUC 0–t, Week 4 /AUC 0–t, 
Day 1 for each subject.  
In addition to the Week 6 versus Day 1 comparison, ac cumulation will also be assessed by 
comparing the trough and 2 -hour post-dose NGM282 levels collected over the course of the 
study.  
PK parameters will be estimated , where  appropriate, using validated commercial software.  
Additional software, if required, will be detailed in the SAP.  Other parameters may  be added 
as appropriate. PK analysis will use  actual times as recorded on the CRF.  
12.12 Interim Analysis  
A single interim analysis (IA) is planned to be conducted in the double -blind cohort after 
approximately 12 subject s per arm have completed 12 weeks of treatment.  The final analysis 
of the double-blind cohort is planned to be conducted after all double- blind subject s have 
completed Week 16. The IA  will include review of all safety and selected efficacy endpoi nts. 
The final analysis of the double- blind cohort will review  all endpoints (safety, efficacy, and 
exploratory).  The double blind will be maintained for the IA  as the results in the summary listings and 
tables will be presented only by treatment group. The data will be fully unblinded at the final 
analysis of the double-blind cohort as the database will include all randomized and completed have undergone a soft- lock at that time.   
There will be no formal IA s performed in the open- label single -blind cohort. 
A single IA is planned to be conducted in the placebo-controlled 24- week cohort after at least  
50% subjects (2:1 randomization) have completed 24 weeks of treatment. The IA will include review of safety and selected efficacy endpoints by treatment group. The IA is being conducted only for internal planning purposes and the study will not be stopped early based on the results of the IA. Therefore, no formal hypothesis testing will occur with no effect on available alpha for the final planned analyses.   The  final analysis is planned to be conducted 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 111 of 125 after all subjects have completed Week 30 .  Results for individual subjects will not be shared 
with study investigators.   
Further details of the IA  and final analyses, including statistical considerations and anal yses, 
will be included in the SAP . 
 
13 Administrative Aspects  
13.1 Protocol Ad herence 
The PI must adhere to the protocol as detailed in this document and agree that the Sponsor 
must approve any changes to the protocol prior to seeking approval from the EC. No alterations in the protocol will occur without agreement between the Sponsor and the PI. No 
alterations in the protocol affecting patient  safety will occur without the express written 
approvals of the Sponsor, PI, and EC. 
13.2 Disclosure  
All information provided re garding the study as well as all information collected/documented 
during the course of the study will be regarded as confidential. The PI agrees not to disclose 
such information in any way without prior written permission from the Sponsor. 
Any publication of the results either in part or in total (articles in journals or newspapers, oral 
presentations, abstracts, etc.) by the PI or their representative(s) shall require prior notification and review within a reasonable time frame by the Sponsor and cannot be made in violation of the Sponsor’s confidentiality restrictions or to the detriment of the Sponsor’s intellectual property rights.  
13.3 Monitoring  
The Sponsor’s or designee’s Clinical Research Associate (CRA) will be responsible for monitoring this clinical trial.  The CRA will monitor the study conduct, proper CRF and 
source documentation completion and retention, and accurate study-drug accountability. To this end, the CRA will visit the study site at suitable intervals and be in frequent contact 
through verbal and written communication. The PI will grant access to all documents (related to the study and the individual subjects) at any time these are requested.  In turn, the CRA 
will adhere to all requirements for patient confidentiality as outlined in the ICF.  The PI and 
PI’s staff will be expected to cooperate with the CRA, to be available during a portion of the monitoring visit to answer questions, and to provide any missing information. 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 112 of 125 13.4 Ethics C ommittee  
This protocol, the informed consent document, and all relevant supporting data must be 
submitted to the EC for approval. EC approval of the protocol, informed consent document, and any advertisement used to recruit study patient s must be obtained before the study may 
be initiated.  
The PI is responsible for keeping the EC advised of the progress of the study and of any changes made to the protocol as deemed appropriate, but in any case, at least once a year.  
The PI is also responsible for notifying the EC of any reportable AEs that occur during the study. 
13.5 Inform ed Consent  
This study will be conducted in compliance with International Conference on Harmonisation 
(ICH) E6 Good Clinical Practice: Consolidated Guidelines pertaining to informed consent. 
At the first visit, prior to initiation of any study -related proce dures, patient s must give their 
written consent to participate in the study after having been informed about the nature and purpose of the study, participation/termination conditions, and risks and benefits. The informed consent document must be signed and dated by the patient and PI, or designee, 
prior to study participation. A copy of the informed consent document must be provided to the patient. Signed consent forms must remain in the patient’s study file and be available for verification by Sponsor or i ts representative at any time.  
13.6 Records 
The results from Screening and data collected during the study will be recorded in the patient ’s CRF.  To maintain confidentiality, the patient s will be identified only by numbers 
and initials.  
The completed CRFs will be transferred to the Sponsor or designee. Copies of each CRF will be retained by the PI. All source documents, records, and reports will be retained by the clinic.  
All primary source data  or copies thereof (e.g., laboratory records, CRFs, data sheets, 
correspondence, photographs, and computer records) that  are a result of the original 
observations and activities of the study and are necessary for the reconstruction and evaluation of any study report will be retained in the clinic archives.  
Sponsor will inf orm the PI of the time period for retaining these records to comply with all 
applicable regulatory requirements.  The minimum retention time will meet the strictest 
(longest) standard applicable to that site for the study, as dictated by any institutional requirements or local laws or regulations, or Sponsor standards/procedures; otherwise, the 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 113 of 125 retention period will default to the retention period of 15  years following completion of the 
clinical trial.   
13.7 Financing and I nsurance 
The financing and insurance for this study are outlined in the Clinical Trial Research 
Agreement.  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 114 of 125 Investigator Protocol Review and Signature F orm 
Protocol Number: 15-0105 
 
Protocol Title: A Phase 2, Randomized, Double-Blind, Placebo- Controlled, Parallel -Group 
Multiple -Center Study with  Additional Open- Label Single -Blind and Placebo-Controlled 
24-Week Histology Cohorts to Evaluate the Safety, Tolerability, and Efficacy of NGM282 
Administered for Up to 24 Weeks in Patients with Histologically Confirmed Nonalcoholic 
Steatohepatitis (NASH) 
 
I have read the above-mentioned Protocol Amendment 9 dated  29 March 2019 
I agree to conduct the study as detailed herein and in compliance with ICH Guidelines for 
Good Clinical Practice and applicable regulatory requirements, and to inform all who assist me in the conduct of this study of their responsibilities and obligations.  
 
    
__________________________________________ 
Principal Investigator (Please PRINT)  
 
  
__________________________________________ __________________ 
Principal Investigator (Signature)   Date  
 
 __________________________________________ 
Name of Institution (Please PRINT) 
 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 116 of 125 14 References  
14.1 Clinical Study References  
Study No.  Phase  Study Title  Study Population  
12-0101  1 A Phase 1 Randomized, Double Blind, Placebo Controlled, 
Single Ascending Dose and Multiple Ascending Dose Study to 
Evaluate the Safety, Tolerability, and Pharmacokinetics of 
NGM282 in Healthy Adult Participants  Normal  
volunteers  
13-0102  2a A Randomized, Double Blind, Placebo Controlled, Parallel 
Group, Multiple Center Study to Evaluate the Safe ty, 
Tolerability, and Activity of NGM282 Administered for 28 Days 
to Participants with Type 2 Diabetes Mellitus  T2D 
13-0103  2a A Phase 2, Randomized, Double Blind, Placebo Controlled, 
Parallel Group, Multiple Center Study to Evaluate the Safety, 
Tolerability, and Pharmacodynamic Activity of NGM282 in 
Combination with Ursodeoxycholic Acid (UDCA) Administered 
for 28 Days in Patients with Primary Biliary Cirrhosis (PBC)  PBC  
14-0104  2b A Phase 2, Multicenter Study to Evaluate Four Doses of 
NGM282 Administered For 52 Weeks in Patients with Primary 
Biliary Cirrhosis (PBC)  PBC  
15-0106  2 A Phase 2, Randomized, Double Blind, Placebo Controlled, 
Parallel Group, Multiple Center Study to Evaluate the Safety, 
Tolerability, and Efficacy of NGM282 Administered for 
12 Weeks in Patients with Primary Sclerosing Cholangitis (PSC)  PSC 
 
14.2 Nonclinical Study References  
Study No  Study Title  
Study 11 -MP-NGM282 -1001  Direct Effects of NGM282 on Mouse and Human Adipocytes  
Study 11 -MP-NGM282 -1002  Analysis of NGM282 Binding to Fibrobl ast Growth Factor Receptors  
Study 11 -PD-NGM282 -1001 A 24 -week Study of Ectopic NGM282 Expression  following Intravenous 
Adeno -Associated Viral  Delivery to db/db Mice  
Study 11 -PD-NGM282 -1003 A Single or 14 -Day Efficacy Study of NGM282  Following Subcutaneou s 
Administration in ob/ob  Mice  
Study 11 -PD-NGM282 -1004 Effects of NGM282 on Glucose Metabolism and Body  Weight Following 
14-Day Daily Subcutaneous  Administration in Diet- Induced Obese (DIO) 
Mice  
Study 11 -TX-NGM282 -1002 A 28 -Day Subcutaneous Toxicity and  Toxicokinetic Study with NGM282 in 
Cynomolgus  Monkeys with a 14 -Day Recovery Phase  
Study 12 -MP-NGM282 -1006 Effects of NGM282 Treatment on CYP7a1 Expression in Primary Mouse, 
Rat, and Human Hepatocytes  
Study 13 -MP-NGM282 -1004 NGM282 Activation of Elk -1 in L6 Cells Expressing Mouse, Rat, Rabbit, 
Cynomolgus, or Human  FGFR1c -βklotho Co -Receptors  
Study 13-MP-NGM282 -1005 Activation of FGFR4 -β-klotho -Mediated Signaling by NGM282 in a Rat 
Myoblast Cell Line  
Study 13 -PD-NGM282 -1007 A 24 -Week Study of Ectopic NGM282 Expression following  Intravenous 
Adeno -Associated Viral De livery in FXR -deficient  Mice  
Study 13 -TX-NGM282 -1004 A 13/26 -Week Subcutaneous Toxicity and Toxicokinetic  Study of NGM282 
in Cynomolgus Monkey  
 
  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 117 of 125 14.3 Literature References  
Afzali A, Berry K, Ioannou GN. Excellent posttransplant survival for patients with non alcoholic steatohepatitis 
in the United States. Liver Transpl 2012;18:29– 37. 
Alisi A, Ceccarelli S, Panera N, et al. Association between serum atypical fibroblast growth factors 21 and 19 
and pediatric nonalcoholic fatty liver disease. PLoS One 2013;8:e67160.  
Aranha MM, Cortez -Pinto H, Costa A , et al. Bile acid levels are increased in the liver of patients with 
steatohepatitis. Eur J  Gastroenterol Hepatol 2008;20:519– 25. 
Argo CK, Caldwell SH. Epidemiology and natural history of non -alcoholic steatohepa titis. Clin Liver Dis 
2009;13:511– 31.  
Banerjee R, Pavlides M, Tunnicliffe EM, et al. Multiparametric magnetic resonance for the non -invasive 
diagnosis of liver disease. J Hepatol 2014 Jan;60:69 –77. 
Bechmann LP, Kocabayoglu P, Sowa JP, et al. Free fatty acids r epress small heterodimer partner (SHP) 
activation and adiponectin counteracts bile acid -induced liver injury in superobese patients with nonalcoholic 
steatohepatitis. Hepatology 2013;57 :1394– 406.  
Belfort R, Harrison SA, Brown K, et al. A placebo -controlle d trial of pioglitazone in subjects with nonalcoholic 
steatohepatitis.  N Engl J Med  2006;355:2297– 307. 
Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des  
2013;19:5169– 76. 
Brunt EM, Kleiner DE, Wilson L A, et al. Portal chronic inflammation in nonalcoholic fatty liver disease 
(NAFLD): a histo logic marker of advanced NAFLD -clinicopathologic correlations from the nonalcoholic 
steatohepatitis clinical research network.  Hepatology  2009 ;49:809 –20.  
Caldwell SH , Chang CY, Nakamoto RK, et al. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis  
2004;8:595 –617. 
Cazzo E, Jimenez LS, Pareja JC, et al. Effect of Roux -en-y gastric b ypass on nonalcoholic fatty liver disease 
evaluated through NAFLD fibrosis score: a prospective s tudy. Obes Surg. 2015 Jun;25(6):982 -5. 
Center s for Disease Control  US Obesity Trends  http://www.cdc.gov/obesity/data/index.html (Accessed 12 
December 2014) . 
Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver tr ansplantation for nonalcoholic 
steatohepatitis in the United States. Gastroenterology  2011;141:1249– 53.  
Corey KE, Vuppalanchi R, Wilson LA, et al. NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or  non-HDL -C levels. Aliment Pharmacol Ther 2015;41:301 –9. 
Djedjos C, Kirby B, Billin A, et al. Pharmacodynamic Effects of the Oral, Non -Steroidal Farnesoid X Receptor 
Agonist GS -9674 in Healthy Volunteers. Hepatology 2016; 64 (suppl  1);543A (abstract 1077). 
Cummings DE, Overduin J, Foster Schubert KE, et al. Role of the bypassed proximal intestine in the 
anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis 2007;3:109 –15. 
Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic s teatohepatitis: pathophysiology 
and clinical implications. Gastroenterology 2012;142:711 –25. 
Eren F, Kurt R, Ermis F, et al. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in 
patients with biopsy -proven nonalcoholic fatty live r disease. Clin Biochem 2012;45:655 –8. 
Faubion  WA, Guicciardi ME, Miyoshi H, et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct 
activation of Fas.  Clin Invest 1999;103:137 –45. 
Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 i ncreases metabolic rate and reverses dietary and 
leptin deficient diabetes. Endocrinology 2004;145: 2594– 603.  
Glass LM, Dickson RC, Anderson JC , et al. Total b ody weight  loss of ≥10 % is a ssociated with improved 
hepatic f ibrosis  in patients with nonalcohol ic steatohepatitis. Dig Dis Sci  2015;60:1024– 30. 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 118 of 125 Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients 
with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485 –90. 
Harrison SA, Abdelmalek MF, Trotter JF, et al. NGM82, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a phase 2, multicenter, randomized, double -blinded, 
placebo controlled trial in biopsy -confirmed NASH patients. International  Liver Congress, Abstract LLB0 -07, 
22 April 2017 Amsterdam, NL . 
Higuchi H , Gores GJ. Bile acid regulation of hepatic physiology: IV. Bile acids and death receptors.  Am J 
Physiol Gastrointes t Liver Physiol 2003;284:G734–8.  
Jia X , Naito H, Yetti H, et al. Dy sregulated bile acid synthesis, metabolism and excretion in a high 
fat-cholesterol diet -induced fibrotic steatohepatitis in rats. Dig Dis Sci  
2013;58:2212– 22. 
Kang GH, Cruite I, Shiehmorteza M, et al. Reproducibility of MRI- determined proton density fat fraction 
across two different MR scanner platforms. J Magn Reson Imaging 2011;34:928 –4. 
Kim D, Kim WR, Kim HJ, T  et al.  Association between noninvasive fibrosis markers and mortality among 
adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57:1357 –65. 
Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin independent activator of hepatic protein 
and glycogen synthesis. Science 2011;331:1621– 4. 
Kleiner DE, Brunt EM, Van Natta M, et a l. Design and validation of a histological scoring system for 
nonalcoholic fatty liver disease. Hepatology 2005 ;41:1313– 21. 
Lake AD, Novak P, Shipkova P, et al. Decreased hepatotoxic bile acid composition and altered synthesis in 
progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol 2013;268:132 –40. 
Loomba R, Lawitz E, Mantry P, et al. GS -4997, an inhibitor of apoptosis signal -regulating kinase (ASK1), 
alone or in combination with simtuzumab for the treatment of nonalcoholic steatohepat itis (NASH): a 
randomized , phase 2 trial. Hepatology 2016; 64 (suppl 1);1119A (abstract LB -3). 
Lundasen T, Gälman C, Angelin B, et al. Circulating intestinal fibroblast growth factor 19 has a pronounced 
diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006;260:530 –6. 
Marschall H, Luketic V, Lovgren -Sandblom A, et al. The FXR agonist obeticholic acid i ncreases plasma 
FGF19 concentrations and decreases bile acid synthesis in primary biliary cirrhosis . J Hepatol 2012;56:S377.  
Mehta R, Birerdinc A, Younossi ZM.  Host genetic variants in obesity -related nonalcoholic fatty liver disease. 
Clin Liver Dis 2014;18:249 –67. 
Meisamy S, Hines CD, Hamilton G, et al. Quantification of hepatic steatosis with T1 -independent, T2- corrected 
MR ima ging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 
2011;258:767 –75. 
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 
diabetes. N Engl J Med 2012;366:1577 –85. Epub 2012 Mar 26.  
Neuschwander -Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks 
of treatment with the PPAR- gamma ligand rosiglitazone. Hepatology 2003;38:1008 –17. 
Neuschwander -Tetri BA , Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic aci d for 
non-cirrhotic, non -alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo -controlled trial. Lancet 
2014 Nov 7. pii: S0140- 6736(14)61933– 4. 
Pan JJ, Fallon MB. Gender and racial differen ces in nonalcoholic fatty liver disease. World J Hepatol 
2014 ;6:274–83. 
Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often 
develop without significant liver fibrosis: a pathological analysis. Hepatol ogy 2009 ;49:851– 9. 
Patel  J, Bettencourt R, Cui J , et al. Association of noninvasive quantitative decline in liver fat content on MRI 
with histologic response in nonalcoholic steatohepatitis. Therap  Adv Gastroenterol 2016;9: 692– 701. 
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 119 of 125 Pavlides M, Banerjee R, Tunnicliffe EM, et al. Multi- parametric magnetic resonance imaging for the 
assessment of non -alcoholic fatty liver disease severity. Liver Int 2016 Oct 25. doi:10.1111/liv.13284. [Epub 
ahead of print]  
Permutt Z, Le TA, Peterson MR, et al. Correlation between liver histology and novel magnetic resonance 
imaging in adult patients with non -alcoholic fatty liver disease —MRI accurately quantifies hepatic steatosis in 
NAFLD. Aliment Pharmacol Ther 2012;36:22 –9. 
Potthoff MJ, Boney -Montoya J, Choi M, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the 
CREB PGC 1 alpha pathway. Cell Metab 2011;13:729 –38. 
Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatol ogy 2010;51:121 –9. 
Ratziu  V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator -activated 
receptor -α and  -δ, induces resolution of nonalcoholic steatohepatitis without f ibrosis w orsening. 
Gastroenterology. 2016a May;150:1147– 59. 
Ratziu V, Harrison SA, Francque S, et al. ALT as a non -invasive biomarker of histological response to 
pharmacotherapy in NASH patients: insights from the elafibranor GOLDEN505 trial. Hepatology 2016 b; 
64(Suppl 1);581A (abstract 1154).  
Rosuvastatin calcium [package insert]. Actavis Pharma, Inc., Parsippany, NJ; July 2016.  
Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vi tamin E, or placebo for nonalcoholic 
steatohepatitis. N Engl J Med 2010;362:1675 –85. 
Sanyal AJ, Ratziu V, Harrison SA, et al. Cenicriviroc vs. placebo for the treatment of non -alcoholic 
steatohepatitis with liver fibrosis: results from the year 1 primary a nalysis of the phase 2b CENTAUR study. 
Hepatology 2016;64 (suppl 1);1118A (abstract LB -1). 
Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic roux en y gastric bypass on type 2 diabetes 
mellitus. Ann Surg 2003;238:467– 84. 
Schauer PR, Kashy ap S, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients 
with diabetes. N Engl J Med 2012;366:1567 –76.  
Schreuder TC, Marsman HA, Lenicek M, et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic f atty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010;298:G440 –
5. 
Singh S, All en AM, Wang Z, et al. Fibrosis progression in n onalcoholic fatty liver vs nonalcoholic 
steatohepatitis: a systematic review and m eta-analysis of  paired -biopsy studies. Clin Gastroenterol Hepatol  
2014 Apr 24. pii: S1542- 3565(14)00602 –8. 
Stejskal D, Karpísek M, Hanulová Z, et al.  Fibroblast growth factor -19: development, analytical 
characterization and clinical evaluation of a new ELISA test. Scand J Clin Lab Invest  2008;68:501– 7. 
Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet  2011 ;378:804 –14. 
Tanaka N, Matsubara T, Krausz KW, et al. Disruption of phospholipid and bile acid h omeostasis in mice with 
nonalcoholic  steatohepatitis.  Hepatology 2012;56:118 –29. 
Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor 19 display 
increased metabolic rate and decreased adiposity. Endocrinology  
2002;143:1741– 7. 
Torres  DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. 
Clin Gastroenterol Hepatol  2012;10:837 –58. 
Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from 
pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009;2009:831670.  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 120 of 125 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics 
Evaluation and Research. Guidance for industry: toxicity gr ading scale for healthy adult and adolescent 
volunteers enrolled in preventive vaccine clinical trials. September 2007.  
Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely  middle -aged population utilizing ultrasound and liver biopsy: a prospective 
study. Gastroenterology 2011;140:124 –31.  
Wojcik M, Janus D, Dolezal- Oltarzewska K, et al. A decrease in fasting FGF19 levels is associated with the 
development of non- alcoholic f atty liver disease in obese adolescents. J  Pediatr Endocrinol Metab  
2012;25:1089– 93.  
World Health Organization Uppsala Monitoring Centre. Drug dictionary enhanced. September 2012. http://who -umc.org/DynPage.aspx?id=98105&mn1=7347&mn2=7252&mn3=7254&mn4=733 8 
Xie MH, Holcomb I, Deuel B, et al. FGF 19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999;11:729– 35. 
Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and preve ntion. Nat Rev Gastroenterol Hepatol. 2017 Sep 20. doi: 10.1038/nrgastro.2017.109. [Epub 
ahead of print] Review. PubMed PMID: 28930295.  
  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 121 of 125 15 Appendices 
Appendix  A. NASH Clinical Research Network  (CRN)  NAFLD Activity Sco re and 
Fibrosis Score 
Steatosis  S 
Score  Lobular 
Inflammation  L 
Score  Hepatocyte 
Ballooning B 
Score  
< 5%  0 None  0 None  0 
5%–33% 1 < 2 1 Few ballooned cells  1 
34%–66% 2 2–4 2 Many ballooned cells  2 
> 66% 3 > 4 3 — — 
NAFLD = nonalcoholic fatty liver disease . 
Note : NAFLD activity grade score = total score:  S + L + B (range 0 –8). 
 
Fibrosis Stage  Score  
0 No Fibrosis  
1a Zone 3, Mild  
1b Zone 3, Moderate  
1c Periportal Only  
2 Zone 3 and Periportal  
3 Bridging  
4 Cirrhosis  
 
  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 122 of 125 Appendix  B. Food and Drug Administration Toxicity Grading Scale: 
Clinical Abnormalities in Local Injection -Site Symptom Assessments  
Local Reaction to 
Injection Product Mild  
(Grade 1)  Moderate 
(Grade 2 )  Severe 
(Grade 3)  Potentially  
Life-Threatening 
(Grade 4)  
Pain Does not 
interfere with 
activity  Repeated use of 
non-narcotic 
pain reliever 
more than 
24 hours or 
interferes with 
activity  Any use of 
narcotic pain 
reliever or 
prevents daily 
activity  Emergency room 
(ER) visit or 
hospitalization  
     
Tenderness  Mild di scomfort 
to touch  Discomfort with 
movement Significant 
discomfort at rest  ER visit or 
hospitalization  
     
Erythema/Redness a 2.5–5 cm  5.1–10 cm  > 10 cm  Necrosis or 
exfoliative 
dermatitis  
     
Induration/Swelling b 2.5–5 cm and 
does not 
interfere with 
activity  5.1–10 cm or 
interferes with 
activity  > 10 cm or 
prevents daily 
activity  Necrosis  
ER = emergency room.  
Note: The FDA Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers enrolled in 
Preventive Vaccine Clinical Trials can be found at  
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/
Vaccines/ucm074775.htm.  
a. In addition to grading the measured local reaction at the greatest single diameter, the measurements 
should be recorded as a continuous  variable.  
b Induration or Swelling should be evaluated and graded using the functional scale as well as the actual 
measurement.  
 
  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 123 of 125 Appendix  C. Rosuvastatin Package Insert  
The package insert for rosuvastatin currently being used in the open- label single-blind cohort 
can be found at the following web link: 
 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/079167Orig1s000lbl.pdf   
 
The package insert for rosuvastatin currently being used in the placebo -controlled 24- week 
histology cohort  can be found at the following web link: 
 
http://www.torrentia n.com/pisheet/Upload/PI_Sheet_US/181_2.pdf  
  
NGM282  
16.1.1 Study 15 -0105 Protocol Amendment 9  
NGM Biopharmaceuticals, Inc.  Confidential  Page 124 of 125 Appendix  D. Ezetimibe Package Insert  
 
The package insert for ezetimibe  related to  the placebo -controlled 24-week histology cohort 
can be found at the following web link: 
 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021445s019lbl.pdf  
  